LakeShore Biopharma (LSB) 20-F 15 Aug 24 2024 FY Annual report (foreign) Financial data

Document And Entity Information

Document And Entity Information	12 Months Ended
	Mar. 31, 2024 shares
Document Information Line Items
Entity Registrant Name	LakeShore Biopharma Co., Ltd
Document Type	20-F
Current Fiscal Year End Date	--03-31
Entity Common Stock, Shares Outstanding	190,227,959
Amendment Flag	false
Entity Central Index Key	0001946399
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Non-accelerated Filer
Entity Well-known Seasoned Issuer	No
Document Period End Date	Mar. 31, 2024
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	FY
Entity Emerging Growth Company	true
Entity Shell Company	false
Entity Ex Transition Period	false
ICFR Auditor Attestation Flag	false
Document Registration Statement	false
Document Annual Report	true
Document Transition Report	false
Document Shell Company Report	false
Entity File Number	001-41598
Entity Incorporation, State or Country Code	E9
Entity Address, Address Line One	Building No. 2
Entity Address, Address Line Two	38 Yongda Road
Entity Address, Address Line Three	Daxing Biomedical Industry ParkDaxing District
Entity Address, City or Town	Beijing
Entity Address, Country	CN
Entity Address, Postal Zip Code	102629
Entity Interactive Data Current	Yes
Document Financial Statement Error Correction [Flag]	false
Document Accounting Standard	U.S. GAAP
Auditor Firm ID	2388
Auditor Name	Wei, Wei & Co., LLP
Auditor Location	Flushing, New York
Business Contact
Document Information Line Items
Entity Address, Address Line One	Building No. 2
Entity Address, Address Line Two	38 Yongda Road
Entity Address, Address Line Three	Daxing Biomedical Industry ParkDaxing District
Entity Address, City or Town	Beijing
Entity Address, Country	CN
Entity Address, Postal Zip Code	102629
Contact Personnel Name	Hui Shao
City Area Code	010
Local Phone Number	89202086
Ordinary share, par value US$0.00002 per share
Document Information Line Items
Trading Symbol	LSB
Title of 12(b) Security	Ordinary share, par value US$0.00002 per share
Security Exchange Name	NASDAQ
Warrants, each exercisable for one ordinary share
Document Information Line Items
Trading Symbol	LSBPW
Title of 12(b) Security	Warrants, each exercisable for one ordinary share
Security Exchange Name	NASDAQ

Consolidated Balance Sheets

Consolidated Balance Sheets		Mar. 31, 2024 CNY (¥)	Mar. 31, 2024 USD ($)	Mar. 31, 2023 CNY (¥)
Current assets
Cash		¥ 246,351,231	$ 34,721,808	¥ 370,108,059
Restricted cash		200,000	28,189	261,766
Accounts receivable, net		444,161,291	62,602,014	463,051,792
Advance to suppliers, net		1,662,739	234,354	6,763,326
Inventories, net		203,422,602	28,671,262	185,380,952
Prepaid expenses and other current assets		7,370,089	1,038,772	10,412,769
Total current assets		903,167,952	127,296,399	1,035,978,664
Non-current assets
Property, plant and equipment, net		473,348,006	66,715,716	571,756,443
Operating lease right-of-use assets, net		7,275,367	1,025,422	11,132,428
Deferred tax assets, net		23,634,189	3,331,105	1,905,581
Intangible assets, net		71,245,336	10,041,626	78,056,792
Other assets, non-current		34,356,506	4,842,355	20,923,703
Total non-current assets		609,859,404	85,956,224	683,774,947
Total assets		1,513,027,356	213,252,623	1,719,753,611
Current liabilities
Bank loans and other borrowings - current		318,540,732	44,896,509	193,736,563
Accounts payable		67,774,798	9,552,473	80,439,489
Accrued expenses and other liabilities		408,737,969	57,609,301	377,536,644
Operating lease liabilities - current		5,156,540	726,785	4,753,547
Deferred government grants - current		2,015,693	284,100	2,295,701
Total current liabilities		802,225,732	113,069,168	658,761,944
Non-current liabilities
Bank loans and other borrowings – non-current		98,983,780	13,951,202	293,790,596
Operating lease liabilities - non-current		1,783,593	251,387	6,348,890
Deferred government grants - non-current		20,279,945	2,858,343	23,606,507
Warrants liability		4,548,004	641,015	8,792,389
Total non-current liabilities		125,595,322	17,701,947	332,538,382
Total liabilities		927,821,054	130,771,115	991,300,326
Shareholders’(deficit)/equity
Ordinary shares, par value US$0.00002 per share; 9,950,000,000 shares authorized; 93,058,197 and 190,227,959 shares issued and outstanding as of March 31, 2023 and 2024, respectively *	[1]	26,105	3,679	12,297
Additional paid-in capital		2,950,862,914	415,907,387	2,656,891,036
Accumulated deficit		(2,307,502,836)	(325,229,434)	(1,874,037,965)
Accumulated other comprehensive loss		(58,179,881)	(8,200,124)	(54,412,083)
Total shareholders’ equity		585,206,302	82,481,508	728,453,285
Total liabilities and shareholders’ equity		¥ 1,513,027,356	$ 213,252,623	¥ 1,719,753,611
[1] Gives retroactive effect to the business combination in March 2023.

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - $ / shares		Mar. 31, 2024	Mar. 31, 2023
Statement of Financial Position [Abstract]
Ordinary shares, par value (in Dollars per share)	[1]	$ 0.00002	$ 0.00002
Ordinary shares, shares authorized	[1]	9,950,000,000	9,950,000,000
Ordinary shares, issued	[1]	190,227,959	93,058,197
Ordinary shares, outstanding	[1]	190,227,959	93,058,197
[1] Gives retroactive effect to the business combination in March 2023.

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss		12 Months Ended
		Mar. 31, 2024 CNY (¥) ¥ / shares shares	Mar. 31, 2024 USD ($) $ / shares shares	Mar. 31, 2023 CNY (¥) ¥ / shares shares	Mar. 31, 2022 CNY (¥) ¥ / shares shares
Income Statement [Abstract]
Revenues		¥ 573,418,256	$ 80,820,050	¥ 687,201,070	¥ 502,949,894
Cost of revenues		117,688,301	16,587,498	153,360,262	117,066,090
Gross profit		455,729,955	64,232,552	533,840,808	385,883,804
Operating expenses:
Selling and marketing		301,259,528	42,460,821	272,927,356	185,999,704
General and administrative		140,086,062	19,744,336	72,939,790	98,144,146
Impairment loss on inventory, property, plant and equipment and other assets		157,415,875	22,186,875	8,655,487	9,476,354
Research and development		302,800,992	42,678,082	318,700,526	211,222,263
Total operating expenses		901,562,457	127,070,114	673,223,159	504,842,467
Loss from operations		(445,832,502)	(62,837,562)	(139,382,351)	(118,958,663)
Other income (expenses):
Late fees for taxes other than income tax				(3,603)	(231,231)
Late fees for social security insurance		(756,201)	(106,582)	(747,609)	(1,852,378)
Government grants		20,708,778	2,918,785	26,072,517	23,020,413
Financial expenses, net		(44,344,808)	(6,250,149)	(30,857,673)	(2,717,433)
Fair value changes of warrant liability		4,458,844	628,449	21,358
Other (expense) income, net		10,572,411	1,490,121	551,760	(327,987)
Total other income (expense), net		(9,360,976)	(1,319,376)	(4,963,250)	17,891,384
Loss before income taxes		(455,193,478)	(64,156,938)	(144,345,601)	(101,067,279)
Income tax (expense) benefit		21,728,607	3,062,524	(1,133,504)	(4,937,122)
Net loss		(433,464,871)	(61,094,414)	(145,479,105)	(106,004,401)
Accretion to redemption value of convertible redeemable preferred shares				(137,991,697)	(130,662,326)
Other comprehensive income (loss): foreign currency translation adjustment		(3,767,798)	(531,050)	(137,500,063)	38,864,606
Net loss attributable to Lakeshore Group		(433,464,871)	(61,094,414)	(283,470,802)	(236,666,727)
Net loss		(433,464,871)	(61,094,414)	(145,479,105)	(106,004,401)
Total comprehensive loss		¥ (437,232,669)	$ (61,625,464)	¥ (282,979,168)	¥ (67,139,795)
Loss per share*:
Loss per share basic (in Dollars per share and Yuan Renminbi per share) | (per share)	[1]	¥ (4.05)	$ (0.57)	¥ (2.35)	¥ (1.71)
Weighted average number of ordinary shares outstanding*:
Weighted average number of ordinary shares outstanding basic (in Shares)	[1]	106,923,121	106,923,121	61,785,466	61,827,883
[1] Gives retroactive effect to the business combination in March 2023.

Consolidated Statements of Op_2

Consolidated Statements of Operations and Comprehensive Loss (Parentheticals)		12 Months Ended
		Mar. 31, 2024 $ / shares shares	Mar. 31, 2024 ¥ / shares shares	Mar. 31, 2023 ¥ / shares shares	Mar. 31, 2022 ¥ / shares shares
Income Statement [Abstract]
Loss per share diluted (in Dollars per share and Yuan Renminbi per share) | (per share)	[1]	$ (0.57)	¥ (4.05)	¥ (2.35)	¥ (1.71)
Weighted average number of ordinary shares outstanding diluted	[1]	106,923,121	106,923,121	61,785,466	61,827,883
[1] Gives retroactive effect to the business combination in March 2023.

Consolidated Statements of Chan

Consolidated Statements of Changes In Shareholders’ (Deficit)/Equity		Ordinary shares CNY (¥) shares		Ordinary shares USD ($) shares		Additional paid-in capital CNY (¥)	Additional paid-in capital USD ($)	Deficit CNY (¥)	Deficit USD ($)	Accumulated other comprehensive income/(loss) CNY (¥)	Accumulated other comprehensive income/(loss) USD ($)	CNY (¥) shares		USD ($) shares
Balance (in Dollars)		¥ 7,978	[1]			¥ 800,806,378		¥ (1,353,900,436)		¥ 44,223,373		¥ (508,862,707)
Balance at Mar. 31, 2021		¥ 7,978	[1]			800,806,378		(1,353,900,436)		44,223,373		(508,862,707)
Balance (in Shares) at Mar. 31, 2021 | shares	[1]	61,827,883		61,827,883
Accretion to redemption value of convertible redeemable preferred shares								(130,662,326)				(130,662,326)
Net loss								(106,004,401)				(106,004,401)
Share-based compensation			[1]			7,764,448						7,764,448
Share-based compensation (in Shares) | shares
Foreign currency translation adjustment						(68,808)				38,864,606		38,795,798
Balance at Mar. 31, 2022		¥ 7,978	[1]			808,502,018		(1,590,567,163)		83,087,979		(698,969,188)
Balance (in Shares) at Mar. 31, 2022 | shares	[1]	61,827,883		61,827,883
Balance (in Dollars)		¥ 7,978	[1]			808,502,018		(1,590,567,163)		83,087,979		(698,969,188)
Accretion to redemption value of convertible redeemable preferred shares								(137,991,697)				(137,991,697)
Conversion of mezzanine equity		¥ 3,007	[1]			1,636,894,077						1,636,897,084
Conversion of mezzanine equity (in Shares) | shares	[1]	21,740,862		21,740,862
Net loss								(145,479,105)				(145,479,105)
Share-based compensation		¥ (20)	[1]			3,505,021						3,505,001
Share-based compensation (in Shares) | shares	[1]	(143,750)		(143,750)
Issuance of common stock		¥ 1,332	[1]			216,376,861						216,378,193
Issuance of common stock (in Shares) | shares	[1]	9,633,202		9,633,202
Warrant from business combination						(8,870,007)						(8,870,007)
Additional paid-in capital from business combination						483,066						483,066
Foreign currency translation adjustment										(137,500,062)		(137,500,062)
Balance at Mar. 31, 2023		¥ 12,297	[1]			2,656,891,036		(1,874,037,965)		(54,412,083)		¥ 728,453,285
Balance (in Shares) at Mar. 31, 2023 | shares		93,058,197	[1]	93,058,197	[1]							93,058,197	[2]	93,058,197	[2]
Balance (in Dollars)		¥ 12,297	[1]			2,656,891,036		(1,874,037,965)		(54,412,083)		¥ 728,453,285
Accretion to redemption value of convertible redeemable preferred shares
Net loss								(433,464,871)				(433,464,871)		(61,094,414)
Share-based compensation		¥ 270	[1]			9,789,416						9,789,686
Share-based compensation (in Shares) | shares	[1]	1,900,000		1,900,000
Issuance of common stock		¥ 13,538	[1]			284,182,462						284,196,000
Issuance of common stock (in Shares) | shares	[1]	95,269,762		95,269,762
Foreign currency translation adjustment										(3,767,798)		(3,767,798)
Balance at Mar. 31, 2024		¥ 26,105	[1]	$ 3,679	[1]	2,950,862,914	$ 415,907,387	(2,307,502,836)	$ (325,229,434)	(58,179,881)	$ (8,200,124)	¥ 585,206,302		$ 82,481,508
Balance (in Shares) at Mar. 31, 2024 | shares		190,227,959	[1]	190,227,959	[1]							190,227,959	[2]	190,227,959	[2]
Balance (in Dollars)		¥ 26,105	[1]	$ 3,679	[1]	¥ 2,950,862,914	$ 415,907,387	¥ (2,307,502,836)	$ (325,229,434)	¥ (58,179,881)	$ (8,200,124)	¥ 585,206,302		$ 82,481,508
[1] Gives retroactive effect to the business combination in March 2023. Gives retroactive effect to the business combination in March 2023.

Consolidated Statements of Cash

Consolidated Statements of Cash Flows	12 Months Ended
	Mar. 31, 2024 CNY (¥)	Mar. 31, 2024 USD ($)	Mar. 31, 2023 CNY (¥)	Mar. 31, 2022 CNY (¥)
Cash flows from operating activities:
Net loss	¥ (433,464,871)	$ (61,094,414)	¥ (145,479,105)	¥ (106,004,401)
Adjustments to reconcile net loss to net cash used in operating activities:
Deferred income taxes expense (benefit)	(21,728,608)	(3,062,524)	1,133,504	4,937,120
Depreciation of property, plant and equipment	35,373,927	4,985,754	29,735,024	24,475,736
Amortization of intangible assets	6,811,456	960,036	6,952,783	6,678,233
Loss on disposal of property, plant and equipment	13,135	1,851		273,982
Provision for impairment of property, plant and equipment	80,236,996	11,308,949
Share-based compensation	9,789,686	1,379,801	3,505,001	7,764,448
Bad debt provision of accounts receivable	4,987,206	702,918	10,750,949	5,084,924
Write-down (reversal) of inventories to net realizable value	68,221,017	9,615,365	(723,583)	4,393,630
Non-cash lease expense	4,778,623	673,520	4,423,612	3,787,628
Fair value changes of warrant liability	(4,458,844)	(628,449)	(21,358)
Changes in operating assets and liabilities:
Inventories	(86,262,667)	(12,158,234)	(18,151,804)	(89,459,313)
Accounts receivable	13,903,295	1,959,591	(165,247,635)	(99,137,291)
Amounts due from related parties				30,088,833
Prepaid expenses and other current assets	(5,289,535)	(745,530)	8,992,573	59,229,802
Accounts payable	(12,664,691)	(1,785,016)	49,628,389	14,427,864
Accrued expenses and other liabilities	53,220,366	7,501,109	43,029,496	(35,633,487)
Deferred government grants	(3,606,570)	(508,326)	(6,447,010)	(656,673)
Operating lease liabilities	(5,089,524)	(717,340)	(4,550,232)	(3,796,392)
Net cash used in operating activities	(295,229,603)	(41,610,939)	(182,469,396)	(173,545,357)
Cash flows from investing activities:
Proceeds from disposal of property, plant and equipment			68,001	8,000
Purchases of property, plant and equipment	(44,250,714)	(6,236,887)	(52,758,124)	(295,314,351)
Purchases of intangible assets			(4,291,597)	(3,617,607)
Net cash used in investing activities	(44,250,714)	(6,236,887)	(56,981,720)	(298,923,958)
Cash flows from financing activities:
Proceeds from issuance of ordinary shares	284,196,000	40,055,814
Proceeds from business combination			252,457,329
Offering cost			(35,884,661)
Proceeds from bank loans and other borrowings	337,851,075	47,618,192	247,387,392	414,116,587
Repayment of bank loans and other borrowings	(416,785,723)	(58,743,583)	(146,510,134)	(49,558,442)
Net cash provided by financing activities	205,261,352	28,930,423	317,449,926	364,558,145
Effect of foreign exchange rate on cash	10,400,371	1,465,874	21,303,512	(11,478,411)
Net (decrease) increase in cash	(123,818,594)	(17,451,529)	99,302,322	(119,389,581)
Cash at the beginning of the year	370,369,825	52,201,526	271,067,503	390,457,084
Cash at the end of the year	246,551,231	34,749,997	370,369,825	271,067,503
Supplemental disclosures of cash flow information:
Income taxes paid
Interest paid	30,131,238	4,246,827	27,289,057	2,404,357
Non-cash transactions:
Accretion to redemption value of convertible redeemable preferred shares			137,991,697	130,662,326
Operating right-of-use assets recognized for related operating lease liabilities	829,703	116,942	331,218	1,516,478
Equity transaction from warrants			(8,870,007)
Equity transaction from preferred shares			¥ 1,636,897,084

Organization and Business Descr

Organization and Business Description	12 Months Ended
	Mar. 31, 2024
Organization and Business Description [Abstract]
ORGANIZATION AND BUSINESS DESCRIPTION	NOTE 1 – ORGANIZATION AND BUSINESS DESCRIPTION Lakeshore Biopharma Co., Ltd (“Lakeshore Biopharma”), formerly known as YS Biopharma Co., Ltd. (with the name effective on May 23, 2024), was incorporated under the laws of the Cayman Islands as an exempted company with limited liability in November 2020. It owns four companies and their subsidiaries that were incorporated in the Cayman Islands, United States of America (“US”), Singapore, Hong Kong and the People’s Republic of China (“China” or the “PRC”) (collectively, the “Company” or “Lakeshore Group”). Lakeshore Group is principally engaged in the research, development, manufacturing and sale of vaccines and therapeutic biologics. It developed a PIKA immunomodulating technology platform and a series of product candidates targeting rabies, hepatitis B, influenza and other indications. It also produces and sells YSJA™ (依生君安™) rabies vaccine, the first aluminum-free lyophilized rabies vaccine launched in China. Business Combination On August 15, 2022, Oceanview Bioscience Acquisition Co., Ltd. (“Oceanview Bioscience”) and Hudson Biomedical Group Co., Ltd. (“Hudson Biomedical”) were incorporated under the laws of Cayman Islands as exempted companies with limited liability. The companies were incorporated to effect a merger with Summit Healthcare Acquisition Corp (“Summit”), a Special Purpose Acquisition Company (“SPAC”). On September 29, 2022, Lakeshore Biopharma entered into the Business Combination Agreement with Summit Oceanview Bioscience Acquisition Co., Ltd., (“Merger Sub I”) and Hudson Biomedical Group Co., Ltd., (“Merger Sub II”). The Business Combination Agreement provides for (1) the merger of Merger Sub I with and into Summit (the “First Merger”), with Summit surviving the First Merger as the surviving entity (the “Surviving Entity”) and becoming a wholly-owned subsidiary of Lakeshore Biopharma, and (2) the merger of the Surviving Entity with and into Merger Sub II (the “Second Merger,” and together with the First Merger, the “Mergers,” together with other transactions contemplated by the Business Combination Agreement, the “Business Combination”), with Merger Sub II surviving the Second Merger as the surviving company (the “Surviving Company”) and remaining as a wholly-owned subsidiary of Lakeshore Biopharma. In accordance with the Business Combination Agreement, on the date of closing of the Mergers (“First Merger and Second Merger”), (1) each Lakeshore Biopharma’s preferred share was converted into one pre-consolidation Ordinary Share; (2) every four of the pre-consolidation Ordinary Shares and every four pre-consolidation options of Lakeshore Biopharma were consolidated into one Ordinary Share and one option of Lakeshore Biopharma, respectively, subject to rounding up to the nearest whole number of Ordinary Shares. On March 16, 2023 (the “Closing Date”), Lakeshore Biopharma announced the completion of its business combination with Summit pursuant to the above Business Combination Agreement. On May 9, 2023, Lakeshore Biopharma (Philippines) Inc. (“Philippines Yisheng”) was incorporated under the laws of Philippines as an entity owned by Lakeshore Group. Philippines Yisheng was incorporated for the purpose of research, development, producing, wholesaling and commercializing pharmaceutical products, including vaccines and other biological products. Below is Lakeshore Group’s current legal entity structure: As of March 31, 2024, Lakeshore Group consists of the following legal entities: Legal Entity Nature of Operations Date of Incorporation Place of Incorporation Lakeshore Biopharma Co., Ltd. (“Lakeshore Biopharma”)*** Holding Company November 16, 2020 Cayman Islands YishengBio (Hong Kong) Holdings Limited (“HK Yisheng”) Holding Company December 28, 2020 Hong Kong Lakeshore Biopharma (Singapore) Pte. Ltd. (“Singapore Yisheng”)** Research and development of vaccines and therapeutic biologics November 28, 2009 Singapore Yisheng US Biopharma Inc. (“US Yisheng”) Research of vaccines and therapeutic biologics September 29, 2009 US Liaoning Yisheng Biopharma Co., Ltd. (“Liaoning Yisheng”)* Research and development, manufacturing and commercialization of vaccines and therapeutic biologics May 26, 1994 PRC Beijing Yisheng Biotechnology Co., Ltd. (“Beijing Yisheng”) Research and development of vaccines and therapeutic biologics February 4, 2021 PRC Hudson Biomedical Group Co., Ltd. Purpose of effecting a merger August 15, 2022 Cayman Islands YS Biopharma (Philippines) Inc. (“Philippines Yisheng”) Researching, developing, producing, wholesaling and commercializing pharmaceutical products May 9, 2023 Philippines * Liaoning Yisheng was incorporated May 26, 1994, and acquired by Lakeshore Group in fiscal 2005. On March 26, 2024, Liaoning Yisheng Biopharma Co., Ltd. Beijing Branch (“Liaoning Yisheng Beijing Branch”) was incorporated for research and development, manufacturing and commercialization of vaccines and therapeutic biologics. ** Singapore Yisheng was incorporated November 28, 2009, and acquired by Lakeshore Group in fiscal 2011. Singapore Yisheng was formerly known as Yisheng Biopharma (Singapore) Pte. Ltd. with the name effective on July 22, 2024 *** Lakeshore Biopharma, formerly known as YS Biopharma Co., Ltd, with the name effective on May 23, 2024.

Going Concern Uncertainty

Going Concern Uncertainty	12 Months Ended
	Mar. 31, 2024
Going Concern Uncertainty [Abstract]
GOING CONCERN UNCERTAINTY	NOTE 2 – GOING CONCERN UNCERTAINTY As reflected in the accompanying consolidated financial statements (“CFS”), the Company reported net loss of RMB106,004,401, RMB145,479,105 and RMB433,464,871 for the years ended March 31, 2022, 2023 and 2024, respectively. In addition, the Company had negative cash flows from operations in each of the years during the two-year period ended March 31, 2024, and reported accumulated deficit of RMB1,874,037,965 and RMB2,307,502,836 as of March 31, 2023 and 2024. In assessing its liquidity, management monitors and analyzes the Company’s cash flow requirements, its ability to generate sufficient revenue sources in the future, and its operating and capital expenditure commitments. As of March 31, 2024, the Company had cash of approximately RMB246.4 million (US$34.7 million). As of March 31, 2024, the Company had outstanding bank loans and other borrowings of approximately RMB417.5 million (US$58.8 million) from various financial institutions. On December 27, 2023, HK Yisheng received a letter from R-Bridge Healthcare Fund, LP (“R-Bridge”), as agent, (the “R-Bridge Letter”), notifying the Company it had reason to believe HK Yisheng defaulted under financial covenants and other obligations under the facility agreement, and under the instructions of the lenders to urge the Company to reach an amicable solution with the lenders, including, without limitation, repaying the loan of $40.0 million in full, as soon as possible. The Company repaid $15.0 million, $10.0 million and $18.1 million respectively in February, March and April, 2024. As of April 29, 2024, the Company repaid its full amount of $40.0 million and accrued interest of $3.1 million. On February 9, 2024, the Company announced it entered into a share purchase agreement with an institutional investor for the sale of 95,269,762 ordinary shares of the Company, par value US$0.00002 per share, in a private placement of US$40.0 million at $0.41986 per Ordinary Share. On May 30, 2024 and June 1, 2024, two entities controlled by Mr. Zhang filed arbitration claims respectively against Liaoning Yisheng and Beijing Yisheng and applied for property preservation to freeze Lakeshore Group’s bank deposits or finished goods. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The Company’s ability to continue as a going concern is dependent on management’s ability to successfully execute its business plan, which includes increasing revenues while controlling operating expenses, as well as, generating operational cash flows and continuing to gain support from outside sources of financing. The Company believes that available loan facility and financial support from outside sources will be sufficient to support the Company to meet the cash requirements to fund planned operations and other commitments for at least the next 12 months. The Company’s CFS were prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. These financial statements do not include any adjustments related to the recoverability and/or classification of the recorded asset amounts and/or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Mar. 31, 2024
Summary of Significant Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation These CFS and related notes of Lakeshore Group were prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). In the opinion of management, all adjustments necessary to present fairly in all material respects the financial position, results of operations and cash flows for all periods presented were made. Reclassification Certain prior year amounts have been reclassified to conform with the current year presentation, as follows (in RMB). Previously reported March 31, (Decrease)/ March 31, (Reclassified) Consolidated Statements of Operations and Comprehensive Loss General and administrative 81,595,277 (8,655,487 ) 72,939,790 Impairment loss on inventory, property, plant and equipment and other assets - 8,655,487 8,655,487 Previously reported March 31, (Decrease)/ March 31, (Reclassified) Consolidated Statements of Operations and Comprehensive Loss General and administrative 107,620,500 (9,476,354 ) 98,144,146 Impairment loss on inventory, property, plant and equipment and other assets - 9,476,354 9,476,354 These reclassifications had no effect on the reported results of operations. Basis of Consolidation The CFS include the financial statements of Lakeshore Group and its wholly-owned subsidiaries. All significant intercompany transactions and balances were eliminated in consolidation. The CFS were prepared on a historical cost basis, except for financial assets and financial liabilities which were measured at fair value (“FV”). The functional currency of Lakeshore Group and its Hong Kong subsidiary, US subsidiary is the United States dollars (“US$”). The functional currency of Lakeshore Group’s Singapore subsidiary is the Singapore dollars (“S$”). The functional currency of Lakeshore Group’s PRC subsidiaries is the Chinese Renminbi (“RMB”). The determination of functional currency is based on the criteria of Accounting Standard Codifications (“ASC”) as promulgated by the Financial Accounting Standards Board, ASC 830, Foreign Currency Matters (“ASC 830”). Lakeshore Group uses the RMB as its reporting currency. Use of Estimates The preparation of the CFS in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the CFS and the reported amounts of revenues and expenses during the reporting periods. Significant estimates and assumptions reflected in these CFS include, but are not limited to, the valuation of Lakeshore Group’s convertible redeemable preferred shares and ordinary shares, accrual of stock-based compensation expense, allowance for estimated credit losses and obsolete inventories, useful life of property, plant and equipment, income taxes and uncertain tax positions. Actual amounts could differ from those estimates. Changes in estimates are recorded in the period when they become known. Due to the risks and uncertainties involved in Lakeshore Group’s business and evolving market conditions and, given the subjective element of the estimates and assumptions made, actual results may differ from estimated results. Foreign Currency Translation Lakeshore Group’s CFS are reported using the RMB. The results of operations and the consolidated statements of cash flows denominated in foreign currency are translated at the average rate of exchange during the reporting period. Assets and liabilities denominated in foreign currencies at the balance sheet date are translated at the applicable rates of exchange in effect at that date. The equity denominated in the functional currency is translated at the historical rate of exchange at the time of capital transaction. Because cash flows are translated based on the average translation rate, amounts related to assets and liabilities reported on the consolidated statements of cash flows will not necessarily agree with changes in the corresponding balances on the consolidated balance sheets. Foreign currency translation adjustments arising from the use of different exchange rates from period to period are included as a separate component of accumulated other comprehensive income included in Lakeshore Group’s consolidated statements of changes in shareholders’ deficit. Gains and losses from foreign currency transactions are included in Lakeshore Group’s consolidated statements of operations and comprehensive loss. The value of RMB against US$ and other currencies may fluctuate and is affected by, among other things, changes in the PRC’s political and economic conditions. The following table outlines the currency exchange rates used in preparing Lakeshore Group’s CFS: As of March 31, Years Ended March 31, 2023 2024 2022 2023 2024 Foreign currency Balance Sheet Balance Sheet Profit/Loss Profit/Loss Profit/Loss RMB:1US$ 6.8717 7.0950 6.4598 6.6100 6.9834 RMB:1S$ 5.1760 5.2762 4.7850 4.9346 5.2261 RMB:1PHP NA 0.1286 NA NA 0.1275 Convenience translation Amounts in US$ are presented for the convenience of the reader and translated at US$1.00 to RMB7.0950, representing the central parity rate release of the People’s Bank of China on March 31, 2024. No representation is made that the RMB amounts could have been, or converted, realized or settled into US$ at such rate. Cash Cash includes cash on hand and demand deposits in accounts maintained with commercial banks. Lakeshore Group maintains bank accounts in China. Cash balances in bank accounts in China are not insured by the Federal Deposit Insurance Corporation or other programs. Restricted Cash Restricted cash balances mainly relate to restrictions imposed on banks as cash deposits for the issuance of letters of credit or asset preservation in litigation. And it is included in the total cash, cash equivalents, and restricted cash in the consolidated statements of cash flows. Expected Credit Losses On April 1, 2023, Lakeshore Group adopted ASC 326, Credit Losses (“ASC 326”), which replaced previously issued guidance regarding the impairment of financial instruments with an expected loss methodology that will result in more timely recognition of credit losses. Lakeshore Group used a modified retrospective approach and did not restate the comparable prior periods. The adoption did not have a material impact on the Company’s CFS. Upon adoption of ASC 326, Lakeshore Group maintains an allowance for credit losses in accordance with ASC 326 and records the allowance for credit losses as an offset to assets such as accounts receivable, etc., and the estimated credit losses charged to the allowance are classified as impairment loss on inventory, property, plant and equipment and other assets in the consolidated statements of operations and comprehensive income (loss). Lakeshore Group assesses collectability by reviewing receivables on a collective basis where similar characteristics exist. In determining the amount of the allowance for credit losses, Lakeshore Group considers historical collectability based on past due status, the age of the receivable balances, credit quality of customers based on ongoing credit evaluations, current economic conditions, reasonable and supportable forecasts of future economic conditions, and other factors that may affect Lakeshore Group’s ability to collect from customers. Bad debts are written off as incurred. Advance to Suppliers Advance to suppliers are advanced to vendors or suppliers for providing raw materials to Lakeshore Group. The suppliers usually require advance payments when Lakeshore Group orders materials and the advance will be utilized to offset Lakeshore Group’s actual payment obligations. These amounts are unsecured, non-interest bearing and generally short term in nature. Lakeshore Group will reduce its advance to suppliers by recording an allowance that approximates the extent of the advance that may not be realizable during the procurement process. Lakeshore Group recorded nil Inventories Inventories are stated at the lower of cost or net realizable value. Cost is determined on the weighted average basis and comprises all cost of purchase and other costs incurred in bringing the inventories to their present location and condition. Net realizable value is based on estimated selling prices less any estimated costs to be incurred to completion and disposal. Lakeshore Group reviews the carrying amounts of the inventories on a quarterly basis to determine if the inventories are carried at lower of cost or net realizable value. The net realizable value is estimated based on current market conditions and historical experience. Adjustments are recorded to write down the cost of inventory based on evaluation of, among other things, the expiration date of raw materials and the estimate of future usage, and the likelihood of receiving approval from the CDC (centers for food and drug control) to sell the finished goods. Write-downs are recorded as impairment loss on inventory in the consolidated statements of operations and comprehensive loss. Write-off of inventories during the production process due to damage or destruction are recorded in cost of revenues in the consolidated statements of operations and comprehensive loss. Property, Plant and Equipment Property, plant and equipment are stated at cost less accumulated depreciation and any impairment losses. The cost of property, plant and equipment comprises its purchase price and any directly attributable costs of bringing the asset to its working condition and location for its intended use. Expenditure incurred after items of property, plant and equipment have been put into operation, such as repairs and maintenance, are expensed when incurred. In situations where the recognition criteria are satisfied, the expenditure for a major reconstruction is capitalized as a replacement. Where significant parts of property, plant and equipment are required to be replaced at intervals, Lakeshore Group recognizes such parts as individual assets with specific useful lives and depreciates them accordingly. Depreciation is calculated on the straight-line basis to reduce the cost of each item of property, plant and equipment to its residual value over its estimated useful life. Category Estimated useful life Plant and building 6-20 years Machinery and equipment 5-10 years Furniture and fixtures 3-7 years Motor vehicle 4-5 years Leasehold improvement Lesser of the lease term or life of assets Where parts of an item of property, plant and equipment have different useful lives, the cost of that item is allocated on a reasonable basis among the parts and each part is depreciated separately. Residual values, useful lives and the depreciation method are reviewed, and adjusted if appropriate, at least at each quarter end. An item of property, plant and equipment including any significant part initially recognized is derecognized upon disposal or when no future economic benefits are expected from its use or disposal. Any gain or loss on disposal or retirement recognized in the statement of operations in the period the asset is derecognized is the difference between the net sales proceeds and the carrying amount of the relevant asset. Intangible assets Intangible assets acquired separately are measured at initial cost. The cost of intangible assets acquired in a business combination is the FV at the date of acquisition. The useful lives of intangible assets are assessed to be either finite or indefinite. Intangible assets with finite lives are amortized over the useful economic life and assessed for impairment whenever there is an indication that the intangible asset may be impaired. The amortization period and the amortization method for an intangible asset with a finite useful life is reviewed for appropriateness at each financial year end. Intangible assets with indefinite useful lives or not yet available for use are tested for impairment annually either individually or at the cash-generating unit level. Such intangible assets, including vaccine license and patent with indefinite useful lives, are not amortized. The useful life of an intangible asset with an indefinite life is reviewed annually to determine whether the indefinite life assessment continues to be supportable. If not, the change in the useful life assessment from indefinite to finite is accounted for on a prospective basis. Patents with definite useful lives are stated at cost less any impairment losses and are amortized on the straight-line basis over their estimated useful lives of 15 years. Software and laboratory information system are amortized on the straight-line basis over their estimated useful lives of 10 years. An intangible asset that is determined to have an indefinite useful life is not amortized until its useful life is determined to be no longer indefinite. Management evaluates the remaining useful life of an intangible asset that is not being amortized in each reporting period to determine whether events and circumstances continue to support an indefinite useful life. Indefinite-lived intangible assets are subject to impairment testing at least annually. Management believes that Lakeshore Group’s Drug Manufacturing License that was granted by the Liaoning Food and Drug Administration (“FDA”) is an intangible asset with an indefinite useful life because the certificate may be renewed indefinitely at little cost and has historically been renewed by Liaoning Yisheng. Liaoning Yisheng intends to renew the certificate indefinitely, and has the ability to do so. Cash flows from the certificate are expected to continue indefinitely. Therefore, the Drug Manufacturing License is not amortized until its estimated useful life is believed to be no longer indefinite. All research and development costs are expensed as incurred. Expenditure incurred on projects to develop new products is capitalized and deferred only when Lakeshore Group can demonstrate the technical feasibility of completing the intangible asset so that it will be available for use or sale, its intention to complete and its ability to use or sell the asset, how the asset will generate future economic benefits, the availability of resources to complete the project and the ability to measure reliably the expenditure during the development. Product development expenditures which do not meet these criteria are expensed when incurred. Land use rights: Land lease payments are amounts paid for the rights to use land in the PRC and are recorded net of accumulated amortization. Amortization is provided on a straight-line basis over the term of the lease agreement, which ranges from 48.75 to 50 years. Impairment of Long-lived Assets Lakeshore Group reviews long-lived assets, including definitive-lived intangible assets and property and equipment, for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. When such events occur, Lakeshore Group assesses the recoverability of the asset group based on the undiscounted future cash flows the asset group is expected to generate and recognizes an impairment loss when estimated undiscounted future cash flows expected to result from the use of the asset group plus net proceeds expected from disposition of the asset group, if any, is less than the carrying value of the asset group. If Lakeshore Group identifies an impairment, Lakeshore Group reduces the carrying amount of the asset group to its estimated FV based on a discounted cash flow approach or, when available and appropriate, to comparable market values and the impairment loss, if any, is recognized as impairment loss in the consolidated statements of operations. Lakeshore Group uses estimates and judgments in its impairment tests and if different estimates or judgments had been utilized, the timing or the amount of any impairment charges could be different. Asset groups to be disposed of would be reported at the lower of the carrying amount or FV less costs to sell, and they are no longer depreciated. Impairment was recorded in impairment loss on inventory, property, plant and equipment and other assets on the consolidated statements of operations and comprehensive loss. Concentrations of Credit Risk and Significant Suppliers Financial instruments that potentially subject Lakeshore Group to concentration of credit risk consist of cash. Lakeshore Group mitigates this risk by maintaining its cash with high quality, accredited financial institutions. As of March 31, 2024, Lakeshore Group’s cash was deposited at more than two financial institutions and it did not have any foreign currency exchange contracts, option contracts or other hedging arrangements. Lakeshore Group has not experienced any losses on its deposits of cash and does not believe that it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships. Lakeshore Group’s sales are made primarily to Centers for Disease Control and Prevention (“CDCs”) in China. Lakeshore Group does not have a concentration of its revenue and accounts receivable with specific customers. As of March 31, 2024 and 2023, there was no customer which accounted for more than 10% of Lakeshore Group’s accounts receivable balance. During the years ended March 31, 2024, 2023 and 2022, there were no customers that accounted for more than 10% of Lakeshore Group’s net revenues. Details of Lakeshore Group’s top 5 vendors accounting for total purchases are as follows: Year Ended March 31, 2024 (RMB) (US$) Vendor D 36,567,150 $ 5,153,932 20.2 % Vendor I 19,635,180 2,767,467 10.8 % Vendor C 13,260,918 1,869,051 7.3 % Vendor J 10,090,875 1,422,252 5.6 % Vendor G 9,544,080 1,345,184 5.3 % Total 89,098,203 $ 12,557,886 49.2 % Year Ended March 31, 2023 (RMB) (US$) Vendor A 48,006,500 $ 6,986,117 37.9 % Vendor F 15,178,020 2,208,772 12.0 % Vendor G 10,053,600 1,463,044 7.9 % Vendor H 6,846,214 996,291 5.4 % Vendor C 4,746,530 690,736 3.7 % Total 84,830,864 $ 12,344,960 66.9 % Year Ended March 31, 2022 (RMB) (US$) Vendor A 35,172,250 $ 5,540,508 20.9 % Vendor B 16,227,146 2,556,181 9.6 % Vendor C 9,995,189 1,574,492 5.9 % Vendor D 7,426,500 1,169,859 4.4 % Vendor E 6,621,300 1,043,020 3.9 % Total 75,442,385 $ 11,884,060 44.7 % Details of Lakeshore Group’s key vendors accounting for accounts payable are as follows: As of March 31, 2024 (RMB) (US$) Vendor D 3,408,375 480,391 5.0 % Total 3,408,375 $ 480,391 5.0 % As of March 31, 2023 (RMB) (US$) Vendor A 3,220,000 $ 468,589 4.0 % Vendor F 420 61 0.0 % Vendor H 16,118 2,346 0.0 % Total 3,236,538 $ 470,996 4.0 % Lakeshore Group’s business operation has been, and may continue to be, negatively affected by the outbreak of COVID-19. While many of the restrictions on movements within China have been relaxed, there is great uncertainty around the future of the COVID-19 outbreak and how it will impact Lakeshore Group’s operations. If the outbreak persists or escalates, Lakeshore Group may be subject to further negative impact on business operations and financial condition. Fair Value Measurements ASC 825- 10 requires certain disclosures regarding the FV of financial instruments. FV is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. A three-level FV hierarchy prioritizes the inputs used to measure FV. The hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure FV are as follows: ● Level 1 - inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets. ● Level 2 - inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, quoted market prices for identical or similar assets in markets that are not active, inputs other than quoted prices that are observable and inputs derived from or corroborated by observable market data. ● Level 3 - inputs to the valuation methodology are unobservable. Unless otherwise disclosed, the FV of Lakeshore Group’s financial instruments including cash, restricted cash, accounts receivable, advance to suppliers, prepaid expenses and other current assets, short-term bank loans and other borrowings, accounts payable, warrant liability, and accrued expenses and other current liabilities approximate their recorded values due to their short-term maturities. The FV of longer-term leases approximates their recorded values as their stated interest rates approximate the rates currently available. Lakeshore Group’s non-financial assets, such as property and equipment would be measured at FV only if they were determined to be impaired. Social Security Insurance Employees of Lakeshore Group’s subsidiaries that operate in the PRC are required to participate in a pension scheme operated by the local municipal government. According to the Social Insurance Law of the PRC (the “Social Security Insurance Law”) promulgated by the Standing Committee of the National People’s Congress (the “Standing Committee”) that became effective on December 29, 2018, there are five basic types of social security insurance, which include: basic pension, basic medical, unemployment, work-related injury and maternity insurance (collectively known as “social security insurance”). Both employees and employers make contributions for the first three kinds of social security insurance; and only employers make contributions for the latter two kinds, which means the employers must pay all or a portion of the social security insurance premiums for their employees. If the Lakeshore Group does not fully comply with the relevant requirements and does not make social insurance contributions in full to the social insurance scheme for the employees of PRC affiliated entities, the Lakeshore Group will be required to make up the social insurance contributions as well as to pay late fees at 0.05% per day of the outstanding amount from the due date. If the Lakeshore Group fails to make up for the shortfalls within the prescribed time limit, the relevant administrative authorities could impose a fine of one to three times the outstanding amount and file applications to competent courts for compulsory enforcement of payment and deposit. No fine or compulsory enforcement had been imposed by relevant authorities in connection with the delayed payment of the social security insurance premiums by the Lakeshore Group. As of March 31, 2024, 2023 and 2022, Lakeshore Group’s recorded late fees of RMB10.7 million, RMB9.9 million and RMB9.5 million, respectively, for its liabilities related to social security insurance. Leases Under ASC Topic 842, Leases (“ASC 842”), Lakeshore Group determines if an arrangement is or contains a lease at inception. For leases with a term of 12 months or less, Lakeshore Group does not recognize a right-of-use (“ROU”) asset or lease liability. Lakeshore Group’s operating leases are recognized on its consolidated balance sheets as noncurrent assets, current liabilities and noncurrent liabilities. Lakeshore Group does not have any finance leases. ROU assets are Lakeshore Group’s right to use an underlying asset for the lease term and lease liabilities represent Lakeshore Group’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. As Lakeshore Group’s leases typically do not provide an implicit rate, Lakeshore Group uses an estimate of its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. The lease terms may include options to extend or terminate the lease when it is reasonably certain that Lakeshore Group will exercise that option. Lease expense is recognized on a straight-line basis over the lease term. For leases with terms greater than 12 months, Lakeshore Group records the related asset and lease liability at the present value of lease payments over the lease term. For leases with terms less than 12 months, Lakeshore Group records rents in administrative expenses. Government Grants Government grants are primarily subsidies received from PRC governments for operating a business in their jurisdictions and in compliance with specific policies promoted by the government authorities. Lakeshore Group’s PRC-based subsidiaries received specific subsidies and other subsidies from certain local governments. Specific subsidies are subsidies the local government has set certain conditions for the subsidies. Other subsidies are subsidies the local government has not set any conditions and are not tied to future trends or performance of Lakeshore Group, receipt of such subsidy is not contingent upon any further actions or performance of Lakeshore Group and the amounts do not have to be refunded under any circumstances. Specific subsidies are recorded as deferred government grants upon receipt and are recognized as government grants recognized in income when the conditions are met. Other subsidies are recognized as other income upon receipt as further performance by Lakeshore Group is not required. Government grants for research and development (“R&D”) are recognized as a reduction to R&D expenses when the conditions attached to the grants are met or recognized as government grants recognized in income in the period when the conditions are met after the expenses are incurred. Government grants for property, plant and equipment are deferred and recognized as a reduction to the related depreciation and amortization expenses in the same manner as the property, plant and equipment are depreciated. Warrants Lakeshore Group accounts for warrants as either equity-method or liability-method instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in ASC 480 and ASC 815. Warrants recorded as equity are recorded at their relative FV determined at the issuance date and remeasurement is not required. Warrants recorded as liabilities are recorded at their FV, within warrant liabilities on the consolidated balance sheets and are remeasured on each reporting date with changes recorded in FV changes of warrant liabilities on the consolidated statements of operations and comprehensive loss. Upon the consummation of the Business Combination, each Summit Warrant outstanding immediately prior had ceased to be a warrant with respect to Summit Public Shares and was assumed by Lakeshore Biopharma and converted into a Lakeshore Biopharma Warrant entitling the holder thereof to purchase such number of Ordinary Share on a one-on-one basis. After the merger with Summit, the Company accounted for the 10,750,000 public warrants as equity and 6,000,000 private warrants as liabilities. Revenue from Contracts with Customers Lakeshore Group follows ASC 606 - “Revenue from Contracts with Customers” for all periods presented. ASC 606 established principles for reporting information about the nature, amount, timing, and uncertainty of revenue and cash flows arising from our contracts to provide services to customers. Based on the following five steps analysis, revenues from contracts with customers are recognized when control of the promised goods or services is transferred to the customers, in an amount that reflects the consideration Lakeshore Group expects to be entitled in exchange for those goods or services. Step 1: Identify the contract with the customer; Step 2: Identify the performance obligations in the contract; Step 3: Determine the transaction price; Step 4: Allocate the transaction price to the performance obligations in the contract; and Step 5: Recognize revenue when Lakeshore Group satisfies a performance obligation Lakeshore Group is principally engaged in the research, development, manufacturing and sale of vaccines and therapeutic biologics. Lakeshore Group’s revenues primarily streams from the sales of vaccines. The core principle underlying the revenue recognition in ASC 606 is that Lakeshore Group recognizes revenue for the transfer of vaccines to customers in an amount that reflects the consideration to which Lakeshore Group expects to be entitled. This requires Lakeshore Group to identify contractual performance obligations and determine whether revenue should be recognized at a point in time or over time. Lakeshore Group’s sales contracts of vaccines have one performance obligation that is to sell vaccines to the customers. The sales contracts with customers do not involve variable considerations, such as discounts and rebates. And according to the historical operation, discounts and rebates have never occurred. The customer pays after acceptance of the vaccines. According to ASC 606, the relevant revenue recognition is based on customer acceptance confirmation. In accordance with ASC606-10-55-36 through 55-40, Lakeshore Group evaluates whether it is appropriate to record the gross amount of vaccines and related costs or the net amount earned as commissions. When the entity is a principal, that the entity obtains control of the specified goods or services before they are transferred to the customers, the revenues should be recognized in the gross amount of consideration to which it expects to be entitled in exchange for the specified goods or services transferred. When the entity is an agent and its obligation is to facilitate third parties in fulfilling their performance obligation for specified goods or services, the revenues should be recognized in the net amount for the amount of commission which the entity earns in exchange for arranging for the specified goods or services to be provided by other parties. Revenues are recorded net of value-added taxes. Lakeshore Group sells vaccines to the customers, and it obtains control of the vaccines before customer acceptance confirmation. Therefore, Lakeshore Group is a principal, and the revenues should be recognized according to the gross method. Cost of Revenues Cost of revenues consists primarily of the cost of merchandise sold and write-down of inventories during the production process due to damage or destruction General and Administrative Expenses General and administrative expenses consist mainly of payroll and related costs for employees involved in general corporate functions, including accounting, finance, tax, legal and human resources, professional fees, value-added taxes and other general corporate expenses as well as costs associated with the use by these functions of facilities and equipment, such as depreciation and rental expenses. Selling and Marketing Expenses Selling and marketing expenses consist mainly of payroll and benefits for employees involved in the sales and distribution functions, meeting/event fees, promotion fees, marketing and selling expenses that are related to events and activities at Lakeshore Group’s service centers designed to promote product sales as well as operating expenses related to the service centers. Research and Development Expenses Research and development expenses include costs directly attributable to the conduct of research and development projects, primarily consist of salaries and other employee benefits, testing and clinical trial expenses, consulting service fees, depreciation and amortization, and office and leasing expenses. All costs associated with research and development are expensed as incurred. Other Income (Expenses Other income (expenses) consists of miscellaneous income and expenses not directly related to Lakeshore Group’s core business operations. Other income primarily consists of recovery of previously written-off accounts receivable, and write-off of payment obligations that are either more than three years old or no longer justifiable. Other expenses primarily consist of late fees related to Lakeshore Group’s income tax and social security insurance payment obligations, charitable donation, medical waste disposal fee and financial expenses. From December 2013 to June 2019, because Lakeshore Group was undergoing the construction and certification process of new manufacturing plant, Lakeshore Group didn’t produce and market its rabies vaccine and did not pay any income taxes nor social security insurance for its employees. It accounts for late fees as disclosed in the statements of operations. Income Taxes Cayman Islands. Hong K

Accounts Receivable, Net

Accounts Receivable, Net	12 Months Ended
	Mar. 31, 2024
Accounts Receivable, Net [Abstract]
ACCOUNTS RECEIVABLE, NET	NOTE 4 – ACCOUNTS RECEIVABLE, NET Accounts receivable, net are as follows: As of March 31, 2023 2024 2024 (RMB) (RMB) (US$) Trade receivables 487,418,616 473,515,321 $ 66,739,298 Allowance for expected credit losses (24,366,824 ) (29,354,030 ) (4,137,284 ) Accounts receivable, net 463,051,792 444,161,291 $ 62,602,014 The allowance for expected credit losses reflects Lakeshore Group’s best estimate of probable losses inherent in the accounts receivable balance. In determining the amount of the allowance for credit losses, Lakeshore Group considers historical collectability based on past due status, the age of the receivable balances, credit quality of customers based on ongoing credit evaluations, current economic conditions, reasonable and supportable forecasts of future economic conditions, and other factors that may affect Lakeshore Group’s ability to collect from customers. Bad debts are written off as incurred. During the years ended March 31, 2022, 2023 and 2024, no Lakeshore Group’s accounts receivable had been written off. Below is an analysis of the movements in the allowance for expected credit losses: Year Ended March 31, 2022 2023 2024 2024 (RMB) (RMB) (RMB) (US$) Balance at beginning of the year 8,530,951 13,615,875 24,366,824 $ 3,434,366 Additions 5,084,924 10,750,949 4,987,206 702,918 Balance at end of the year 13,615,875 24,366,824 29,354,030 $ 4,137,284

Inventories, Net

Inventories, Net	12 Months Ended
	Mar. 31, 2024
Inventories, Net [Abstract]
INVENTORIES, NET	NOTE 5 – INVENTORIES, NET Lakeshore Group’s inventories consist of the following: As of March 31, 2023 2024 2024 (RMB) (RMB) (US$) Raw materials 50,453,180 68,613,919 $ 9,670,743 Work in progress 61,275,177 49,083,445 6,918,033 Finished goods 78,432,041 153,879,476 21,688,439 Allowance for damaged inventories (4,779,446 ) (68,154,238 ) (9,605,953 ) Inventories, net 185,380,952 203,422,602 $ 28,671,262 The movement in the allowance for damaged inventories is as follows: Year Ended March 31, 2022 2023 2024 2024 (RMB) (RMB) (RMB) (US$) Balance at beginning of the year 41,301,797 5,503,029 4,779,446 $ 673,636 Additions 4,393,629 3,670,046 68,221,016 9,615,365 Inventories written off (40,192,397 ) (4,393,629 ) (4,846,224 ) (683,048 ) Balance at end of the year 5,503,029 4,779,446 68,154,238 $ 9,605,953

Property, Plant and Equipment,

Property, Plant and Equipment, Net	12 Months Ended
	Mar. 31, 2024
Property, Plant and Equipment, Net [Abstract]
PROPERTY, PLANT AND EQUIPMENT, NET	NOTE 6 – PROPERTY, PLANT AND EQUIPMENT, NET Property, plant and equipment consists of the following: As of March 31, 2023 2024 2024 (RMB) (RMB) (US$) Cost Construction in progress 309,948,621 255,113,837 $ 35,956,848 Plant and buildings 178,756,490 217,248,236 30,619,906 Machinery and equipment 237,637,928 255,507,522 36,012,336 Electronic equipment 11,117,440 10,335,481 1,456,727 Motor vehicles 3,031,087 3,081,506 434,321 Office equipment and furniture 34,423,995 42,870,071 6,042,294 Leasehold improvements 5,597,019 4,862,781 685,381 Total Cost 780,512,580 789,019,434 111,207,813 Less: accumulated depreciation (178,864,241 ) (205,542,536 ) (28,970,054 ) Less: asset impairment (29,891,896 ) (110,128,892 ) (15,522,043 ) Property and equipment, net 571,756,443 473,348,006 $ 66,715,716 In fiscal 2014, based on an evaluation of the Company’s related production plan and the conditions of its property, plant and equipment, the Company recorded an asset impairment of approximately RMB29.9 million on property, plant and equipment that could no longer be used for production. In fiscal 2024, based on an evaluation of the Company’s production facilities for PIKA recombinant protein COVID-19 vaccine, the Company recorded an asset impairment of approximately RMB80.2 million (US$11.3 million) on the related property, plant and equipment that could no longer be used for other vaccine production.

Prepaid Expenses and Other Curr

Prepaid Expenses and Other Current Assets, Net	12 Months Ended
	Mar. 31, 2024
Prepaid Expenses and Other Current Assets, Net [Abstract]
PREPAID EXPENSES AND OTHER CURRENT ASSETS, NET	NOTE 7 – PREPAID EXPENSES AND OTHER CURRENT ASSETS, NET Prepaid expenses and other current asset, net consist of the following: As of March 31, 2023 2024 2024 (RMB) (RMB) (US$) Deposits (1) 4,339,791 4,043,044 $ 569,844 Staff advances (2) 606,859 174,810 24,638 Staff’s social security (3) 252,090 158,872 22,392 Value added tax recoverable (4) 4,249,718 1,598,117 225,246 Clinical trial insurance (5) 178,699 - - Other receivables (6) 901,355 1,395,246 196,652 Allowance (7) (115,743 ) - - Total 10,412,769 7,370,089 $ 1,038,772 (1) Deposits primarily are to Centers for Disease Control and Prevention (“CDCs”) in connection with participation in the public tender process held by province-level CDCs. (2) Staff advances primarily are paid to employees in advance of their expected business travel or in connection with various expenses incurred in the ordinary course of business, such as sales and marketing activities. (3) Staff social security primarily is the portion of the government mandated defined contribution plan that should be made by employees. But this portion should be paid to the government by Lakeshore Group on behalf of the employees pursuant to PRC labor regulation. When Lakeshore Group pays wages to employees, this portion should be deducted accordingly. (4) Value-added taxes (“VAT”) includes input tax on purchase and output tax on sales. VAT collected from customers relating to product sales and remitted to governmental authorities is presented on a net basis, and it is excluded from revenue. Lakeshore Group is in a net VAT recoverable position when its input tax on purchase in the current year is greater than the output tax on sales. Such net amount can be deducted in the following years. (5) Clinical trial insurance is for human clinical trial legal liability insurance for evaluating the safety, immunogenicity and preliminary efficacy of multiple ascending doses of PIKA recombinant protein COID-19 Vaccine in the treatment of adult patients with mild to moderate COVID-19 infection. (6) Other receivables primarily consist of prepayment to third parties, such as freight, water and electricity, and promotion fees. (7) The allowance reflects Lakeshore Group’s best estimate of probable amounts not fully recoverable from the other receivables balance. Due to the fact that some employees resigned and lost contact, the cash paid to them in advance of their expected business travel or in connection with various expense incurred in the ordinary course of business might not be recovered.

Intangible Assets, Net

Intangible Assets, Net	12 Months Ended
	Mar. 31, 2024
Intangible Assets, Net [Abstract]
INTANGIBLE ASSETS, NET	NOTE 8 – INTANGIBLE ASSETS, NET Lakeshore Group’s intangible assets are presented below: As of March 31, 2023 2024 2024 (RMB) (RMB) (US$) Cost Patents 79,608,000 79,608,000 $ 11,220,296 Licenses, software and laboratory information system 10,435,478 10,435,478 1,470,821 Land use rights 67,181,860 67,181,860 9,468,902 Total Cost 157,225,338 157,225,338 22,160,019 Less: Accumulated Amortization (79,168,546 ) (85,980,002 ) (12,118,393 ) Intangible Assets, net 78,056,792 71,245,336 $ 10,041,626

Bank Loans and Other Borrowings

Bank Loans and Other Borrowings	12 Months Ended
	Mar. 31, 2024
Bank Loans and Other Borrowings [Abstract]
BANK LOANS AND OTHER BORROWINGS	NOTE 9 – BANK LOANS AND OTHER BORROWINGS As of March 31, Maturity Interest 2023 2024 2024 Date Rate (RMB) (RMB) (US$) China Guangfa Bank Co., Ltd. - Shenyang Branch (1) 41,191,031 18,357,574 $ 2,587,396 2024/9/1-2024/9/10 4.50 % Shanghai Pudong Development Bank Co., Ltd. Shenyang Branch (2) 82,964,518 44,983,415 6,340,157 2024/4/12-2025/3/21 4.00 % China CITIC Bank Shenyang Tiexi Branch (3) 23,596,350 12,388,064 1,746,027 2024/5/29 4.75%-5.00 % China CITIC Bank Shenyang Tiexi Branch (4) 5,000,000 - - 2023/5/25-2023/7/17 3.25 % China Construction Bank Shenyang Heping Branch (5) 31,330,000 38,990,000 5,495,419 2024/7/24-2024/12/6 4.00 % China Construction Bank Shenyang Heping Branch (6) 988,000 712,400 100,409 2024/7/19 3.90 % Zhongguancun Technology Leasing Co., Ltd (7) 8,666,664 8,666,664 1,221,517 2025/11/7 5.00 % China CITIC Bank Shenyang Tiexi Branch (8) - 1,400,000 197,322 2024/5/15-2024/11/15 4.55 % China CITIC Bank Shenyang Tiexi Branch (9) - 900,000 126,850 2024/7/8-2025/1/18 4.55 % China CITIC Bank Shenyang Tiexi Branch (10) - 880,000 124,031 2024/7/18-2025/1/18 4.55 % Industrial Bank Shenyang Branch (11) - 29,776,670 4,196,853 2024/8/15-2024/9/17 4.00 % R-Bridge Healthcare Fund, LP (12) - 118,354,060 16,681,333 2026/9/15 4.00 % Minsheng Bank Shenyang Huanghe Street Branch (13) - 29,990,032 4,226,925 2024/7/7-2025/1/16 4.00 % CITIC Financial Leasing Co., Ltd (15) - 13,141,853 1,852,270 2026/5/29 4.80 % Bank loans due within one year 193,736,563 318,540,732 $ 44,896,509 R-Bridge Healthcare Fund, LP (12) 274,868,000 - - 2026/9/15 4.00 % China Construction Bank Shenyang Heping Branch (5) 4,430,000 4,820,000 679,352 2025/10/15-2025/11/14 4.00 % Zhongguancun Technology Leasing Co., Ltd (7) 14,492,596 5,777,784 814,346 2025/11/7 5.00 % Shanghai Pudong Development Bank Co., Ltd. Shenyang Branch (2) - 38,428,802 5,416,322 2025/4/12-2025/11/7 4.00 % China CITIC Bank Shenyang Tiexi Branch (8) - 5,503,290 775,658 2025/5/15-2025/11/15 4.55 % China CITIC Bank Shenyang Tiexi Branch (9) - 3,618,982 510,075 2025/7/8-2026/1/18 4.55 % China CITIC Bank Shenyang Tiexi Branch (10) - 3,503,099 493,742 2025/7/18-2026/1/18 4.55 % Industrial Bank Shenyang Branch (14) - 19,993,041 2,817,906 2026/7/31-2026/9/3 4.25 % CITIC Financial Leasing Co., Ltd (15) - 17,338,782 2,443,801 2026/5/29 4.80 % Long-term bank loans 293,790,596 98,983,780 $ 13,951,202 Total bank loans 487,527,159 417,524,512 $ 58,847,711 (1) On September 13, 2021, Lakeshore Group entered into a credit facility of RMB100.0 million with China Guangfa Bank Co., Ltd. Shenyang Branch for three years to finance its working capital requirements. Lakeshore Group drew RMB35.8 million from June 19, 2023 to August 24, 2023, with interest at 5.66%, which was due from December 16, 2023 to March 12, 2024. The Company drew RMB 18.4 million from November 21, 2023 to March 1, 2024, with interest at 4.50%, which is due from September 1, 2024 to September 10, 2024. From June 2, 2023 to January 2, 2024, Lakeshore Group repaid RMB77.0 million. As of March 31, 2024, the balance of RMB18.4 million (US$2.6 million) was outstanding. (2) On July 12, 2021, Lakeshore Group entered into a credit facility of RMB140.0 million with Shanghai Pudong Development Bank Co., Ltd. Shenyang Branch for three years to finance its working capital requirements. Lakeshore Group drew RMB6.7 million on April 28, 2023 with interest at 5.30%, which was due on December 23, 2023, and drew RMB85.0 million from September 27, 2023 to February 28, 2024, of which RMB46.6 million is due from March 21, 2024 to March 21, 2025 and RMB38.4 million is due from April 12, 2025 to November 7, 2025. From April 4, 2023 to March 21, 2024, Lakeshore Group repaid RMB91.3 million. As of March 31, 2024, the balance of RMB83.4 million (US$11.8 million) is outstanding, of which RMB45.0 million (US$6.3 million) is due within one year. In April, 2024, RMB3.4 million (US$0.5 million) was repaid. (3) On January 13, 2023, Lakeshore Group entered into a credit facility of RMB40.0 million with China CITIC Bank Shenyang Tiexi Branch, due on November 1, 2025, to finance its working capital requirements. Lakeshore Group drew RMB12.8 million from May 24, 2023 to July 11, 2023 with interest at 5.00%, which was due from February 6, 2024 to May 29, 2024, and drew RMB3.55 million from July 17, 2023 to July 18,2023, with interest at 4.75%, which is due on May 29, 2024. From October 13, 2023 to February 19, 2024, Lakeshore Group repaid RMB27.6 million. As of March 31, 2024, the balance of RMB12.4 million (US$1.7 million) is outstanding. On May 29, 2024, RMB12.4 million (US$1.7 million) was repaid. (4) On May 6, 2022, China CITIC Bank Shenyang Tiexi Branch issued one letter of credit of RMB5.0 million to Lakeshore Group with interest at 3.25%. As of March 31, 2024, Lakeshore Group repaid it. (5) From September 9, 2022 to November 25, 2022, Lakeshore Group borrowed RMB31.3 million in total with interest at 4.00% from China Construction Bank Shenyang Heping Branch for one year. The loan was due from September 8, 2023 to November 24, 2023. From March 17, 2023 to November 15, 2023, Lakeshore Group borrowed RMB43.8 million with interest at 4.00% from China Construction Bank Shenyang Heping Branch. The loan will be due from July 24, 2024 to November 14, 2025. From June 5, 2023 to October 8, 2023, Lakeshore Group repaid RMB31.3 million. As of March 31, 2024, the balance of RMB43.8 million (US$6.2 million) is outstanding, of which RMB 39.0 million (US$5.5 million) is due within one year. On July 29, 2024, Lakeshore Group repaid RMB3.1 million (US$0.4 million). (6) On January 16, 2023, Lakeshore Group borrowed RMB988,000 with interest at 3.90% from China Construction Bank Shenyang Heping Branch for one year. On July 20, 2023, Lakeshore Group borrowed RMB712,400 with interest at 3.90% from China Construction Bank Shenyang Heping Branch for one year. On December 8, 2023, Lakeshore Group repaid RMB988,000. The balance of RMB0.7 million (US$0.1 million) as of March 31, 2024 was repaid on July 18, 2024. (7) On November 8, 2022, Lakeshore Group borrowed RMB26.0 million with interest at 5.00% from Zhongguancun Technology Leasing Co., Ltd for 36 months. Lakeshore Group shall repay RMB722,222 monthly from December 15, 2022 to October 15, 2025 and pay the last repayment of RMB722,230 on November 7, 2025. Lakeshore Group repaid RMB2.9 million from December 2022 to March 2023 and 8.7 million from April 2023 to March 2024. As of March 31, 2024, the balance of RMB14.4 million (US$2.0 million) is outstanding, of which RMB8.7 million (US$1.2 million) is due within one year. (8) On November 15, 2023, Lakeshore Group borrowed RMB6.9 million from China CITIC Bank Shenyang Tiexi Branch to finance working capital requirements, with interest at 4.55%. This loan will mature on November 15, 2025. As of March 31, 2024, the balance of RMB6.9 million (US$1.0 million) is outstanding, of which RMB1.4 million (US$0.2 million) is due within one year. In May 2024, RMB0.7 million (US$0.1 million) was repaid. (9) On January 8, 2024, Lakeshore Group borrowed RMB4.5 million with interest at 4.55% from China CITIC Bank Shenyang Tiexi Branch to finance working capital requirements. The loan will be due from July 8, 2024 to January 8, 2026. As of March 31, 2024, the balance of RMB4.5 million (US$0.6 million) is outstanding, of which RMB0.9 million (US$0.1 million) is due within one year. On July 4, 2024, RMB0.5 million (US$0.1 million) was repaid. (10) On January 18, 2024, Lakeshore Group borrowed RMB4.4 million with interest at 4.55% from China CITIC Bank Shenyang Tiexi Branch to finance working capital requirements. The loan will be due from July 18, 2024 to January 18, 2026. As of March 31, 2024, the balance of RMB4.4 million (US$0.6 million) is outstanding, of which RMB0.9 million (US$0.1 million) is due within one year. On July 17, 2024, RMB0.4 million (US$0.1 million) was repaid. (11) From August 16, 2023 to September 18, 2023, Lakeshore Group borrowed RMB29.8 million with interest at 4.00% from Industrial Bank Shenyang Branch for one year. The loan will be due from August 15, 2024 to September 17, 2024. As of March 31, 2024, the balance of RMB29.8 million (US$4.2 million) is outstanding. (12) On March 16, 2022, Lakeshore Group entered into a facility agreement with R-Bridge Healthcare Fund, LP (“R-Bridge”), as agent, to finance RMB274,868,000 (US$40,000,000) for 54 months with interest at 4.00%. On December 27, 2023, HK Yisheng received a letter from R-Bridge (the “R-Bridge Letter”), notifying the Company that it has reason to believe HK Yisheng defaulted under financial covenants and other obligations under the facility agreement, and under the instructions of the lenders to urge the Company to consider and reach an amicable solution with the lenders, including, without limitation, repaying the loan of $40.0 million in full, as soon as possible. The Company repaid $15.0 million, $10.0 million and $18.1 million respectively in February, March and April, 2024. As of April 29, 2024, the Company repaid its full amount of $40.0 million and accrued interest of $3.1 million. (13) From July 7, 2023 to January 16, 2024, Lakeshore Group borrowed RMB30.0 million with interest at 4.0% from Minsheng Bank Shenyang Huanghe Street Branch, due from July 7, 2024 to January 16, 2025. As of March 31, 2024, the balance of RMB30.0 million (US$4.2 million) is outstanding. In July, 2024, RMB11.3 million (US$1.6 million) was repaid. (14) From August 14, 2023 to September 14, 2023, Lakeshore Group borrowed RMB20.0 million with interest at 4.25% from Industrial Bank Shenyang Branch for about three years. The loan will be due from July 31, 2026 to September 3, 2026. As of March 31, 2024, the balance of RMB20.0 million (US$2.8 million) is outstanding. (15) On May 29, 2023, Lakeshore Group borrowed RMB40.0 million with interest at 4.80% from CITIC Financial Leasing Co., Ltd for three years. The loan will be due on May 29, 2026. From August 15, 2023 to February 18, 2024, Lakeshore Group repaid RMB9.5 million. As of March 31, 2024, the balance of RMB30.5 million (US$4.3 million) is outstanding, of which RMB13.1 million (US$1.9 million) is due within one year. Lakeshore Group recorded RMB47.5 million, RMB32.0 million and RMB2.8 million of interest expense for the years ended March 31, 2024, 2023 and 2022, respectively.

Leases

Leases	12 Months Ended
	Mar. 31, 2024
Leases [Abstract]
LEASES	NOTE 10 – LEASES A summary of Lakeshore Group’s operating leases as of March 31, 2024 and 2023 is as follows: As of March 31, 2023 2024 2024 (RMB) (RMB) (US$) Operating lease ROU assets 11,132,428 7,275,367 $ 1,025,422 Operating lease liabilities – current 4,753,547 5,156,540 $ 726,785 Operating lease liabilities – non-current 6,348,890 1,783,593 $ 251,387 Weighted average remaining lease term 2.5 1.5 1.5 Weighted average discount rate 4.7 % 4.8 % 4.8 % A summary of lease cost recognized in Lakeshore Group’s CFS and supplemental cash flow information related to operating leases is as follows: Years Ended March 31, 2022 2023 2024 2024 (RMB) (RMB) (RMB) (US$) Operating lease cost 4,594,967 5,002,684 5,252,026 $ 740,243 Cash paid for operating leases 4,587,894 3,349,856 5,272,746 $ 743,164 A summary of maturity of operating lease liabilities under the Lakeshore Group’s non-cancelable operating leases as of March 31, 2024 is as follows: Year Ended March 31, (RMB) (US$) 2025 5,386,340 $ 759,174 2026 1,813,582 255,614 Total lease payments 7,199,922 1,014,788 Less: Interest (259,789 ) (36,616 ) Present value of operating lease liabilities 6,940,133 $ 978,172

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	12 Months Ended
	Mar. 31, 2024
Accrued Expenses and Other Current Liabilities [Abstract]
ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES	NOTE 11 – ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES Accrued expenses and other current liabilities consist of the following: As of March 31, 2023 2024 2024 (RMB) (RMB) (US$) Salaries and social security insurance (1) 55,188,497 59,297,454 $ 8,357,640 Promotion service fee (2) 87,567,459 114,508,487 16,139,322 Taxes other than income tax 379,595 3,012,548 424,602 Late fees (3) 9,927,056 10,683,258 1,505,745 Payable for property, plant and equipment 47,579,463 20,413,798 2,877,209 CDC transportation and storage fee 49,976,200 53,515,233 7,542,668 Guarantee deposits (4) 108,795,884 119,313,398 16,816,547 Professional service fee (5) 5,121,970 7,346,813 1,035,492 Interest payable (6) 6,055,245 9,909,655 1,396,710 Other (7) 6,945,275 10,737,325 1,513,366 Total 377,536,644 408,737,969 $ 57,609,301 (1) This includes unpaid salaries and outstanding social security insurance. During fiscal 2023, Lakeshore Group paid approximately RMB2.3 million to reduce its payable for salaries and social security insurance. During fiscal 2024, Lakeshore Group paid approximately RMB14.6 million to reduce its payable for salaries and social security insurance. Salaries and social security insurance payables consist of the following: As of March 31, 2023 2024 2024 (RMB) (RMB) (US$) Salaries 47,390,831 51,990,629 $ 7,327,784 Social security insurance 7,179,828 6,656,034 938,130 Union Fee 617,838 650,791 91,726 Total 55,188,497 59,297,454 $ 8,357,640 (2) Promotion service fee primarily represents fees for the vaccine promotion, including design and implementation of academic activities, and collection of market information. (3) Late fees primarily are for corporate income tax, taxes other than income tax and social security insurance and housing reserve fund contributions due to the fact Lakeshore Group failed to pay income tax for calendar 2011 to calendar 2013, taxes other than income tax for calendar 2014 to the beginning of calendar 2021 and social security insurance for calendar 2015 to the beginning of calendar 2021. As of June, 2021, Lakeshore Group has paid the unpaid taxes, including income tax and other taxes other than income tax, as well as the late fees charge of them. From fiscal 2022, the late fee is incurred for unpaid social insurance. (4) Guarantee deposits primarily are refundable deposits paid to Lakeshore Group by external service providers to guarantee the external service providers will provide us with high quality and reasonable professional services. The external service providers’ professional service scope includes conducting market research and analysis, monitoring product clinical information, collecting and reporting adverse events of the product use, providing academic visits and education seminars, assisting product shipment and payment collections. Their services don’t assume inventory risk for the vaccines before they are transferred to the end customers. (5) Professional service fees primarily are from consultants and other advisors. (6) Interest payable primarily includes interest and royalties payable to R-Bridge Healthcare Fund, LP. (7) Others primarily are employees’ reimbursement and value added tax.

Warrants

Warrants	12 Months Ended
	Mar. 31, 2024
Warrants [Abstract]
WARRANTS	NOTE 12 – WARRANTS As of March 31, 2024, Lakeshore Group has 10,750,000 public warrants and 6,000,000 private warrants. Lakeshore Group accounts for its outstanding warrants in accordance with ASC 815-40-15-7D and 7F. Management determined the private warrants do not meet the criteria for equity treatment and must be recorded as liabilities. Accordingly, Lakeshore Group classifies the private warrants as liabilities at their FV and adjusts the private warrants to FV at each reporting period. Management further determined that its public warrants qualify for equity treatment. Warrant liability is subject to re-measurement at each balance sheet date until exercised, and any change in FV is recognized in statements of operations. The private warrants are valued using a Binomial Option Pricing Model. Upon the consummation of the business combination, each Summit Warrant outstanding immediately prior ceased to be a warrant with respect to Summit Public Shares and was assumed by Lakeshore Biopharma and converted into a Lakeshore Biopharma Warrant entitling the holder thereof to purchase such number of Ordinary Share on a one-on-one basis. Each Lakeshore Biopharma Warrant will otherwise continue to have and be subject to substantially the same terms and conditions as were applicable to such Summit Warrant immediately prior to the consummation of the Business Combination (including any repurchase rights and cashless exercise provisions). Upon the consummation of the Business Combination with Summit, Lakeshore Group has 10,000,000 public and 6,000,000 private warrants. The private warrants are accounted for as liabilities in accordance with ASC 815-40 and are presented within warrant liabilities on the balance sheets. The warrants were classified as Level 3 at the initial measurement date due to the use of unobservable inputs. The Binomial Option Pricing Model with the following key assumptions is used for estimating the FV of private warrants. As of Fair value of the underlying asset as of the Valuation Date 0.1 Strike price 11.5 Life to expiration (Years.) 4.0 Volatility 88.5 % Number of steps 100 Redemption price (per share) 0.1 As of March 31, 2024, the value of the private warrants was RMB4.5 million. The change in FV from April 1, 2023 to March 31, 2024 was RMB4.5 million. The table below reflects the movement of warrant liabilities for the year ended March 31, 2024: April 1, Change in Foreign March 31, March 31, (RMB) (RMB) (RMB) (RMB) (US$) Private Warrants 8,792,389 (4,458,844 ) 214,459 4,548,004 $ 641,015 Total 8,792,389 (4,458,844 ) 214,459 4,548,004 $ 641,015

Warrants Accounted as Equity-Me

Warrants Accounted as Equity-Method Instruments	12 Months Ended
	Mar. 31, 2024
Warrants Accounted as Equity-Method Instruments [Abstract]
WARRANTS ACCOUNTED AS EQUITY-METHOD INSTRUMENTS	NOTE 13 – WARRANTS ACCOUNTED AS EQUITY-METHOD INSTRUMENTS Upon consummation of the Business Combination with Summit, Summit’s 10,000,000 public warrants were converted into Lakeshore Biopharma warrants, and Lakeshore Group sold additional 750,000 public warrants. Following the Business Combination, Lakeshore Biopharma may redeem public warrants prior to their exercise at a time that is disadvantageous to the holders of such warrants, thereby making such warrants worthless. More specifically: ● Lakeshore Biopharma can redeem outstanding warrants at any time after they become exercisable and prior to their expiration, at $0.01 per warrant, provided the last reported sales price of Lakeshore Biopharma Ordinary Shares equals or exceeds $18.00 per share (as adjusted for capitalization, share dividends, split-up and the like) for any 20 trading days within a 30 trading-day period ending on the third trading day prior to proper notice of such redemption and provided that certain other conditions are met. ● Lakeshore Biopharma also can redeem outstanding warrants at any time after they become exercisable and prior to their expiration, at $0.10 per warrant upon a minimum of 30 days’ prior written notice of redemption provided that the last reported sales price of Lakeshore Biopharma Ordinary Shares equals or exceeds $10.00 per share (as adjusted for capitalization, share dividends, split-up and the like) for any 20 trading days within a 30 trading-day period ending on the third trading day prior to proper notice of such redemption and provided that certain other conditions are met, including that holders of the Warrants will be able to exercise their Warrants prior to redemption for a number of Lakeshore Biopharma Ordinary Shares determined based on the redemption date and the fair market value of the Lakeshore Biopharma Ordinary Shares. The value received upon exercise of the Warrants (1) may be less than the value the holders would have received if they had exercised their Warrants at a later time where the underlying share price is higher and (2) may not compensate the holders for the value of the warrants, including because the number of Lakeshore Biopharma Ordinary Shares received is capped at 0.361 Lakeshore Biopharma Ordinary Shares per warrant (subject to adjustment) irrespective of the remaining life of the warrants. In each case, Lakeshore Biopharma may only call the Warrants for redemption upon a minimum of 30 days’ prior notice of redemption. Redemption of the outstanding Warrants could force holders of the Warrants to (a) exercise Warrants and pay the exercise price therefor at a time when it may be disadvantageous for such holders to do so, (b) sell Warrants at the then-current market price when they might otherwise wish to hold their Warrants or (c) accept the nominal redemption price which, at the time the outstanding Warrants are called for redemption, is likely to be substantially less than the market value of the Warrants.

Stock-Based Compensation

Stock-Based Compensation	12 Months Ended
	Mar. 31, 2024
Stock-Based Compensation [Abstract]
STOCK-BASED COMPENSATION	NOTE 14 – STOCK-BASED COMPENSATION Lakeshore Group operates a share-based payment scheme (the “Scheme”) for the purpose of providing incentives and rewards to eligible participants who contribute to the success of Lakeshore Group’s operations. Eligible participants of the Scheme include Lakeshore Group’s directors, employees and consultants. The 2010 Share Incentive Plan On June 21, 2010, Lakeshore Group adopted the 2010 Share Incentive Plan (the “Plan”) that has a contractual term of 10 years. The Plan provides for the granting of stock options and other stock-based awards to employees and directors. Lakeshore Group’s Board of Directors authorized and reserved for the issuance of up to 2,725,650 ordinary shares under the Plan for the period from 2010 to 2013, giving retroactive effect of combination in March 2023. Starting from January 1, 2014, the maximum number of shares subject to awards that may be granted during any single calendar year is 1.5% of total issued and outstanding shares as of the first business day of that calendar year. The stock options granted to employees are accounted for as equity awards and measured at their grant date fair values. Options that vest based on service conditions generally will become vested over a three On January 1, 2015, an annual grant of 127,500 options, giving retroactive effect of combination in March 2023, which vest based on performance conditions, were granted to various employees. The annual grant was applicable for calendar 2015, 2016, 2017, 2018, 2019 and 2020, respectively. The options become vest in equal quarterly instalments based on performance targets established on January 1st of each calendar year from 2015 to 2020. There are no more grants after December 31, 2020 under the 2010 share incentive plan. For options granted to Lakeshore Group’s senior executives, the grantee can exercise vested options after the commencement date of exercise and before the earlier of: 1) its contractual term (i.e., 10 years after each of its vesting date); or 2) 5 years after the grantee terminates their employment if the vested option has not been exercised. For options granted to the remaining employees, the grantee can exercise vested options after the commencement date of exercise and before the earlier of: 1) its contractual term (i.e., 10 years after each of its vesting date); or 2) 12 months after the grantee terminates their employment if the vested option has not been exercised. For those awards, evaluations are made as of each reporting period to assess the likelihood of performance criteria being met. Share-based payment expenses are then adjusted to reflect the revision of original estimates. The exercise prices and exercise periods, giving retroactive effect of combination in March 2023, of the share options outstanding as at the end of each of the Relevant Periods are as follows: Number of Average (RMB) As of March 31, 2021 3,253,565 29.3156 Granted during the period - - Forfeited during the period - - Exercised during the period - - Expired during the period - - As of March 31, 2022 3,253,565 29.3156 Granted during the period - - Forfeited during the period - - Exercised during the period - - Expired during the period - - As of March 31, 2023 3,253,565 32.4020 Granted during the period - Forfeited during the period - - Exercised during the period - - Expired during the period - - As of March 31, 2024 3,253,565 32.4020 The exercise prices and exercise periods, giving retroactive effect of combination in March 2023, of the share options outstanding as at the end of the reporting periods are as follows: Year Ended 31 March 2024 Number of options Exercise price Exercise period (RMB) 1,533,252 13.938 2021-2031 613,369 25.8524 2021-2026 1,106,944 52.5376 2021-2026 3,253,565 Bonus incentive plan On January 1, 2015, Lakeshore Group launched a bonus incentive program effective for six years from launch date. The bonus incentive program is divided into two six-month periods each calendar year. The bonus incentive program specifies for each monthly tranche in the six-month period an independent performance condition for a stated period of service (i.e., one month). The bonus amount is determined on a monthly basis at month-end by the human resources department based on a reasonably objective performance criteria that serves as a basis for promotion and other compensation decisions. A fixed conversion price is then applied to the employee’s month end bonus to determine the number of ordinary shares to be issued to the employee for each individual month. At the end of each respective six-month period, Lakeshore Group finalizes the vested ordinary shares to be issued to the employee. Based on the above, the employee does not receive a number of ordinary shares with a FV equal to a predominantly fixed dollar amount on the delivery date. Hence, the ordinary shares granted to employees are accounted for as equity awards. In addition, each monthly tranche should be accounted for as a separate award with its own service inception date, grant-date FV, and respective requisite service period because the employee’s ability to retain (vest in) the award pertaining to the current month is not dependent on service beyond the current month. Restricted share units (“RSU”) Giving retroactive effect of combination in March 2023, on February 1, 2018, Lakeshore Group granted 692,500 RSUs to employees under the Plan. The weighted average grant-date FV of restricted shares units granted was $7.24, which was derived from the FV of the underlying ordinary shares. 405,000 out of the 692,500 RSUs were subject to service conditions vesting in six equal semi-annual instalments over three years or eight equal semi-annual instalments over four years, respectively. The remaining 287,500 RSUs had been vested on March 16, 2023 due to the successful closing of the public offering. As of March 31, 2023, all the granted options are vested, and there were no Giving retroactive effect of combination in March 2023, on July 25, 2018, Lakeshore Group granted 270,000 units of RSUs to three independent directors. Starting from the effective date of August 1, 2018, 30,000 RSUs will be awarded to each of the three directors annually, which shall be vested in equal portion of 7,500 units per three months’ Director services rendered by each director. For each of the new directors, 5,000 units will be vested for the two no On March 25, 2024, Lakeshore Group granted 1,900,000 units of RSUs to three employees. The RSUs became fully vested upon the date of grant. The grant-date FV of the RSU was $0.65, which was derived from the FV of the underlying ordinary shares. As of March 31, 2024, all the granted options are vested and there were no unrecognized share-based payment expenses related to unvested restricted shares. The 2020 Share Incentive Plan On December 31, 2020, Lakeshore Group’s board of directors adopted the 2020 Share Incentive Plan for the purpose of granting share-based compensation awards to employees, directors and consultants to incentivize their performance and align their interests with Lakeshore Group. Pursuant to such plan, Lakeshore Group can grant awards to directors, employees and consultants of Lakeshore Group with rights to subscribe for up to 8,750,000 underlying ordinary shares of Lakeshore Biopharma. As of the date of this report, (1) 2,093,418 shares as RSU incentive shares have been fully vested and issued to the respective directors and employees of Lakeshore Group, and (2) 6,656,582 shares are reserved but not issued, among which, options to subscribe for 3,471,546 ordinary shares of Lakeshore Biopharma are granted to certain senior management and employees of Lakeshore Group but not exercised, giving retroactive effect of combination in March 2023. Stock-based compensation expense included in Lakeshore Group’s consolidated statements of operations and comprehensive loss is as follows: Years Ended March 31, 2022 2023 2024 2024 (RMB) (RMB) (RMB) (US$) Research and development 975,171 (997,846 ) - $ - General and administrative 6,789,277 4,502,847 9,789,686 1,379,801 Total stock-based compensation 7,764,448 3,505,001 9,789,686 $ 1,379,801 On August 15, 2022, unanimous written resolution of the board of directors of Lakeshore Group accepted notice from a former employee, for the surrender of 143,750 of issued shares with US$0.00002 each in Lakeshore Group registered in his name, giving retroactive effect of how was this accounts for combination in March 2023.

Related Party Transactions and

Related Party Transactions and Balances	12 Months Ended
	Mar. 31, 2024
Related Party Transactions and Balances [Abstract]
RELATED PARTY TRANSACTIONS AND BALANCES	NOTE 15 – RELATED PARTY TRANSACTIONS AND BALANCES The following companies are related parties that had balances or transactions with Lakeshore Group as of and during the fiscal years ended March 31, 2024, 2023 and 2022: Name of related parties Relationship with Lakeshore Group Yisheng Biopharma Holdings Ltd. An entity controlled by Yi Zhang* Apex Prospect Limited A shareholder of Lakeshore Group Yi Zhang * A shareholder of Lakeshore Group Hui Shao Chief Executive Officer Nan Zhang Daughter of  Yi Zhang Xu Zhang Daughter Yi Zhang Rui Mi Spouse of  Yi Zhang * Yi Zhang was the chairman of the board of directors for the years ended March 31, 2023 and 2022. The entity controlled by him was the related parties of Lakeshore Group during fiscal years 2023 and 2022. Transactions with related parties Lakeshore Group had the following transactions with related parties, all of which are interest-free during the fiscal years ended March 31, 2024, 2023 and 2022: Years Ended March 31, 2022 2023 2024 2024 (RMB) (RMB) (RMB) (US$) Amounts due from related party: Yisheng Biopharma Holdings Limited (Hong Kong) Receivable collected on behalf of Lakeshore Group 2,966,777 - - - Repayment to Lakeshore Group 33,055,610 - - - In fiscal 2022, Lakeshore Group lent RMB2,966,777 to Yisheng Biopharma Holdings Limited (Hong Kong), and Yisheng Biopharma Holdings Limited (Hong Kong) repaid RMB33,055,610 to Lakeshore Group. There were no transactions with related parties during the years ended March 31, 2023 and 2024. In July 2023, Lakeshore Group spent US$20,000 to purchase a vehicle from Rui Mi, spouse of Mr. Yi Zhang, that was subsequently purchased back  by Rui Mi in March 2024.

Income Tax

Income Tax	12 Months Ended
	Mar. 31, 2024
Income Tax [Abstract]
INCOME TAX	NOTE 16 – INCOME TAX Cayman Islands. Hong Kong. Singapore. China. United States. Philippines. The provision for income tax consisted only of deferred tax. The following table reconciles the statutory rate to Lakeshore Group’s effective tax rate: Years Ended March 31, 2022 2023 2024 PRC statutory income tax rate 25.00 % 25.00 % 25.00 % Effect of different tax rates in different jurisdictions (18.26 )% (36.00 )% (13.32 )% Effect of PRC preferential tax rate 4.56 % 8.72 % (3.39 )% Effect of research and development expenses deduction and others 33.20 % 25.50 % 9.97 % Non-deductible expenses - % - % 0.06 % Temporary differences* 4.88 % 0.79 % (4.77 )% Change in valuation allowance (44.47 )% (23.23 )% (18.31 )% Effective tax rate 4.91 % 0.78 % (4.76 )% * Temporary differences primarily relate to impairment of inventories, property, plant and equipment and government grants. Net deferred tax assets as of March 31, 2024 and 2023, consist of the following key components: As of March 31, 2023 2024 2024 (RMB) (RMB) (US$) Deferred tax assets: Write-down of inventories to net realizable value 716,917 10,223,137 $ 1,440,893 Impairment of property, plant and building 1,769,405 13,542,899 1,908,795 Deferred government grants 3,296,223 2,951,867 416,049 Losses available for offsetting against future taxable profits 39,366,020 81,220,037 11,447,503 Less: valuation allowance (39,366,020 ) (81,220,037 ) (11,447,503 ) Total deferred tax assets, net 5,782,545 26,717,903 3,765,737 Deferred tax liabilities: - Fair value adjustments arising from historical acquisition of subsidiaries (3,876,964 ) (3,083,714 ) (434,632 ) Total deferred tax liabilities (3,876,964 ) (3,083,714 ) (434,632 ) Net deferred tax asset 1,905,581 23,634,189 $ 3,331,105 In assessing the realizability of the net deferred tax assets, Lakeshore Group considers all relevant positive and negative evidence in determining whether it is more likely than not that some portion or all of the deferred income tax assets will not be realized. The realization of the gross deferred tax assets is dependent on several factors, including the generation of sufficient taxable income in the future. Based upon an assessment of the level of historical taxable income and projections for future taxable income over the periods in which the deferred tax assets are deductible or can be utilized. The amount of the deferred tax asset is considered unrealizable because it is more likely than not that Lakeshore Group will not generate sufficient future taxable income to utilize this portion of the net operating loss. Uncertain tax positions There were no

Deferred Government Grants

Deferred Government Grants	12 Months Ended
	Mar. 31, 2024
Deferred Government Grants [Abstract]
DEFERRED GOVERNMENT GRANTS	NOTE 17 – DEFERRED GOVERNMENT GRANTS Deferred government grants represent funds received from the PRC government for research and development, investment in building or improvement in Lakeshore Group’s production facilities. These specific subsidies are recorded as deferred government grants upon receipt and are recognized as government grants recognized in income when the conditions are met. Other subsidies are recognized as other income upon receipt as further performance by Lakeshore Group is not required. Lakeshore Group received government grants that were deferred in the amount of RMB3.6 million and RMB4.0 million in fiscal 2024 and 2023, respectively. In addition, Lakeshore Group received RMB15.3 million and RMB15.7 million other subsidies that the government has not set any conditions and are not tied to future trends or performance of Lakeshore Group and were recognized in other income in 2024 and 2023, respectively. Deferred government grants included the following: As of March 31, 2023 2024 2024 (RMB) (RMB) (US$) Government grants for property, plant and equipment Balance at beginning of the year 22,030,690 20,575,012 $ 2,899,931 Addition - 3,600,000 507,400 Recognized as income (1,455,678 ) (2,439,156 ) (343,786 ) Subtotal 20,575,012 21,735,856 $ 3,063,545 - Government grants for research and development - Balance at beginning of the year 10,318,528 5,327,196 $ 750,838 Addition 4,000,000 - - Recognized as income (8,991,332 ) (4,767,414 ) (671,940 ) Subtotal 5,327,196 559,782 $ 78,898 Total deferred government grants 25,902,208 22,295,638 $ 3,142,443 - Less：current portion 2,295,701 2,015,693 $ 284,100 - Non-current portion 23,606,507 20,279,945 $ 2,858,343 Government grants for property, plant and equipment Lakeshore Group has nine deferred government grants for property, plant and equipment. RMB2.4 million was amortized from deferred government grant into government grant recognized in income in fiscal 2024, as compared to RMB1.5 million for fiscal 2023. RMB1.5 million will be amortized in fiscal 2025 which was included in the current deferred government grant and RMB17.7 million will be amortized after 2025 which was included in the non-current portion of deferred government grants. Government grants for research and development Lakeshore Group has one deferred government grants related to various research and development projects. RMB4.8 million was amortized from deferred government grant into government grant recognized in income in fiscal 2024, as compared to RMB9.0 million for the fiscal year ended March 31, 2023. RMB0.5 million will be amortized in fiscal 2025 which was included in the current deferred government grant and RMB2.6 million will be amortized after 2025 which was included in the non-current portion of deferred government grants.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Mar. 31, 2024
Commitments and Contingencies [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 18 – COMMITMENTS AND CONTINGENCIES As of March 31, 2024, Lakeshore Group has the following commitments to purchase raw materials or services: As of March 31, 2024 2024 (RMB) (US$) Construction in progress 27,531,843 $ 3,880,457 Other professional service fee 3,050,850 430,000 Purchase raw materials 38,275,819 5,394,760 Research and development 51,593,189 7,271,767 Total 120,451,701 $ 16,976,984 In 2018, Liaoning Yisheng filed a sales contract dispute with Hebei Defense Biological Products Supply Center. The Supreme People’s Court of Liaoning supported the Liaoning Yisheng’s claim the defendant Hebei Weifang should pay RMB2,465,807 for Liaoning Yisheng vaccine within 20 days after the judgment came into effect. As of the date of this report, Lakeshore Group received RMB1,636,755 from Hebei Defense Biological Products Supply Center, and the balance of RMB829,052 may be received in fiscal 2025. In October, 2023, Liaoning Yisheng filed an engineering dispute with Shenyang Baimu Technology Co., Ltd (“Shenyang Baimu”), claiming Shenyang Baimu should pay a penalty of RMB2,180,000 for engineering delays and refund the overpaid funds. As the proceedings are under trial, there is uncertainty regarding the timing or ultimate resolution of such matters, and therefore, an estimate for the reasonably possible gain or a range of reasonably possible gains cannot be made. In December, 2023, Liaoning Yisheng filed an engineering dispute with Aoxing Pharmaceutical Equipment (Shijiazhuang) Co., Ltd (“Aoxing”), claiming Aoxing should refund RMB1,860,000 and pay a penalty of RMB155,000 for engineering delays. As the proceedings are under trial, there is uncertainty regarding the timing or ultimate resolution of such matters, and therefore, an estimate for the reasonably possible gain or a range of reasonably possible gains cannot be made. In March, 2024, Shenyang Jiayixin Decoration Engineering Design Co., Ltd filed a dispute with h Liaoning Yisheng, claiming Liaoning Yisheng should refund RMB522,716 and interest of RMB34,400. As the proceedings are in the early stages, there is uncertainty regarding the timing or ultimate resolution of such matters, and therefore, an estimate for the reasonably possible loss or a range of reasonably possible losses cannot be made. In April, 2024, Jilin Ruisheng Science and Trade Company (“Jilin Ruisheng”) filed a dispute with Liaoning Yisheng, claiming Liaoning Yisheng should refund RMB164,141 and interest of RMB28,314. As the proceedings are in the early stages, there is uncertainty regarding the timing or ultimate resolution of such matters, and therefore, an estimate for the reasonably possible loss or a range of reasonably possible losses cannot be made. Lakeshore Group was also involved in labor disputes as of March 31, 2024. As the proceedings are in the early stages or the second appeal, there is uncertainty regarding the timing or ultimate resolution of such matters, and therefore, an estimate for the reasonably possible loss or a range of reasonably possible losses cannot be made. Since December 2023, the Company has been involved in several legal proceedings in the Cayman Islands against Mr. Yi Zhang, the former chairperson of the Board, and his associates. On December 22, 2023, the Grand Court of the Cayman Islands (the “Grand Court”) granted the Company an injunction against Mr. Zhang, which restrained Mr. Zhang from, among other things, taking any steps to exercise any powers of, or hold himself out to be, chairperson of the Board. That injunction was discharged by the Grand Court on February 6, 2024. On February 16, 2024, the Company obtained another injunction from the Grand Court which restrained Mr. Zhang and his associates, including Nan Zhang, Yun (Monica) Zhang, Lui Chi Keung and Jing Xian Li from, among other things, holding themselves out to be directors of the Company and from taking any steps to exercise any powers as though they were directors. On April 3, 2024, the Company filed an Amended Statement of Claim with the Grand Court in its proceedings against Mr. Zhang and his associates. The Amended Statement of Claim seeks various forms of declaratory and injunctive relief against the defendants as well as damages. On June 7, 2024, Mr. Zhang filed a Defence with the Grand Court which, among other things, alleges that certain present and former directors of the Company took steps to improperly oust Mr. Zhang from, and to seize control of, the Company and that certain present and former directors of the Company breached their fiduciary duties to the Company (which Mr. Zhang has pleaded will be the subject of separate derivative proceedings) and denies the Company’s entitlement to the relief the Company has claimed in its Amended Statement of Claim. On August 2, 2024, the Company filed and served its Reply by which the Company has, among other things, denied these allegations. In 2024, Mr. Zhang filed a writ of summons (the “Writ of Summons”) with the Grand Court against the Company and certain of its directors and executive officers and Apex Prospect Limited, seeking, amongst other things, (i) a declaration that the issue by the Company of 95,269,762 shares to Apex (the “Apex Shares”) was invalid and of no effect; (ii) an injunction restraining Apex from exercising any voting rights in respect of the Apex Shares; (iii) a declaration that the removal of Mr. Zhang as a director of the Company on February 12, 2024 was invalid and of no effect; and (iv) a declaration that the appointment of new directors to the Company on February 13, 2024 was invalid and of no effect and an injunction restraining the individuals appointed as new directors of the Company on February 13, 2024 from holding themselves out to be directors of the Company or exercising any power as directors of the Company. As of the date of this Annual Report, the Writ of Summons has not yet been served on the Company or any of the other defendants. In May 2024, two entities controlled by Mr. Zhang (each, a “Claimant,” and collectively, the “Claimants”) filed arbitration claims respectively with the Kaifeng Arbitration Commission in China against Liaoning Yisheng. The Claimants sought an aggregate amount of RMB919 million of payment, primarily covering fees for research and development services of RMB198 million and accrued interest borrowings and other fees of RMB721 million until full payment. The Claimants allege Liaoning Yisheng owes them fees for research and development services from as early as 2002, and that the parties entered into debt confirmation and repayment agreements respectively in March 2024, pursuant to which Liaoning Yisheng purportedly agreed to repay the Claimants approximately RMB723 million in the aggregate, including fees for research and development services of RMB198 million and accrued interest, borrowings and other fees of RMB525 million until full payment. In connection with the arbitration proceedings, Liaoning Yisheng’s inventory of YSJATM rabies vaccine with an appraisal value of approximately RMB902 million had been frozen. Liaoning Yisheng received a decision from the Kaifeng Arbitration Commission on June 18, 2024, to suspend the arbitration, and filed a case with the Kaifeng Intermediate People’s Court on June 12, 2024, to confirm the validity of the arbitration agreement. In May 2024, a Claimant filed arbitration claims with the Kaifeng Arbitration Commission in China against Beijing Yisheng. The Claimant alleged that Beijing Yisheng owed the Claimant certain fees and other amounts since 2021 due to historical reorganization transactions, and that the parties entered into debt confirmation and repayment agreements in March 2024, pursuant to which the Claimant claimed that Beijing Yisheng had agreed to repay the Claimant approximately RMB59 million in the aggregate. The Claimant sought an arbitration award of RMB83 million in payment from Beijing Yisheng. As of the date of this Annual Report, the Kaifeng Arbitration Commission did not issue awards on these three cases.

Segment Information

Segment Information	12 Months Ended
	Mar. 31, 2024
Segment Information [Abstract]
SEGMENT INFORMATION	NOTE 19 – SEGMENT INFORMATION Based on management’s assessment, Lakeshore Group has one operating segment, which is the development, production, marketing and sale of biopharmaceutical products. No operating segments were aggregated to form the reportable operating segment. Lakeshore Group’s non-current assets are located in the PRC and other countries, such as Singapore, United States and Philippines. The location of these non-current assets can be aggregated to form the reportable geographical segment. As of March 31, 2023 2024 2024 (RMB) (RMB) (US$) PRC 645,210,788 527,009,381 $ 74,278,983 Other countries/regions 4,602,447 17,583,961 $ 2,478,360 The non-current asset information above is based on the location of the assets and excludes financial instruments and deferred tax assets.

Subsequent Events

Subsequent Events	12 Months Ended
	Mar. 31, 2024
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 20 – SUBSEQUENT EVENTS Lakeshore Group performed an evaluation of events and transactions for potential recognition or disclosure through the date of this report. Lakeshore Group is not aware of any material subsequent events other than those disclosed below and elsewhere in the notes to the consolidated financial statements. On April 5, 2024, LakeShore Tech Hong Kong Limited and LakeShore Bio Hong Kong Limited were incorporated as holding company its under the laws of Hong Kong as entities owned by Lakeshore Biopharma. On April 19, 2024, Hu’an Yuanhang Technology (Beijing) Co., Ltd was incorporated for research and development, with name changed to Hu’an Yuanhang Biotechnology (Beijing) Co., Ltd on July 11, 2024. From April 18, 2024 to May 17, 2024, Lakeshore Group borrowed RMB19.8 million with interest at 4.0% from Guangfa Bank Shenyang Branch. The loans are due on September 10, 2024. From May 29, 2024 to August 1, 2024, Lakeshore Group borrowed RMB93.4 million with interest at 5.0% from Beijing HRJK Real Estate Co., Ltd. The loans are due on December 31, 2024 Beijing HRJK Real Estate Co., Ltd, an affiliate of Apex Prospect Limited who is a controlling shareholder of the Company. On May 21, 2024, as a special resolution that, the name of the Company be and hereby is changed from YS Biopharma Co., Ltd. to LakeShore Biopharma Co., Ltd. On May 21, 2024, as an ordinary resolution that, the 2024 Share Incentive Plan approved. On May 2, 2024, the Board approved the appointment of Mr. Dave Chenn as the Interim Chief Executive Officer of the Company and Dr. Hui Shao as the Co-Chief Executive Officer. On May 21, 2024, as an ordinary resolution that, each of Dave Chenn, Chunyang Shao, Zengjun Xu, Thomas Xue and Adam Zhao, be appointed as a director of the Company. Each of Dr. Ajit Shetty, Dr. Viren Mehta, Mr. Haitao Zhao, Mr. Henry Chen, Mr. Pierson Yue Pan, Mr. Yuntao Cui and Mr. Jin Wang voluntarily resigned from the board of directors (the “Board”) of LakeShore Biopharma Co., Ltd (the “Company”), effective on May 31, 2024. On June 1, 2024, the Board voted to appoint Mr. Dave Chenn as chairperson. The Audit Committee is constituted Adam Zhao (Chair), Thomas Xue and Chunyang Shao. Compensation Committee is constituted Rachel Yu (Chair), Dave Chenn and Hui Shao (David). Nominating and Corporate Governance Committee is constituted Rachel Yu (Chair), Dave Chenn and Hui Shao (David). On June 4, 2024, the Board appointed Mr. Xu Wang as the Chief Operation Officer of the Company. Ms. Chunyuan Wu (Brenda) resigned from the Board and from her position as the chief financial officer (“CFO”) of the Company, effective June 14, 2024. Ms. Wu advised the Company that her resignation was due to personal reasons and not a result of any disagreement with the Company on any matter related to the operations, policies, or practices of the Company. Following her resignation, the Board appointed Ms. Rachel Yu, a director of the Company, as the interim CFO while the Company searches for a permanent successor as CFO. Mr. Zengjun Xu resigned as a director of the Company, effective June 14, 2024. Mr. Xu advised that his resignation was due to personal reasons and not a result of any disagreement with the Company on any matter related to the operations, policies, or practices of the Company. Following such resignation, the Board is now comprised of six members, including: (1) Mr. Dave Chenn, (2) Dr. Hui Shao (David), (3) Ms. Rachel Yu, (4) Mr. Adam Zhao, (5) Mr. Thomas Xue, and (6) Mr. Chunyang Shao.

Parent Company Only Condensed F

Parent Company Only Condensed Financial Information	12 Months Ended
	Mar. 31, 2024
Parent Company Only Condensed Financial Information [Abstract]
PARENT COMPANY ONLY CONDENSED FINANCIAL INFORMATION	NOTE 21 – PARENT COMPANY ONLY CONDENSED FINANCIAL INFORMATION Pursuant to the requirements of Rule 12-04(a), 5-04(c) and 4-08(e)(3) of Regulation S-X, the condensed financial information of the parent company shall be filed when the restricted net assets of consolidated subsidiaries exceed 25% of consolidated net assets as of the end of the most recently completed fiscal year. Lakeshore Group performed a test on the restricted net assets of consolidated subsidiaries in accordance with such requirement and concluded that it was applicable to Lakeshore Group as the restricted net assets of Lakeshore Group’s PRC subsidiaries exceeded 25% of the consolidated net assets of Lakeshore Group. Therefore, the condensed financial statements of the parent company are included herein. PARENT COMPANY BALANCE SHEETS As of March 31, 2023 2024 2024 (RMB) (RMB) (US$) ASSETS Current Assets Cash 3,045,660 167,227,049 $ 23,569,704 Amounts due from related parties 1,039,986,896 1,145,781,243 161,491,366 Total current assets 1,043,032,556 1,313,008,292 185,061,070 Non-current assets Long-term investments, net 158,734,357 165,416,495 23,314,517 Long-term prepaid expense - 2,341,350 330,000 Total non-current assets 158,734,357 167,757,845 23,644,517 Total Assets 1,201,766,913 1,480,766,137 $ 208,705,587 LIABILITIES AND SHAREHOLDERS’ EQUITY Current Liabilities Accrued expenses and other liabilities 461,105,636 887,485,236 $ 125,086,010 Warrants liability 8,792,389 4,548,004 641,015 Amounts due to related parties 3,415,603 3,526,595 497,054 Total current liabilities 473,313,628 895,559,835 126,224,079 Total Liabilities 473,313,628 895,559,835 126,224,079 Shareholders’ equity: Ordinary shares, par value US$0.00002 per share; 9,950,000,000 shares authorized; 93,058,197 and 190,227,959 shares issued and outstanding as of March 31, 2023 and 2024, respectively* 12,297 26,105 3,679 Additional paid-in capital 2,656,891,036 2,950,862,914 415,907,387 Accumulated deficit (1,874,037,965 ) (2,307,502,836 ) (325,229,434 ) Accumulated other comprehensive loss (54,412,083 ) (58,179,881 ) (8,200,124 ) Total shareholders’ equity 728,453,285 585,206,302 82,481,508 Total liabilities and shareholders’ equity 1,201,766,913 1,480,766,137 $ 208,705,587 * Gives retroactive effect to the business combination in March 2023. PARENT COMPANY STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Years Ended March 31, 2022 2023 2024 2024 (RMB) (RMB) (RMB) (US$) Equity loss of subsidiaries (75,864,722 ) (138,758,136 ) (379,244,652 ) $ (53,452,382 ) Operating expenses: Selling and marketing - - General and administrative 29,178,255 7,630,726 60,553,856 8,534,722 Research and development 988,531 (887,280 ) 33,011 4,653 Total operating expenses 30,166,786 6,743,446 60,586,867 8,539,375 Loss from operations (106,031,508 ) (145,501,582 ) (439,831,519 ) (61,991,757 ) Other income (expenses): Financial expenses, net 27,107 1,119 1,907,804 268,894 Fair value changes of warrant liability - 21,358 4,458,844 628,449 Total other expense, net 27,107 22,477 6,366,648 897,343 Net loss (106,004,401 ) (145,479,105 ) (433,464,871 ) (61,094,414 ) Accretion to redemption value of convertible redeemable preferred shares (130,662,326 ) (137,991,697 ) - - Net loss attributable to Lakeshore Biopharma (236,666,727 ) (283,470,802 ) (433,464,871 ) (61,094,414 ) Net loss (106,004,401 ) (145,479,105 ) (433,464,871 ) (61,094,414 ) Foreign currency translation gain(loss) 38,864,606 (137,500,063 ) (3,767,798 ) (531,050 ) Total comprehensive loss (67,139,795 ) (282,979,168 ) (437,232,669 ) $ (61,625,464 ) Loss per share*: – Basic and Diluted (1.71 ) (2.35 ) (4.05 ) $ (0.57 ) Weighted average number of ordinary shares outstanding*: – Basic and Diluted 61,827,883 61,785,466 106,923,121 106,923,121 * Gives retroactive effect to the business combination in March 2023. PARENT COMPANY STATEMENTS OF CASH FLOWS Years Ended March 31, 2022 2023 2024 2024 (RMB) (RMB) (RMB) (US$) Net loss (106,004,401 ) (145,479,105 ) (433,464,871 ) $ (61,094,414 ) Equity loss of subsidiaries 75,864,722 138,758,136 379,244,652 53,452,382 Share-based compensation 7,764,448 3,505,001 9,789,686 1,379,801 Fair value changes of warrant liability - (21,358 ) (4,458,844 ) (628,449 ) Changes in operating assets and liabilities: Amounts due from related parties (23,299,705 ) (520,750,020 ) (105,794,347 ) (14,911,113 ) Amounts due to related parties (110,893 ) 260,208 110,992 15,644 Accrued expenses and other liabilities (24,732,348 ) 48,377,785 33,181,238 4,676,707 Prepaid expense - - (2,341,350 ) (330,000 ) Net cash used in operating activities (70,518,177 ) (475,349,353 ) (123,732,844 ) (17,439,442 ) Cash flows from investing activities: Payment for long-term investment (813,776 ) - (1,523,970 ) (214,795 ) Net cash used in investing activities (813,776 ) - (1,523,970 ) (214,795 ) Cash flows from financing activities: Proceeds from issuance of ordinary shares - - 284,196,000 40,055,814 Proceeds from acquisition - 252,457,329 - - Offering cost (35,884,661 ) - - Net cash provided by financing activities - 216,572,668 284,196,000 40,055,814 Effect of exchange rate on cash (6,353,461 ) 9,210,810 5,242,203 738,859 Net (decrease) increase in cash (77,685,414 ) (249,565,875 ) 164,181,389 23,140,436 Cash at the beginning of the year 330,296,949 252,611,535 3,045,660 429,268 Cash at the end of the year 252,611,535 3,045,660 167,227,049 $ 23,569,704 Non-cash transactions: Accretion to redemption value of convertible redeemable preferred shares 130,662,326 (137,991,697 ) - $ - Equity transaction from warrants - (8,870,007 ) - $ - Equity transaction from preferred shares - 1,636,897,084 - $ -

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	12 Months Ended
	Mar. 31, 2024
Summary of Significant Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation These CFS and related notes of Lakeshore Group were prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). In the opinion of management, all adjustments necessary to present fairly in all material respects the financial position, results of operations and cash flows for all periods presented were made.
Reclassification	Reclassification Certain prior year amounts have been reclassified to conform with the current year presentation, as follows (in RMB). Previously reported March 31, (Decrease)/ March 31, (Reclassified) Consolidated Statements of Operations and Comprehensive Loss General and administrative 81,595,277 (8,655,487 ) 72,939,790 Impairment loss on inventory, property, plant and equipment and other assets - 8,655,487 8,655,487 Previously reported March 31, (Decrease)/ March 31, (Reclassified) Consolidated Statements of Operations and Comprehensive Loss General and administrative 107,620,500 (9,476,354 ) 98,144,146 Impairment loss on inventory, property, plant and equipment and other assets - 9,476,354 9,476,354 These reclassifications had no effect on the reported results of operations.
Basis of Consolidation	Basis of Consolidation The CFS include the financial statements of Lakeshore Group and its wholly-owned subsidiaries. All significant intercompany transactions and balances were eliminated in consolidation. The CFS were prepared on a historical cost basis, except for financial assets and financial liabilities which were measured at fair value (“FV”). The functional currency of Lakeshore Group and its Hong Kong subsidiary, US subsidiary is the United States dollars (“US$”). The functional currency of Lakeshore Group’s Singapore subsidiary is the Singapore dollars (“S$”). The functional currency of Lakeshore Group’s PRC subsidiaries is the Chinese Renminbi (“RMB”). The determination of functional currency is based on the criteria of Accounting Standard Codifications (“ASC”) as promulgated by the Financial Accounting Standards Board, ASC 830, Foreign Currency Matters (“ASC 830”). Lakeshore Group uses the RMB as its reporting currency.
Use of Estimates	Use of Estimates The preparation of the CFS in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the CFS and the reported amounts of revenues and expenses during the reporting periods. Significant estimates and assumptions reflected in these CFS include, but are not limited to, the valuation of Lakeshore Group’s convertible redeemable preferred shares and ordinary shares, accrual of stock-based compensation expense, allowance for estimated credit losses and obsolete inventories, useful life of property, plant and equipment, income taxes and uncertain tax positions. Actual amounts could differ from those estimates. Changes in estimates are recorded in the period when they become known. Due to the risks and uncertainties involved in Lakeshore Group’s business and evolving market conditions and, given the subjective element of the estimates and assumptions made, actual results may differ from estimated results.
Foreign Currency Translation	Foreign Currency Translation Lakeshore Group’s CFS are reported using the RMB. The results of operations and the consolidated statements of cash flows denominated in foreign currency are translated at the average rate of exchange during the reporting period. Assets and liabilities denominated in foreign currencies at the balance sheet date are translated at the applicable rates of exchange in effect at that date. The equity denominated in the functional currency is translated at the historical rate of exchange at the time of capital transaction. Because cash flows are translated based on the average translation rate, amounts related to assets and liabilities reported on the consolidated statements of cash flows will not necessarily agree with changes in the corresponding balances on the consolidated balance sheets. Foreign currency translation adjustments arising from the use of different exchange rates from period to period are included as a separate component of accumulated other comprehensive income included in Lakeshore Group’s consolidated statements of changes in shareholders’ deficit. Gains and losses from foreign currency transactions are included in Lakeshore Group’s consolidated statements of operations and comprehensive loss. The value of RMB against US$ and other currencies may fluctuate and is affected by, among other things, changes in the PRC’s political and economic conditions. The following table outlines the currency exchange rates used in preparing Lakeshore Group’s CFS: As of March 31, Years Ended March 31, 2023 2024 2022 2023 2024 Foreign currency Balance Sheet Balance Sheet Profit/Loss Profit/Loss Profit/Loss RMB:1US$ 6.8717 7.0950 6.4598 6.6100 6.9834 RMB:1S$ 5.1760 5.2762 4.7850 4.9346 5.2261 RMB:1PHP NA 0.1286 NA NA 0.1275
Convenience translation	Convenience translation Amounts in US$ are presented for the convenience of the reader and translated at US$1.00 to RMB7.0950, representing the central parity rate release of the People’s Bank of China on March 31, 2024. No representation is made that the RMB amounts could have been, or converted, realized or settled into US$ at such rate.
Cash	Cash Cash includes cash on hand and demand deposits in accounts maintained with commercial banks. Lakeshore Group maintains bank accounts in China. Cash balances in bank accounts in China are not insured by the Federal Deposit Insurance Corporation or other programs.
Restricted Cash	Restricted Cash Restricted cash balances mainly relate to restrictions imposed on banks as cash deposits for the issuance of letters of credit or asset preservation in litigation. And it is included in the total cash, cash equivalents, and restricted cash in the consolidated statements of cash flows.
Expected Credit Losses	Expected Credit Losses On April 1, 2023, Lakeshore Group adopted ASC 326, Credit Losses (“ASC 326”), which replaced previously issued guidance regarding the impairment of financial instruments with an expected loss methodology that will result in more timely recognition of credit losses. Lakeshore Group used a modified retrospective approach and did not restate the comparable prior periods. The adoption did not have a material impact on the Company’s CFS. Upon adoption of ASC 326, Lakeshore Group maintains an allowance for credit losses in accordance with ASC 326 and records the allowance for credit losses as an offset to assets such as accounts receivable, etc., and the estimated credit losses charged to the allowance are classified as impairment loss on inventory, property, plant and equipment and other assets in the consolidated statements of operations and comprehensive income (loss). Lakeshore Group assesses collectability by reviewing receivables on a collective basis where similar characteristics exist. In determining the amount of the allowance for credit losses, Lakeshore Group considers historical collectability based on past due status, the age of the receivable balances, credit quality of customers based on ongoing credit evaluations, current economic conditions, reasonable and supportable forecasts of future economic conditions, and other factors that may affect Lakeshore Group’s ability to collect from customers. Bad debts are written off as incurred.
Advance to Suppliers	Advance to Suppliers Advance to suppliers are advanced to vendors or suppliers for providing raw materials to Lakeshore Group. The suppliers usually require advance payments when Lakeshore Group orders materials and the advance will be utilized to offset Lakeshore Group’s actual payment obligations. These amounts are unsecured, non-interest bearing and generally short term in nature. Lakeshore Group will reduce its advance to suppliers by recording an allowance that approximates the extent of the advance that may not be realizable during the procurement process. Lakeshore Group recorded nil
Inventories	Inventories Inventories are stated at the lower of cost or net realizable value. Cost is determined on the weighted average basis and comprises all cost of purchase and other costs incurred in bringing the inventories to their present location and condition. Net realizable value is based on estimated selling prices less any estimated costs to be incurred to completion and disposal. Lakeshore Group reviews the carrying amounts of the inventories on a quarterly basis to determine if the inventories are carried at lower of cost or net realizable value. The net realizable value is estimated based on current market conditions and historical experience. Adjustments are recorded to write down the cost of inventory based on evaluation of, among other things, the expiration date of raw materials and the estimate of future usage, and the likelihood of receiving approval from the CDC (centers for food and drug control) to sell the finished goods. Write-downs are recorded as impairment loss on inventory in the consolidated statements of operations and comprehensive loss. Write-off of inventories during the production process due to damage or destruction are recorded in cost of revenues in the consolidated statements of operations and comprehensive loss.
Property, Plant and Equipment	Property, Plant and Equipment Property, plant and equipment are stated at cost less accumulated depreciation and any impairment losses. The cost of property, plant and equipment comprises its purchase price and any directly attributable costs of bringing the asset to its working condition and location for its intended use. Expenditure incurred after items of property, plant and equipment have been put into operation, such as repairs and maintenance, are expensed when incurred. In situations where the recognition criteria are satisfied, the expenditure for a major reconstruction is capitalized as a replacement. Where significant parts of property, plant and equipment are required to be replaced at intervals, Lakeshore Group recognizes such parts as individual assets with specific useful lives and depreciates them accordingly. Depreciation is calculated on the straight-line basis to reduce the cost of each item of property, plant and equipment to its residual value over its estimated useful life. Category Estimated useful life Plant and building 6-20 years Machinery and equipment 5-10 years Furniture and fixtures 3-7 years Motor vehicle 4-5 years Leasehold improvement Lesser of the lease term or life of assets Where parts of an item of property, plant and equipment have different useful lives, the cost of that item is allocated on a reasonable basis among the parts and each part is depreciated separately. Residual values, useful lives and the depreciation method are reviewed, and adjusted if appropriate, at least at each quarter end. An item of property, plant and equipment including any significant part initially recognized is derecognized upon disposal or when no future economic benefits are expected from its use or disposal. Any gain or loss on disposal or retirement recognized in the statement of operations in the period the asset is derecognized is the difference between the net sales proceeds and the carrying amount of the relevant asset.
Intangible assets	Intangible assets Intangible assets acquired separately are measured at initial cost. The cost of intangible assets acquired in a business combination is the FV at the date of acquisition. The useful lives of intangible assets are assessed to be either finite or indefinite. Intangible assets with finite lives are amortized over the useful economic life and assessed for impairment whenever there is an indication that the intangible asset may be impaired. The amortization period and the amortization method for an intangible asset with a finite useful life is reviewed for appropriateness at each financial year end. Intangible assets with indefinite useful lives or not yet available for use are tested for impairment annually either individually or at the cash-generating unit level. Such intangible assets, including vaccine license and patent with indefinite useful lives, are not amortized. The useful life of an intangible asset with an indefinite life is reviewed annually to determine whether the indefinite life assessment continues to be supportable. If not, the change in the useful life assessment from indefinite to finite is accounted for on a prospective basis. Patents with definite useful lives are stated at cost less any impairment losses and are amortized on the straight-line basis over their estimated useful lives of 15 years. Software and laboratory information system are amortized on the straight-line basis over their estimated useful lives of 10 years. An intangible asset that is determined to have an indefinite useful life is not amortized until its useful life is determined to be no longer indefinite. Management evaluates the remaining useful life of an intangible asset that is not being amortized in each reporting period to determine whether events and circumstances continue to support an indefinite useful life. Indefinite-lived intangible assets are subject to impairment testing at least annually. Management believes that Lakeshore Group’s Drug Manufacturing License that was granted by the Liaoning Food and Drug Administration (“FDA”) is an intangible asset with an indefinite useful life because the certificate may be renewed indefinitely at little cost and has historically been renewed by Liaoning Yisheng. Liaoning Yisheng intends to renew the certificate indefinitely, and has the ability to do so. Cash flows from the certificate are expected to continue indefinitely. Therefore, the Drug Manufacturing License is not amortized until its estimated useful life is believed to be no longer indefinite. All research and development costs are expensed as incurred. Expenditure incurred on projects to develop new products is capitalized and deferred only when Lakeshore Group can demonstrate the technical feasibility of completing the intangible asset so that it will be available for use or sale, its intention to complete and its ability to use or sell the asset, how the asset will generate future economic benefits, the availability of resources to complete the project and the ability to measure reliably the expenditure during the development. Product development expenditures which do not meet these criteria are expensed when incurred. Land use rights: Land lease payments are amounts paid for the rights to use land in the PRC and are recorded net of accumulated amortization. Amortization is provided on a straight-line basis over the term of the lease agreement, which ranges from 48.75 to 50 years.
Impairment of Long-lived Assets	Impairment of Long-lived Assets Lakeshore Group reviews long-lived assets, including definitive-lived intangible assets and property and equipment, for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. When such events occur, Lakeshore Group assesses the recoverability of the asset group based on the undiscounted future cash flows the asset group is expected to generate and recognizes an impairment loss when estimated undiscounted future cash flows expected to result from the use of the asset group plus net proceeds expected from disposition of the asset group, if any, is less than the carrying value of the asset group. If Lakeshore Group identifies an impairment, Lakeshore Group reduces the carrying amount of the asset group to its estimated FV based on a discounted cash flow approach or, when available and appropriate, to comparable market values and the impairment loss, if any, is recognized as impairment loss in the consolidated statements of operations. Lakeshore Group uses estimates and judgments in its impairment tests and if different estimates or judgments had been utilized, the timing or the amount of any impairment charges could be different. Asset groups to be disposed of would be reported at the lower of the carrying amount or FV less costs to sell, and they are no longer depreciated. Impairment was recorded in impairment loss on inventory, property, plant and equipment and other assets on the consolidated statements of operations and comprehensive loss.
Concentrations of Credit Risk and Significant Suppliers	Concentrations of Credit Risk and Significant Suppliers Financial instruments that potentially subject Lakeshore Group to concentration of credit risk consist of cash. Lakeshore Group mitigates this risk by maintaining its cash with high quality, accredited financial institutions. As of March 31, 2024, Lakeshore Group’s cash was deposited at more than two financial institutions and it did not have any foreign currency exchange contracts, option contracts or other hedging arrangements. Lakeshore Group has not experienced any losses on its deposits of cash and does not believe that it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships. Lakeshore Group’s sales are made primarily to Centers for Disease Control and Prevention (“CDCs”) in China. Lakeshore Group does not have a concentration of its revenue and accounts receivable with specific customers. As of March 31, 2024 and 2023, there was no customer which accounted for more than 10% of Lakeshore Group’s accounts receivable balance. During the years ended March 31, 2024, 2023 and 2022, there were no customers that accounted for more than 10% of Lakeshore Group’s net revenues. Details of Lakeshore Group’s top 5 vendors accounting for total purchases are as follows: Year Ended March 31, 2024 (RMB) (US$) Vendor D 36,567,150 $ 5,153,932 20.2 % Vendor I 19,635,180 2,767,467 10.8 % Vendor C 13,260,918 1,869,051 7.3 % Vendor J 10,090,875 1,422,252 5.6 % Vendor G 9,544,080 1,345,184 5.3 % Total 89,098,203 $ 12,557,886 49.2 % Year Ended March 31, 2023 (RMB) (US$) Vendor A 48,006,500 $ 6,986,117 37.9 % Vendor F 15,178,020 2,208,772 12.0 % Vendor G 10,053,600 1,463,044 7.9 % Vendor H 6,846,214 996,291 5.4 % Vendor C 4,746,530 690,736 3.7 % Total 84,830,864 $ 12,344,960 66.9 % Year Ended March 31, 2022 (RMB) (US$) Vendor A 35,172,250 $ 5,540,508 20.9 % Vendor B 16,227,146 2,556,181 9.6 % Vendor C 9,995,189 1,574,492 5.9 % Vendor D 7,426,500 1,169,859 4.4 % Vendor E 6,621,300 1,043,020 3.9 % Total 75,442,385 $ 11,884,060 44.7 % Details of Lakeshore Group’s key vendors accounting for accounts payable are as follows: As of March 31, 2024 (RMB) (US$) Vendor D 3,408,375 480,391 5.0 % Total 3,408,375 $ 480,391 5.0 % As of March 31, 2023 (RMB) (US$) Vendor A 3,220,000 $ 468,589 4.0 % Vendor F 420 61 0.0 % Vendor H 16,118 2,346 0.0 % Total 3,236,538 $ 470,996 4.0 % Lakeshore Group’s business operation has been, and may continue to be, negatively affected by the outbreak of COVID-19. While many of the restrictions on movements within China have been relaxed, there is great uncertainty around the future of the COVID-19 outbreak and how it will impact Lakeshore Group’s operations. If the outbreak persists or escalates, Lakeshore Group may be subject to further negative impact on business operations and financial condition.
Fair Value Measurements	Fair Value Measurements ASC 825- 10 requires certain disclosures regarding the FV of financial instruments. FV is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. A three-level FV hierarchy prioritizes the inputs used to measure FV. The hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure FV are as follows: ● Level 1 - inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets. ● Level 2 - inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, quoted market prices for identical or similar assets in markets that are not active, inputs other than quoted prices that are observable and inputs derived from or corroborated by observable market data. ● Level 3 - inputs to the valuation methodology are unobservable. Unless otherwise disclosed, the FV of Lakeshore Group’s financial instruments including cash, restricted cash, accounts receivable, advance to suppliers, prepaid expenses and other current assets, short-term bank loans and other borrowings, accounts payable, warrant liability, and accrued expenses and other current liabilities approximate their recorded values due to their short-term maturities. The FV of longer-term leases approximates their recorded values as their stated interest rates approximate the rates currently available. Lakeshore Group’s non-financial assets, such as property and equipment would be measured at FV only if they were determined to be impaired.
Social Security Insurance	Social Security Insurance Employees of Lakeshore Group’s subsidiaries that operate in the PRC are required to participate in a pension scheme operated by the local municipal government. According to the Social Insurance Law of the PRC (the “Social Security Insurance Law”) promulgated by the Standing Committee of the National People’s Congress (the “Standing Committee”) that became effective on December 29, 2018, there are five basic types of social security insurance, which include: basic pension, basic medical, unemployment, work-related injury and maternity insurance (collectively known as “social security insurance”). Both employees and employers make contributions for the first three kinds of social security insurance; and only employers make contributions for the latter two kinds, which means the employers must pay all or a portion of the social security insurance premiums for their employees. If the Lakeshore Group does not fully comply with the relevant requirements and does not make social insurance contributions in full to the social insurance scheme for the employees of PRC affiliated entities, the Lakeshore Group will be required to make up the social insurance contributions as well as to pay late fees at 0.05% per day of the outstanding amount from the due date. If the Lakeshore Group fails to make up for the shortfalls within the prescribed time limit, the relevant administrative authorities could impose a fine of one to three times the outstanding amount and file applications to competent courts for compulsory enforcement of payment and deposit. No fine or compulsory enforcement had been imposed by relevant authorities in connection with the delayed payment of the social security insurance premiums by the Lakeshore Group. As of March 31, 2024, 2023 and 2022, Lakeshore Group’s recorded late fees of RMB10.7 million, RMB9.9 million and RMB9.5 million, respectively, for its liabilities related to social security insurance.
Leases	Leases Under ASC Topic 842, Leases (“ASC 842”), Lakeshore Group determines if an arrangement is or contains a lease at inception. For leases with a term of 12 months or less, Lakeshore Group does not recognize a right-of-use (“ROU”) asset or lease liability. Lakeshore Group’s operating leases are recognized on its consolidated balance sheets as noncurrent assets, current liabilities and noncurrent liabilities. Lakeshore Group does not have any finance leases. ROU assets are Lakeshore Group’s right to use an underlying asset for the lease term and lease liabilities represent Lakeshore Group’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. As Lakeshore Group’s leases typically do not provide an implicit rate, Lakeshore Group uses an estimate of its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. The lease terms may include options to extend or terminate the lease when it is reasonably certain that Lakeshore Group will exercise that option. Lease expense is recognized on a straight-line basis over the lease term. For leases with terms greater than 12 months, Lakeshore Group records the related asset and lease liability at the present value of lease payments over the lease term. For leases with terms less than 12 months, Lakeshore Group records rents in administrative expenses.
Government Grants	Government Grants Government grants are primarily subsidies received from PRC governments for operating a business in their jurisdictions and in compliance with specific policies promoted by the government authorities. Lakeshore Group’s PRC-based subsidiaries received specific subsidies and other subsidies from certain local governments. Specific subsidies are subsidies the local government has set certain conditions for the subsidies. Other subsidies are subsidies the local government has not set any conditions and are not tied to future trends or performance of Lakeshore Group, receipt of such subsidy is not contingent upon any further actions or performance of Lakeshore Group and the amounts do not have to be refunded under any circumstances. Specific subsidies are recorded as deferred government grants upon receipt and are recognized as government grants recognized in income when the conditions are met. Other subsidies are recognized as other income upon receipt as further performance by Lakeshore Group is not required. Government grants for research and development (“R&D”) are recognized as a reduction to R&D expenses when the conditions attached to the grants are met or recognized as government grants recognized in income in the period when the conditions are met after the expenses are incurred. Government grants for property, plant and equipment are deferred and recognized as a reduction to the related depreciation and amortization expenses in the same manner as the property, plant and equipment are depreciated.
Warrants	Warrants Lakeshore Group accounts for warrants as either equity-method or liability-method instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in ASC 480 and ASC 815. Warrants recorded as equity are recorded at their relative FV determined at the issuance date and remeasurement is not required. Warrants recorded as liabilities are recorded at their FV, within warrant liabilities on the consolidated balance sheets and are remeasured on each reporting date with changes recorded in FV changes of warrant liabilities on the consolidated statements of operations and comprehensive loss. Upon the consummation of the Business Combination, each Summit Warrant outstanding immediately prior had ceased to be a warrant with respect to Summit Public Shares and was assumed by Lakeshore Biopharma and converted into a Lakeshore Biopharma Warrant entitling the holder thereof to purchase such number of Ordinary Share on a one-on-one basis. After the merger with Summit, the Company accounted for the 10,750,000 public warrants as equity and 6,000,000 private warrants as liabilities.
Revenue from Contracts with Customers	Revenue from Contracts with Customers Lakeshore Group follows ASC 606 - “Revenue from Contracts with Customers” for all periods presented. ASC 606 established principles for reporting information about the nature, amount, timing, and uncertainty of revenue and cash flows arising from our contracts to provide services to customers. Based on the following five steps analysis, revenues from contracts with customers are recognized when control of the promised goods or services is transferred to the customers, in an amount that reflects the consideration Lakeshore Group expects to be entitled in exchange for those goods or services. Step 1: Identify the contract with the customer; Step 2: Identify the performance obligations in the contract; Step 3: Determine the transaction price; Step 4: Allocate the transaction price to the performance obligations in the contract; and Step 5: Recognize revenue when Lakeshore Group satisfies a performance obligation Lakeshore Group is principally engaged in the research, development, manufacturing and sale of vaccines and therapeutic biologics. Lakeshore Group’s revenues primarily streams from the sales of vaccines. The core principle underlying the revenue recognition in ASC 606 is that Lakeshore Group recognizes revenue for the transfer of vaccines to customers in an amount that reflects the consideration to which Lakeshore Group expects to be entitled. This requires Lakeshore Group to identify contractual performance obligations and determine whether revenue should be recognized at a point in time or over time. Lakeshore Group’s sales contracts of vaccines have one performance obligation that is to sell vaccines to the customers. The sales contracts with customers do not involve variable considerations, such as discounts and rebates. And according to the historical operation, discounts and rebates have never occurred. The customer pays after acceptance of the vaccines. According to ASC 606, the relevant revenue recognition is based on customer acceptance confirmation. In accordance with ASC606-10-55-36 through 55-40, Lakeshore Group evaluates whether it is appropriate to record the gross amount of vaccines and related costs or the net amount earned as commissions. When the entity is a principal, that the entity obtains control of the specified goods or services before they are transferred to the customers, the revenues should be recognized in the gross amount of consideration to which it expects to be entitled in exchange for the specified goods or services transferred. When the entity is an agent and its obligation is to facilitate third parties in fulfilling their performance obligation for specified goods or services, the revenues should be recognized in the net amount for the amount of commission which the entity earns in exchange for arranging for the specified goods or services to be provided by other parties. Revenues are recorded net of value-added taxes. Lakeshore Group sells vaccines to the customers, and it obtains control of the vaccines before customer acceptance confirmation. Therefore, Lakeshore Group is a principal, and the revenues should be recognized according to the gross method.
Cost of Revenues	Cost of Revenues Cost of revenues consists primarily of the cost of merchandise sold and write-down of inventories during the production process due to damage or destruction
General and Administrative Expenses	General and Administrative Expenses General and administrative expenses consist mainly of payroll and related costs for employees involved in general corporate functions, including accounting, finance, tax, legal and human resources, professional fees, value-added taxes and other general corporate expenses as well as costs associated with the use by these functions of facilities and equipment, such as depreciation and rental expenses.
Selling and Marketing Expenses	Selling and Marketing Expenses Selling and marketing expenses consist mainly of payroll and benefits for employees involved in the sales and distribution functions, meeting/event fees, promotion fees, marketing and selling expenses that are related to events and activities at Lakeshore Group’s service centers designed to promote product sales as well as operating expenses related to the service centers.
Research and Development Expenses	Research and Development Expenses Research and development expenses include costs directly attributable to the conduct of research and development projects, primarily consist of salaries and other employee benefits, testing and clinical trial expenses, consulting service fees, depreciation and amortization, and office and leasing expenses. All costs associated with research and development are expensed as incurred.
Other Income (Expenses	Other Income (Expenses Other income (expenses) consists of miscellaneous income and expenses not directly related to Lakeshore Group’s core business operations. Other income primarily consists of recovery of previously written-off accounts receivable, and write-off of payment obligations that are either more than three years old or no longer justifiable. Other expenses primarily consist of late fees related to Lakeshore Group’s income tax and social security insurance payment obligations, charitable donation, medical waste disposal fee and financial expenses. From December 2013 to June 2019, because Lakeshore Group was undergoing the construction and certification process of new manufacturing plant, Lakeshore Group didn’t produce and market its rabies vaccine and did not pay any income taxes nor social security insurance for its employees. It accounts for late fees as disclosed in the statements of operations.
Income Taxes	Income Taxes Cayman Islands. Hong Kong. Singapore. China. United States. Philippines. Current tax assets and liabilities are measured at the amount expected to be recovered from or paid to the taxation authorities, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the Relevant Periods, taking into consideration interpretations and practices prevailing in the countries in which Lakeshore Group operates. Deferred tax is provided, using the liability method in accordance with ASC740, Income Taxes Deferred tax liabilities are recognized for all taxable temporary differences, except: ● when the deferred tax liability arises from the initial recognition of goodwill or an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss; and ● in respect of taxable temporary differences associated with investments in subsidiaries when the timing of the reversal of the temporary differences can be controlled and it is probable that the temporary differences will not reverse in the foreseeable future. Deferred tax assets are recognized for all deductible temporary differences, and the carryforward of unused tax credits and any unused tax losses. Deferred tax assets are recognized to the extent that it is probable that taxable profit will be available against which the deductible temporary differences, and the carryforward of unused tax credits and unused tax losses can be utilized, except: ● when the deferred tax asset relating to the deductible temporary differences arises from the initial recognition of an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss; and ● in respect of deductible temporary differences associated with investments in subsidiaries, deferred tax assets are only recognized to the extent that it is probable that the temporary differences will reverse in the foreseeable future and taxable profit will be available against which the temporary differences can be utilized. The carrying amount of deferred tax assets is reviewed at the end of each reporting period and reduced to the extent it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be utilized. Deferred tax assets and liabilities are measured at the tax rates that are expected to apply to the period when the asset is realized or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the Relevant Periods. Deferred tax assets and liabilities are offset if and only if Lakeshore Group has a legally enforceable right to set off current tax assets and current tax liabilities and the deferred tax assets and deferred tax liabilities relate to income taxes levied by the same taxation authority on either the same taxable entity or different taxable entities which intend either to settle current tax liabilities and assets on a net basis, or to realize the assets and settle the liabilities simultaneously, in each future period in which significant amounts of deferred tax liabilities or assets are expected to be settled or recovered. Lakeshore Group records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rate is recognized in tax expense in the period that includes the enactment date of the change in tax rate. Lakeshore Group accounted for uncertainties in income taxes in accordance with ASC 740. Interest and penalties arising from underpayment of income taxes shall be computed in accordance with the related PRC tax law. The amount of interest expense is computed by applying the applicable statutory rate of interest to the difference between the tax position recognized and the amount previously taken or expected to be taken in a tax return. Interest and penalties recognized in accordance with ASC 740 are classified in the consolidated statements of comprehensive loss as non-operating expense.
Value Added Tax	Value Added Tax Value-added taxes (“VAT”) collected from customers for product sales and remitted to governmental authorities are presented on a net basis. VAT collected from customers is excluded from revenue. The VAT payable is presented in the account of accrued expenses and other liabilities.
Taxes other than Income Tax	Taxes other than Income Tax Under the PRC Tax Law, taxes other than income tax primarily include additional tax calculated based on value-added tax payable, individual income tax, property tax, etc.
Share-based Compensation	Share-based Compensation Lakeshore Group has a share option scheme to provide incentives and rewards to eligible participants. Employees (including directors) of Company receive granted shares and share options in the form of share-based payments, whereby employees render services as consideration for equity instruments (“equity-settled transactions”). The cost of equity-settled transactions with employees for grants is measured by reference to the FV of the equity instruments at the date when they are granted. The FV is determined by an external valuer using a binomial model. The cost of equity-settled transactions is recognized in employee benefit expense, together with a corresponding increase in equity, over the period in which the performance and/or service conditions are fulfilled. The cumulative expense recognized for equity-settled transactions at the end of each of the relevant periods until the vesting date reflects the extent to which the vesting period has expired and Lakeshore Group’s best estimate of the number of equity instruments that will ultimately vest. The charge or credit to the statement of profit or loss for a period represents the movement in the cumulative expense recognized as at the beginning and end of that period. Service and non-market performance conditions are not taken into account when determining the grant date FV of awards, but the likelihood of the conditions being met is assessed as part of the Lakeshore Group’s best estimate of the number of equity instruments that will ultimately vest. Market performance conditions are reflected within the grant date FV. Any other conditions attached to an award, but without an associated service requirement, are considered to be non-vesting conditions. Non-vesting conditions are reflected in the FV of an award and lead to an immediate expensing of an award unless there are also service and/or performance conditions. For awards that do not ultimately vest because non-market performance and/or service conditions have not been met, no expense is recognized. Where awards include a market or non-vesting condition, the transactions are treated as vesting irrespective of whether the market or non-vesting condition is satisfied, provided that all other performance and/or service conditions are satisfied. Where the terms of an equity-settled award are modified, as a minimum an expense is recognized as if the terms had not been modified, if the original terms of the award are met. In addition, an expense is recognized for any modification that increases the total fair value of the share-based payments, or is otherwise beneficial to the employee as measured at the date of modification. Where an equity-settled award is cancelled, it is treated as if it had vested on the date of cancellation, and any expense not yet recognized for the award is recognized. This includes any award where non-vesting conditions within the control of either the Lakeshore Group or the employee are not met. However, if a new award is substituted for the cancelled award, and is designated as a replacement award on the date that it is granted, the cancelled and new awards are treated as if they were a modification of the original award, as described in the previous paragraph. When an equity-settled award is surrendered, any expense recognized for the award is reversed immediately.
Comprehensive Loss	Comprehensive Loss Comprehensive loss consists of two components, net loss and other comprehensive income (loss). Other comprehensive income (loss) consists of foreign currency translation adjustment from Lakeshore Group not using RMB as its functional currency.
Loss Per Share	Loss Per Share In accordance with ASC 260, Earnings Per Share, basic loss per share is computed by dividing net loss attributable to ordinary shareholders by the weighted average number of ordinary shares outstanding during the period. Diluted loss per share is calculated by dividing net loss attributable to ordinary shareholders as adjusted for the effect of dilutive ordinary equivalent shares, if any, by the weighted average number of ordinary shares plus dilutive equivalent shares outstanding during the period. Dilutive equivalent shares are excluded from the computation of diluted loss per share if their effects would be anti-dilutive. No potential common shares were included in the computation of diluted loss per share when a loss from continuing operations exists.
Segment Reporting	Segment Reporting ASC 280, “Segment Reporting”, establishes standards for reporting information about operating segments on a basis consistent with Lakeshore Group’s internal organizational structure as well as information about geographical areas, business segments and major customers in the CFS for details on Lakeshore Group’s business segments. Lakeshore Group uses the management approach to determine reportable operating segments. The management approach considers the internal organization and reporting used by Lakeshore Group’s chief operating decision maker (“CODM”) for making decisions, allocating resources and assessing performance. Lakeshore Group’s CODM has been identified as the CEO, who reviews consolidated results when making decisions about allocating resources and assessing performance of Lakeshore Group. Based on management’s assessment, Lakeshore Group has only one operating segment, which is the development, production, marketing and sale of biopharmaceutical products. No operating segments were aggregated to form the reportable operating segment.
Significant Risks	Significant Risks Currency risk A majority of Lakeshore Group’s expenses are denominated in RMB and a significant portion of Lakeshore Group and its subsidiaries’ assets and liabilities are denominated in RMB. RMB is not freely convertible into foreign currencies. In the PRC, certain foreign exchange transactions are required by law to be transacted only by authorized financial institutions at exchange rates set by the People’s Bank of China (“PBOC”). Remittances in currencies other than RMB by Lakeshore Group in China must be processed through the PBOC or other Company foreign exchange regulatory bodies which require certain supporting documentation in order to affect the remittance. Lakeshore Group maintains bank accounts in the PRC. On May 1, 2015, China’s new Deposit Insurance Regulation came into effect, pursuant to which banking financial institutions, such as commercial banks, established in the PRC are required to purchase deposit insurance for deposits in RMB and in foreign currency placed with them. Such Deposit Insurance Regulation would not be effective in providing complete protection for Lakeshore Group’s accounts, as its aggregate deposits are higher than the compensation limit, which is RMB500,000 ($70,472) for one bank. However, Lakeshore Group believes the risk of failure of any of these Chinese banks is remote. Bank failure is uncommon in the PRC and Lakeshore Group believes that those Chinese banks that hold Lakeshore Group’s cash are financially sound based on public available information. Concentration and political risk Currently, Lakeshore Group has significant operations in the PRC. Accordingly, Lakeshore Group’s business, financial condition and results of operations may be influenced by the political, economic and legal environment in the PRC, and by the general state of the PRC’s economy. Lakeshore Group’s operations in the PRC are subject to specific considerations and significant risks not typically associated with companies in North America and Western Europe. Lakeshore Group’s results may be adversely affected by changes in governmental policies in laws and regulations, anti-inflationary measures, currency conversion and remittance abroad, and rates and methods of taxation, among other things. Although Lakeshore Group has not experienced losses from these situations and believes it is in compliance with existing laws, this may not be indicative of future results. Interest rate risk Fluctuations in interest rates may negatively affect Lakeshore Group’s financial condition and results of operations. Lakeshore Group is exposed to floating interest rate risk on cash deposit and floating rate borrowings, and the risks due to changes in interest rates is not material. Lakeshore Group has not used any derivative financial instruments to manage Lakeshore Group’s interest risk exposure.
Related Parties	Related Parties A party is considered related to Lakeshore Group if the party directly or indirectly or through one or more intermediaries, controls, is controlled by, or is under common control with Lakeshore Group. Related parties also include principal owners of Lakeshore Group, its management, members of the immediate families of principal owners of Lakeshore Group and its management and other parties with which Lakeshore Group may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests. A party which can significantly influence the management or operating policies of the transacting parties or if it has an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests is also a related party.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements Segment Reporting (Topic 280), Improvements to Reportable Segment Disclosures: Income Taxes (Topic 740), Improvements to Income Tax Disclosures: In December 2023, the FASB issued ASU 2023-09, which requires disaggregated information about a reporting entity’s effective tax rate reconciliation as well as additional information on income taxes paid. The ASU is effective on a prospective basis for annual periods beginning after December 15, 2024. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance. This ASU will likely result in additional required disclosures being included in CFS when adopted. The Company is currently evaluating the provisions of this ASU. Lakeshore Group does not believe other recently issued but not yet effective accounting standards, if currently adopted, would have a material effect on Lakeshore Group’s CFS.

Organization and Business Des_2

Organization and Business Description (Tables)	12 Months Ended
	Mar. 31, 2024
Organization and Business Description [Abstract]
Schedule of Lakeshore Group Legal Entity	As of March 31, 2024, Lakeshore Group consists of the following legal entities: Legal Entity Nature of Operations Date of Incorporation Place of Incorporation Lakeshore Biopharma Co., Ltd. (“Lakeshore Biopharma”)*** Holding Company November 16, 2020 Cayman Islands YishengBio (Hong Kong) Holdings Limited (“HK Yisheng”) Holding Company December 28, 2020 Hong Kong Lakeshore Biopharma (Singapore) Pte. Ltd. (“Singapore Yisheng”)** Research and development of vaccines and therapeutic biologics November 28, 2009 Singapore Yisheng US Biopharma Inc. (“US Yisheng”) Research of vaccines and therapeutic biologics September 29, 2009 US Liaoning Yisheng Biopharma Co., Ltd. (“Liaoning Yisheng”)* Research and development, manufacturing and commercialization of vaccines and therapeutic biologics May 26, 1994 PRC Beijing Yisheng Biotechnology Co., Ltd. (“Beijing Yisheng”) Research and development of vaccines and therapeutic biologics February 4, 2021 PRC Hudson Biomedical Group Co., Ltd. Purpose of effecting a merger August 15, 2022 Cayman Islands YS Biopharma (Philippines) Inc. (“Philippines Yisheng”) Researching, developing, producing, wholesaling and commercializing pharmaceutical products May 9, 2023 Philippines * Liaoning Yisheng was incorporated May 26, 1994, and acquired by Lakeshore Group in fiscal 2005. On March 26, 2024, Liaoning Yisheng Biopharma Co., Ltd. Beijing Branch (“Liaoning Yisheng Beijing Branch”) was incorporated for research and development, manufacturing and commercialization of vaccines and therapeutic biologics. ** Singapore Yisheng was incorporated November 28, 2009, and acquired by Lakeshore Group in fiscal 2011. Singapore Yisheng was formerly known as Yisheng Biopharma (Singapore) Pte. Ltd. with the name effective on July 22, 2024 *** Lakeshore Biopharma, formerly known as YS Biopharma Co., Ltd, with the name effective on May 23, 2024.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Mar. 31, 2024
Summary of Significant Accounting Policies [Abstract]
Schedule of Consolidated Statements of Operations and Comprehensive Loss	Certain prior year amounts have been reclassified to conform with the current year presentation, as follows (in RMB). Previously reported March 31, (Decrease)/ March 31, (Reclassified) Consolidated Statements of Operations and Comprehensive Loss General and administrative 81,595,277 (8,655,487 ) 72,939,790 Impairment loss on inventory, property, plant and equipment and other assets - 8,655,487 8,655,487 Previously reported March 31, (Decrease)/ March 31, (Reclassified) Consolidated Statements of Operations and Comprehensive Loss General and administrative 107,620,500 (9,476,354 ) 98,144,146 Impairment loss on inventory, property, plant and equipment and other assets - 9,476,354 9,476,354
Schedule of Currency Exchange Rates Used in Preparing Lakeshore Group’s CFS	The following table outlines the currency exchange rates used in preparing Lakeshore Group’s CFS: As of March 31, Years Ended March 31, 2023 2024 2022 2023 2024 Foreign currency Balance Sheet Balance Sheet Profit/Loss Profit/Loss Profit/Loss RMB:1US$ 6.8717 7.0950 6.4598 6.6100 6.9834 RMB:1S$ 5.1760 5.2762 4.7850 4.9346 5.2261 RMB:1PHP NA 0.1286 NA NA 0.1275
Schedule of Property, Plant and Equipment to Its Residual Value Over its Estimated Useful Life	Depreciation is calculated on the straight-line basis to reduce the cost of each item of property, plant and equipment to its residual value over its estimated useful life. Category Estimated useful life Plant and building 6-20 years Machinery and equipment 5-10 years Furniture and fixtures 3-7 years Motor vehicle 4-5 years Leasehold improvement Lesser of the lease term or life of assets
Schedule of Percentage of Lakeshore Group’s Top 5 Vendors Accounting for Total Purchases	Details of Lakeshore Group’s top 5 vendors accounting for total purchases are as follows: Year Ended March 31, 2024 (RMB) (US$) Vendor D 36,567,150 $ 5,153,932 20.2 % Vendor I 19,635,180 2,767,467 10.8 % Vendor C 13,260,918 1,869,051 7.3 % Vendor J 10,090,875 1,422,252 5.6 % Vendor G 9,544,080 1,345,184 5.3 % Total 89,098,203 $ 12,557,886 49.2 % Year Ended March 31, 2023 (RMB) (US$) Vendor A 48,006,500 $ 6,986,117 37.9 % Vendor F 15,178,020 2,208,772 12.0 % Vendor G 10,053,600 1,463,044 7.9 % Vendor H 6,846,214 996,291 5.4 % Vendor C 4,746,530 690,736 3.7 % Total 84,830,864 $ 12,344,960 66.9 % Year Ended March 31, 2022 (RMB) (US$) Vendor A 35,172,250 $ 5,540,508 20.9 % Vendor B 16,227,146 2,556,181 9.6 % Vendor C 9,995,189 1,574,492 5.9 % Vendor D 7,426,500 1,169,859 4.4 % Vendor E 6,621,300 1,043,020 3.9 % Total 75,442,385 $ 11,884,060 44.7 %
Schedule of Balance and Percentage of Lakeshore Group’s Top 5 Vendors Accounting for Total Purchases	Details of Lakeshore Group’s key vendors accounting for accounts payable are as follows: As of March 31, 2024 (RMB) (US$) Vendor D 3,408,375 480,391 5.0 % Total 3,408,375 $ 480,391 5.0 % As of March 31, 2023 (RMB) (US$) Vendor A 3,220,000 $ 468,589 4.0 % Vendor F 420 61 0.0 % Vendor H 16,118 2,346 0.0 % Total 3,236,538 $ 470,996 4.0 %

Accounts Receivable, Net (Table

Accounts Receivable, Net (Tables)	12 Months Ended
	Mar. 31, 2024
Accounts Receivable, Net [Abstract]
Schedule of Accounts Receivable, Net	Accounts receivable, net are as follows: As of March 31, 2023 2024 2024 (RMB) (RMB) (US$) Trade receivables 487,418,616 473,515,321 $ 66,739,298 Allowance for expected credit losses (24,366,824 ) (29,354,030 ) (4,137,284 ) Accounts receivable, net 463,051,792 444,161,291 $ 62,602,014
Schedule of Analysis of the Movements in the Allowance for Doubtful Accounts	Below is an analysis of the movements in the allowance for expected credit losses: Year Ended March 31, 2022 2023 2024 2024 (RMB) (RMB) (RMB) (US$) Balance at beginning of the year 8,530,951 13,615,875 24,366,824 $ 3,434,366 Additions 5,084,924 10,750,949 4,987,206 702,918 Balance at end of the year 13,615,875 24,366,824 29,354,030 $ 4,137,284

Inventories, Net (Tables)

Inventories, Net (Tables)	12 Months Ended
	Mar. 31, 2024
Inventories, Net [Abstract]
Schedule of Inventories	Lakeshore Group’s inventories consist of the following: As of March 31, 2023 2024 2024 (RMB) (RMB) (US$) Raw materials 50,453,180 68,613,919 $ 9,670,743 Work in progress 61,275,177 49,083,445 6,918,033 Finished goods 78,432,041 153,879,476 21,688,439 Allowance for damaged inventories (4,779,446 ) (68,154,238 ) (9,605,953 ) Inventories, net 185,380,952 203,422,602 $ 28,671,262
Schedule of Movements in the Allowance for Slow-Moving or Obsolete Inventories	The movement in the allowance for damaged inventories is as follows: Year Ended March 31, 2022 2023 2024 2024 (RMB) (RMB) (RMB) (US$) Balance at beginning of the year 41,301,797 5,503,029 4,779,446 $ 673,636 Additions 4,393,629 3,670,046 68,221,016 9,615,365 Inventories written off (40,192,397 ) (4,393,629 ) (4,846,224 ) (683,048 ) Balance at end of the year 5,503,029 4,779,446 68,154,238 $ 9,605,953

Property, Plant and Equipment_2

Property, Plant and Equipment, Net (Tables)	12 Months Ended
	Mar. 31, 2024
Property, Plant and Equipment, Net [Abstract]
Schedule of Property, Plant and Equipment	Property, plant and equipment consists of the following: As of March 31, 2023 2024 2024 (RMB) (RMB) (US$) Cost Construction in progress 309,948,621 255,113,837 $ 35,956,848 Plant and buildings 178,756,490 217,248,236 30,619,906 Machinery and equipment 237,637,928 255,507,522 36,012,336 Electronic equipment 11,117,440 10,335,481 1,456,727 Motor vehicles 3,031,087 3,081,506 434,321 Office equipment and furniture 34,423,995 42,870,071 6,042,294 Leasehold improvements 5,597,019 4,862,781 685,381 Total Cost 780,512,580 789,019,434 111,207,813 Less: accumulated depreciation (178,864,241 ) (205,542,536 ) (28,970,054 ) Less: asset impairment (29,891,896 ) (110,128,892 ) (15,522,043 ) Property and equipment, net 571,756,443 473,348,006 $ 66,715,716

Prepaid Expenses and Other Cu_2

Prepaid Expenses and Other Current Assets, Net (Tables)	12 Months Ended
	Mar. 31, 2024
Prepaid Expenses and Other Current Assets, Net [Abstract]
Schedule of Prepaid Expenses and Other Current Asset, Net	Prepaid expenses and other current asset, net consist of the following: As of March 31, 2023 2024 2024 (RMB) (RMB) (US$) Deposits (1) 4,339,791 4,043,044 $ 569,844 Staff advances (2) 606,859 174,810 24,638 Staff’s social security (3) 252,090 158,872 22,392 Value added tax recoverable (4) 4,249,718 1,598,117 225,246 Clinical trial insurance (5) 178,699 - - Other receivables (6) 901,355 1,395,246 196,652 Allowance (7) (115,743 ) - - Total 10,412,769 7,370,089 $ 1,038,772 (1) Deposits primarily are to Centers for Disease Control and Prevention (“CDCs”) in connection with participation in the public tender process held by province-level CDCs. (2) Staff advances primarily are paid to employees in advance of their expected business travel or in connection with various expenses incurred in the ordinary course of business, such as sales and marketing activities. (3) Staff social security primarily is the portion of the government mandated defined contribution plan that should be made by employees. But this portion should be paid to the government by Lakeshore Group on behalf of the employees pursuant to PRC labor regulation. When Lakeshore Group pays wages to employees, this portion should be deducted accordingly. (4) Value-added taxes (“VAT”) includes input tax on purchase and output tax on sales. VAT collected from customers relating to product sales and remitted to governmental authorities is presented on a net basis, and it is excluded from revenue. Lakeshore Group is in a net VAT recoverable position when its input tax on purchase in the current year is greater than the output tax on sales. Such net amount can be deducted in the following years. (5) Clinical trial insurance is for human clinical trial legal liability insurance for evaluating the safety, immunogenicity and preliminary efficacy of multiple ascending doses of PIKA recombinant protein COID-19 Vaccine in the treatment of adult patients with mild to moderate COVID-19 infection. (6) Other receivables primarily consist of prepayment to third parties, such as freight, water and electricity, and promotion fees. (7) The allowance reflects Lakeshore Group’s best estimate of probable amounts not fully recoverable from the other receivables balance. Due to the fact that some employees resigned and lost contact, the cash paid to them in advance of their expected business travel or in connection with various expense incurred in the ordinary course of business might not be recovered.

Intangible Assets, Net (Tables)

Intangible Assets, Net (Tables)	12 Months Ended
	Mar. 31, 2024
Intangible Assets, Net [Abstract]
Schedule of Intangible Assets	Lakeshore Group’s intangible assets are presented below: As of March 31, 2023 2024 2024 (RMB) (RMB) (US$) Cost Patents 79,608,000 79,608,000 $ 11,220,296 Licenses, software and laboratory information system 10,435,478 10,435,478 1,470,821 Land use rights 67,181,860 67,181,860 9,468,902 Total Cost 157,225,338 157,225,338 22,160,019 Less: Accumulated Amortization (79,168,546 ) (85,980,002 ) (12,118,393 ) Intangible Assets, net 78,056,792 71,245,336 $ 10,041,626

Bank Loans and Other Borrowin_2

Bank Loans and Other Borrowings (Tables)	12 Months Ended
	Mar. 31, 2024
Bank Loans and Other Borrowings [Abstract]
Schedule of Bank Loans and Other Borrowings	As of March 31, Maturity Interest 2023 2024 2024 Date Rate (RMB) (RMB) (US$) China Guangfa Bank Co., Ltd. - Shenyang Branch (1) 41,191,031 18,357,574 $ 2,587,396 2024/9/1-2024/9/10 4.50 % Shanghai Pudong Development Bank Co., Ltd. Shenyang Branch (2) 82,964,518 44,983,415 6,340,157 2024/4/12-2025/3/21 4.00 % China CITIC Bank Shenyang Tiexi Branch (3) 23,596,350 12,388,064 1,746,027 2024/5/29 4.75%-5.00 % China CITIC Bank Shenyang Tiexi Branch (4) 5,000,000 - - 2023/5/25-2023/7/17 3.25 % China Construction Bank Shenyang Heping Branch (5) 31,330,000 38,990,000 5,495,419 2024/7/24-2024/12/6 4.00 % China Construction Bank Shenyang Heping Branch (6) 988,000 712,400 100,409 2024/7/19 3.90 % Zhongguancun Technology Leasing Co., Ltd (7) 8,666,664 8,666,664 1,221,517 2025/11/7 5.00 % China CITIC Bank Shenyang Tiexi Branch (8) - 1,400,000 197,322 2024/5/15-2024/11/15 4.55 % China CITIC Bank Shenyang Tiexi Branch (9) - 900,000 126,850 2024/7/8-2025/1/18 4.55 % China CITIC Bank Shenyang Tiexi Branch (10) - 880,000 124,031 2024/7/18-2025/1/18 4.55 % Industrial Bank Shenyang Branch (11) - 29,776,670 4,196,853 2024/8/15-2024/9/17 4.00 % R-Bridge Healthcare Fund, LP (12) - 118,354,060 16,681,333 2026/9/15 4.00 % Minsheng Bank Shenyang Huanghe Street Branch (13) - 29,990,032 4,226,925 2024/7/7-2025/1/16 4.00 % CITIC Financial Leasing Co., Ltd (15) - 13,141,853 1,852,270 2026/5/29 4.80 % Bank loans due within one year 193,736,563 318,540,732 $ 44,896,509 R-Bridge Healthcare Fund, LP (12) 274,868,000 - - 2026/9/15 4.00 % China Construction Bank Shenyang Heping Branch (5) 4,430,000 4,820,000 679,352 2025/10/15-2025/11/14 4.00 % Zhongguancun Technology Leasing Co., Ltd (7) 14,492,596 5,777,784 814,346 2025/11/7 5.00 % Shanghai Pudong Development Bank Co., Ltd. Shenyang Branch (2) - 38,428,802 5,416,322 2025/4/12-2025/11/7 4.00 % China CITIC Bank Shenyang Tiexi Branch (8) - 5,503,290 775,658 2025/5/15-2025/11/15 4.55 % China CITIC Bank Shenyang Tiexi Branch (9) - 3,618,982 510,075 2025/7/8-2026/1/18 4.55 % China CITIC Bank Shenyang Tiexi Branch (10) - 3,503,099 493,742 2025/7/18-2026/1/18 4.55 % Industrial Bank Shenyang Branch (14) - 19,993,041 2,817,906 2026/7/31-2026/9/3 4.25 % CITIC Financial Leasing Co., Ltd (15) - 17,338,782 2,443,801 2026/5/29 4.80 % Long-term bank loans 293,790,596 98,983,780 $ 13,951,202 Total bank loans 487,527,159 417,524,512 $ 58,847,711 (1) On September 13, 2021, Lakeshore Group entered into a credit facility of RMB100.0 million with China Guangfa Bank Co., Ltd. Shenyang Branch for three years to finance its working capital requirements. Lakeshore Group drew RMB35.8 million from June 19, 2023 to August 24, 2023, with interest at 5.66%, which was due from December 16, 2023 to March 12, 2024. The Company drew RMB 18.4 million from November 21, 2023 to March 1, 2024, with interest at 4.50%, which is due from September 1, 2024 to September 10, 2024. From June 2, 2023 to January 2, 2024, Lakeshore Group repaid RMB77.0 million. As of March 31, 2024, the balance of RMB18.4 million (US$2.6 million) was outstanding. (2) On July 12, 2021, Lakeshore Group entered into a credit facility of RMB140.0 million with Shanghai Pudong Development Bank Co., Ltd. Shenyang Branch for three years to finance its working capital requirements. Lakeshore Group drew RMB6.7 million on April 28, 2023 with interest at 5.30%, which was due on December 23, 2023, and drew RMB85.0 million from September 27, 2023 to February 28, 2024, of which RMB46.6 million is due from March 21, 2024 to March 21, 2025 and RMB38.4 million is due from April 12, 2025 to November 7, 2025. From April 4, 2023 to March 21, 2024, Lakeshore Group repaid RMB91.3 million. As of March 31, 2024, the balance of RMB83.4 million (US$11.8 million) is outstanding, of which RMB45.0 million (US$6.3 million) is due within one year. In April, 2024, RMB3.4 million (US$0.5 million) was repaid. (3) On January 13, 2023, Lakeshore Group entered into a credit facility of RMB40.0 million with China CITIC Bank Shenyang Tiexi Branch, due on November 1, 2025, to finance its working capital requirements. Lakeshore Group drew RMB12.8 million from May 24, 2023 to July 11, 2023 with interest at 5.00%, which was due from February 6, 2024 to May 29, 2024, and drew RMB3.55 million from July 17, 2023 to July 18,2023, with interest at 4.75%, which is due on May 29, 2024. From October 13, 2023 to February 19, 2024, Lakeshore Group repaid RMB27.6 million. As of March 31, 2024, the balance of RMB12.4 million (US$1.7 million) is outstanding. On May 29, 2024, RMB12.4 million (US$1.7 million) was repaid. (4) On May 6, 2022, China CITIC Bank Shenyang Tiexi Branch issued one letter of credit of RMB5.0 million to Lakeshore Group with interest at 3.25%. As of March 31, 2024, Lakeshore Group repaid it. (5) From September 9, 2022 to November 25, 2022, Lakeshore Group borrowed RMB31.3 million in total with interest at 4.00% from China Construction Bank Shenyang Heping Branch for one year. The loan was due from September 8, 2023 to November 24, 2023. From March 17, 2023 to November 15, 2023, Lakeshore Group borrowed RMB43.8 million with interest at 4.00% from China Construction Bank Shenyang Heping Branch. The loan will be due from July 24, 2024 to November 14, 2025. From June 5, 2023 to October 8, 2023, Lakeshore Group repaid RMB31.3 million. As of March 31, 2024, the balance of RMB43.8 million (US$6.2 million) is outstanding, of which RMB 39.0 million (US$5.5 million) is due within one year. On July 29, 2024, Lakeshore Group repaid RMB3.1 million (US$0.4 million). (6) On January 16, 2023, Lakeshore Group borrowed RMB988,000 with interest at 3.90% from China Construction Bank Shenyang Heping Branch for one year. On July 20, 2023, Lakeshore Group borrowed RMB712,400 with interest at 3.90% from China Construction Bank Shenyang Heping Branch for one year. On December 8, 2023, Lakeshore Group repaid RMB988,000. The balance of RMB0.7 million (US$0.1 million) as of March 31, 2024 was repaid on July 18, 2024. (7) On November 8, 2022, Lakeshore Group borrowed RMB26.0 million with interest at 5.00% from Zhongguancun Technology Leasing Co., Ltd for 36 months. Lakeshore Group shall repay RMB722,222 monthly from December 15, 2022 to October 15, 2025 and pay the last repayment of RMB722,230 on November 7, 2025. Lakeshore Group repaid RMB2.9 million from December 2022 to March 2023 and 8.7 million from April 2023 to March 2024. As of March 31, 2024, the balance of RMB14.4 million (US$2.0 million) is outstanding, of which RMB8.7 million (US$1.2 million) is due within one year. (8) On November 15, 2023, Lakeshore Group borrowed RMB6.9 million from China CITIC Bank Shenyang Tiexi Branch to finance working capital requirements, with interest at 4.55%. This loan will mature on November 15, 2025. As of March 31, 2024, the balance of RMB6.9 million (US$1.0 million) is outstanding, of which RMB1.4 million (US$0.2 million) is due within one year. In May 2024, RMB0.7 million (US$0.1 million) was repaid. (9) On January 8, 2024, Lakeshore Group borrowed RMB4.5 million with interest at 4.55% from China CITIC Bank Shenyang Tiexi Branch to finance working capital requirements. The loan will be due from July 8, 2024 to January 8, 2026. As of March 31, 2024, the balance of RMB4.5 million (US$0.6 million) is outstanding, of which RMB0.9 million (US$0.1 million) is due within one year. On July 4, 2024, RMB0.5 million (US$0.1 million) was repaid. (10) On January 18, 2024, Lakeshore Group borrowed RMB4.4 million with interest at 4.55% from China CITIC Bank Shenyang Tiexi Branch to finance working capital requirements. The loan will be due from July 18, 2024 to January 18, 2026. As of March 31, 2024, the balance of RMB4.4 million (US$0.6 million) is outstanding, of which RMB0.9 million (US$0.1 million) is due within one year. On July 17, 2024, RMB0.4 million (US$0.1 million) was repaid. (11) From August 16, 2023 to September 18, 2023, Lakeshore Group borrowed RMB29.8 million with interest at 4.00% from Industrial Bank Shenyang Branch for one year. The loan will be due from August 15, 2024 to September 17, 2024. As of March 31, 2024, the balance of RMB29.8 million (US$4.2 million) is outstanding. (12) On March 16, 2022, Lakeshore Group entered into a facility agreement with R-Bridge Healthcare Fund, LP (“R-Bridge”), as agent, to finance RMB274,868,000 (US$40,000,000) for 54 months with interest at 4.00%. On December 27, 2023, HK Yisheng received a letter from R-Bridge (the “R-Bridge Letter”), notifying the Company that it has reason to believe HK Yisheng defaulted under financial covenants and other obligations under the facility agreement, and under the instructions of the lenders to urge the Company to consider and reach an amicable solution with the lenders, including, without limitation, repaying the loan of $40.0 million in full, as soon as possible. The Company repaid $15.0 million, $10.0 million and $18.1 million respectively in February, March and April, 2024. As of April 29, 2024, the Company repaid its full amount of $40.0 million and accrued interest of $3.1 million. (13) From July 7, 2023 to January 16, 2024, Lakeshore Group borrowed RMB30.0 million with interest at 4.0% from Minsheng Bank Shenyang Huanghe Street Branch, due from July 7, 2024 to January 16, 2025. As of March 31, 2024, the balance of RMB30.0 million (US$4.2 million) is outstanding. In July, 2024, RMB11.3 million (US$1.6 million) was repaid. (14) From August 14, 2023 to September 14, 2023, Lakeshore Group borrowed RMB20.0 million with interest at 4.25% from Industrial Bank Shenyang Branch for about three years. The loan will be due from July 31, 2026 to September 3, 2026. As of March 31, 2024, the balance of RMB20.0 million (US$2.8 million) is outstanding. (15) On May 29, 2023, Lakeshore Group borrowed RMB40.0 million with interest at 4.80% from CITIC Financial Leasing Co., Ltd for three years. The loan will be due on May 29, 2026. From August 15, 2023 to February 18, 2024, Lakeshore Group repaid RMB9.5 million. As of March 31, 2024, the balance of RMB30.5 million (US$4.3 million) is outstanding, of which RMB13.1 million (US$1.9 million) is due within one year.

Leases (Tables)

Leases (Tables)	12 Months Ended
	Mar. 31, 2024
Leases [Abstract]
Schedule of Summary of Operating Leases	A summary of Lakeshore Group’s operating leases as of March 31, 2024 and 2023 is as follows: As of March 31, 2023 2024 2024 (RMB) (RMB) (US$) Operating lease ROU assets 11,132,428 7,275,367 $ 1,025,422 Operating lease liabilities – current 4,753,547 5,156,540 $ 726,785 Operating lease liabilities – non-current 6,348,890 1,783,593 $ 251,387 Weighted average remaining lease term 2.5 1.5 1.5 Weighted average discount rate 4.7 % 4.8 % 4.8 %
Schedule of Summary of Lease Cost Recognized Supplemental Cash Flow Information Related To Operating Leases	A summary of lease cost recognized in Lakeshore Group’s CFS and supplemental cash flow information related to operating leases is as follows: Years Ended March 31, 2022 2023 2024 2024 (RMB) (RMB) (RMB) (US$) Operating lease cost 4,594,967 5,002,684 5,252,026 $ 740,243 Cash paid for operating leases 4,587,894 3,349,856 5,272,746 $ 743,164
Schedule of Summary of Maturity of Operating Lease Liabilities Under the Non-Cancelable Operating Leases	A summary of maturity of operating lease liabilities under the Lakeshore Group’s non-cancelable operating leases as of March 31, 2024 is as follows: Year Ended March 31, (RMB) (US$) 2025 5,386,340 $ 759,174 2026 1,813,582 255,614 Total lease payments 7,199,922 1,014,788 Less: Interest (259,789 ) (36,616 ) Present value of operating lease liabilities 6,940,133 $ 978,172

Accrued Expenses and Other Cu_2

Accrued Expenses and Other Current Liabilities (Tables)	12 Months Ended
	Mar. 31, 2024
Accrued Expenses and Other Current Liabilities [Abstract]
Schedule of Accrued Expenses and Other Current Liabilities	Accrued expenses and other current liabilities consist of the following: As of March 31, 2023 2024 2024 (RMB) (RMB) (US$) Salaries and social security insurance (1) 55,188,497 59,297,454 $ 8,357,640 Promotion service fee (2) 87,567,459 114,508,487 16,139,322 Taxes other than income tax 379,595 3,012,548 424,602 Late fees (3) 9,927,056 10,683,258 1,505,745 Payable for property, plant and equipment 47,579,463 20,413,798 2,877,209 CDC transportation and storage fee 49,976,200 53,515,233 7,542,668 Guarantee deposits (4) 108,795,884 119,313,398 16,816,547 Professional service fee (5) 5,121,970 7,346,813 1,035,492 Interest payable (6) 6,055,245 9,909,655 1,396,710 Other (7) 6,945,275 10,737,325 1,513,366 Total 377,536,644 408,737,969 $ 57,609,301 (1) This includes unpaid salaries and outstanding social security insurance. During fiscal 2023, Lakeshore Group paid approximately RMB2.3 million to reduce its payable for salaries and social security insurance. During fiscal 2024, Lakeshore Group paid approximately RMB14.6 million to reduce its payable for salaries and social security insurance. Salaries and social security insurance payables consist of the following: (2) Promotion service fee primarily represents fees for the vaccine promotion, including design and implementation of academic activities, and collection of market information. (3) Late fees primarily are for corporate income tax, taxes other than income tax and social security insurance and housing reserve fund contributions due to the fact Lakeshore Group failed to pay income tax for calendar 2011 to calendar 2013, taxes other than income tax for calendar 2014 to the beginning of calendar 2021 and social security insurance for calendar 2015 to the beginning of calendar 2021. As of June, 2021, Lakeshore Group has paid the unpaid taxes, including income tax and other taxes other than income tax, as well as the late fees charge of them. From fiscal 2022, the late fee is incurred for unpaid social insurance. (4) Guarantee deposits primarily are refundable deposits paid to Lakeshore Group by external service providers to guarantee the external service providers will provide us with high quality and reasonable professional services. The external service providers’ professional service scope includes conducting market research and analysis, monitoring product clinical information, collecting and reporting adverse events of the product use, providing academic visits and education seminars, assisting product shipment and payment collections. Their services don’t assume inventory risk for the vaccines before they are transferred to the end customers. (5) Professional service fees primarily are from consultants and other advisors. (6) Interest payable primarily includes interest and royalties payable to R-Bridge Healthcare Fund, LP. (7) Others primarily are employees’ reimbursement and value added tax.
Schedule of Salaries and Social Security Insurance Payables	During fiscal 2024, Lakeshore Group paid approximately RMB14.6 million to reduce its payable for salaries and social security insurance. Salaries and social security insurance payables consist of the following: As of March 31, 2023 2024 2024 (RMB) (RMB) (US$) Salaries 47,390,831 51,990,629 $ 7,327,784 Social security insurance 7,179,828 6,656,034 938,130 Union Fee 617,838 650,791 91,726 Total 55,188,497 59,297,454 $ 8,357,640

Warrants (Tables)

Warrants (Tables)	12 Months Ended
	Mar. 31, 2024
Warrants [Abstract]
Schedule of Private Warrants are Accounted for as Liabilities	The Binomial Option Pricing Model with the following key assumptions is used for estimating the FV of private warrants. As of Fair value of the underlying asset as of the Valuation Date 0.1 Strike price 11.5 Life to expiration (Years.) 4.0 Volatility 88.5 % Number of steps 100 Redemption price (per share) 0.1
Schedule of the Warrant Liabilities	The table below reflects the movement of warrant liabilities for the year ended March 31, 2024: April 1, Change in Foreign March 31, March 31, (RMB) (RMB) (RMB) (RMB) (US$) Private Warrants 8,792,389 (4,458,844 ) 214,459 4,548,004 $ 641,015 Total 8,792,389 (4,458,844 ) 214,459 4,548,004 $ 641,015

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	12 Months Ended
	Mar. 31, 2024
Stock-Based Compensation [Abstract]
Schedule of Share Options Outstanding	The exercise prices and exercise periods, giving retroactive effect of combination in March 2023, of the share options outstanding as at the end of each of the Relevant Periods are as follows: Number of Average (RMB) As of March 31, 2021 3,253,565 29.3156 Granted during the period - - Forfeited during the period - - Exercised during the period - - Expired during the period - - As of March 31, 2022 3,253,565 29.3156 Granted during the period - - Forfeited during the period - - Exercised during the period - - Expired during the period - - As of March 31, 2023 3,253,565 32.4020 Granted during the period - Forfeited during the period - - Exercised during the period - - Expired during the period - - As of March 31, 2024 3,253,565 32.4020
Schedule of Exercise Prices and Exercise Periods	The exercise prices and exercise periods, giving retroactive effect of combination in March 2023, of the share options outstanding as at the end of the reporting periods are as follows: Year Ended 31 March 2024 Number of options Exercise price Exercise period (RMB) 1,533,252 13.938 2021-2031 613,369 25.8524 2021-2026 1,106,944 52.5376 2021-2026 3,253,565
Schedule of Stock-Based Compensation Expense	Stock-based compensation expense included in Lakeshore Group’s consolidated statements of operations and comprehensive loss is as follows: Years Ended March 31, 2022 2023 2024 2024 (RMB) (RMB) (RMB) (US$) Research and development 975,171 (997,846 ) - $ - General and administrative 6,789,277 4,502,847 9,789,686 1,379,801 Total stock-based compensation 7,764,448 3,505,001 9,789,686 $ 1,379,801

Related Party Transactions an_2

Related Party Transactions and Balances (Tables)	12 Months Ended
	Mar. 31, 2024
Related Party Transactions and Balances [Abstract]
Schedule of Related Parties that had Balances or Transactions	The following companies are related parties that had balances or transactions with Lakeshore Group as of and during the fiscal years ended March 31, 2024, 2023 and 2022: Name of related parties Relationship with Lakeshore Group Yisheng Biopharma Holdings Ltd. An entity controlled by Yi Zhang* Apex Prospect Limited A shareholder of Lakeshore Group Yi Zhang * A shareholder of Lakeshore Group Hui Shao Chief Executive Officer Nan Zhang Daughter of  Yi Zhang Xu Zhang Daughter Yi Zhang Rui Mi Spouse of  Yi Zhang * Yi Zhang was the chairman of the board of directors for the years ended March 31, 2023 and 2022. The entity controlled by him was the related parties of Lakeshore Group during fiscal years 2023 and 2022.
Schedule of Transactions with Related Parties	Lakeshore Group had the following transactions with related parties, all of which are interest-free during the fiscal years ended March 31, 2024, 2023 and 2022: Years Ended March 31, 2022 2023 2024 2024 (RMB) (RMB) (RMB) (US$) Amounts due from related party: Yisheng Biopharma Holdings Limited (Hong Kong) Receivable collected on behalf of Lakeshore Group 2,966,777 - - - Repayment to Lakeshore Group 33,055,610 - - -

Income Tax (Tables)

Income Tax (Tables)	12 Months Ended
	Mar. 31, 2024
Income Tax [Abstract]
Schedule of Effective Tax Rate	The following table reconciles the statutory rate to Lakeshore Group’s effective tax rate: Years Ended March 31, 2022 2023 2024 PRC statutory income tax rate 25.00 % 25.00 % 25.00 % Effect of different tax rates in different jurisdictions (18.26 )% (36.00 )% (13.32 )% Effect of PRC preferential tax rate 4.56 % 8.72 % (3.39 )% Effect of research and development expenses deduction and others 33.20 % 25.50 % 9.97 % Non-deductible expenses - % - % 0.06 % Temporary differences* 4.88 % 0.79 % (4.77 )% Change in valuation allowance (44.47 )% (23.23 )% (18.31 )% Effective tax rate 4.91 % 0.78 % (4.76 )% * Temporary differences primarily relate to impairment of inventories, property, plant and equipment and government grants.
Schedule of Net Deferred Tax Assets	Net deferred tax assets as of March 31, 2024 and 2023, consist of the following key components: As of March 31, 2023 2024 2024 (RMB) (RMB) (US$) Deferred tax assets: Write-down of inventories to net realizable value 716,917 10,223,137 $ 1,440,893 Impairment of property, plant and building 1,769,405 13,542,899 1,908,795 Deferred government grants 3,296,223 2,951,867 416,049 Losses available for offsetting against future taxable profits 39,366,020 81,220,037 11,447,503 Less: valuation allowance (39,366,020 ) (81,220,037 ) (11,447,503 ) Total deferred tax assets, net 5,782,545 26,717,903 3,765,737 Deferred tax liabilities: - Fair value adjustments arising from historical acquisition of subsidiaries (3,876,964 ) (3,083,714 ) (434,632 ) Total deferred tax liabilities (3,876,964 ) (3,083,714 ) (434,632 ) Net deferred tax asset 1,905,581 23,634,189 $ 3,331,105

Deferred Government Grants (Tab

Deferred Government Grants (Tables)	12 Months Ended
	Mar. 31, 2024
Deferred Government Grants [Abstract]
Schedule of Deferred Government Grants	Deferred government grants included the following: As of March 31, 2023 2024 2024 (RMB) (RMB) (US$) Government grants for property, plant and equipment Balance at beginning of the year 22,030,690 20,575,012 $ 2,899,931 Addition - 3,600,000 507,400 Recognized as income (1,455,678 ) (2,439,156 ) (343,786 ) Subtotal 20,575,012 21,735,856 $ 3,063,545 - Government grants for research and development - Balance at beginning of the year 10,318,528 5,327,196 $ 750,838 Addition 4,000,000 - - Recognized as income (8,991,332 ) (4,767,414 ) (671,940 ) Subtotal 5,327,196 559,782 $ 78,898 Total deferred government grants 25,902,208 22,295,638 $ 3,142,443 - Less：current portion 2,295,701 2,015,693 $ 284,100 - Non-current portion 23,606,507 20,279,945 $ 2,858,343

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Mar. 31, 2024
Commitments and Contingencies [Abstract]
Schedule of Commitments to Purchase Raw Materials or Service	As of March 31, 2024, Lakeshore Group has the following commitments to purchase raw materials or services: As of March 31, 2024 2024 (RMB) (US$) Construction in progress 27,531,843 $ 3,880,457 Other professional service fee 3,050,850 430,000 Purchase raw materials 38,275,819 5,394,760 Research and development 51,593,189 7,271,767 Total 120,451,701 $ 16,976,984

Segment Information (Tables)

Segment Information (Tables)	12 Months Ended
	Mar. 31, 2024
Segment Information [Abstract]
Schedule of Non-Current Assets	The location of these non-current assets can be aggregated to form the reportable geographical segment. As of March 31, 2023 2024 2024 (RMB) (RMB) (US$) PRC 645,210,788 527,009,381 $ 74,278,983 Other countries/regions 4,602,447 17,583,961 $ 2,478,360

Parent Company Only Condensed_2

Parent Company Only Condensed Financial Information (Tables)	12 Months Ended
	Mar. 31, 2024
Parent Company Only Condensed Financial Information [Abstract]
Schedule of Parent Company Balance Sheets	As of March 31, 2023 2024 2024 (RMB) (RMB) (US$) ASSETS Current Assets Cash 3,045,660 167,227,049 $ 23,569,704 Amounts due from related parties 1,039,986,896 1,145,781,243 161,491,366 Total current assets 1,043,032,556 1,313,008,292 185,061,070 Non-current assets Long-term investments, net 158,734,357 165,416,495 23,314,517 Long-term prepaid expense - 2,341,350 330,000 Total non-current assets 158,734,357 167,757,845 23,644,517 Total Assets 1,201,766,913 1,480,766,137 $ 208,705,587 LIABILITIES AND SHAREHOLDERS’ EQUITY Current Liabilities Accrued expenses and other liabilities 461,105,636 887,485,236 $ 125,086,010 Warrants liability 8,792,389 4,548,004 641,015 Amounts due to related parties 3,415,603 3,526,595 497,054 Total current liabilities 473,313,628 895,559,835 126,224,079 Total Liabilities 473,313,628 895,559,835 126,224,079 Shareholders’ equity: Ordinary shares, par value US$0.00002 per share; 9,950,000,000 shares authorized; 93,058,197 and 190,227,959 shares issued and outstanding as of March 31, 2023 and 2024, respectively* 12,297 26,105 3,679 Additional paid-in capital 2,656,891,036 2,950,862,914 415,907,387 Accumulated deficit (1,874,037,965 ) (2,307,502,836 ) (325,229,434 ) Accumulated other comprehensive loss (54,412,083 ) (58,179,881 ) (8,200,124 ) Total shareholders’ equity 728,453,285 585,206,302 82,481,508 Total liabilities and shareholders’ equity 1,201,766,913 1,480,766,137 $ 208,705,587 * Gives retroactive effect to the business combination in March 2023.
Schedule of Parent Company Statements of Operations and Comprehensive Loss	Years Ended March 31, 2022 2023 2024 2024 (RMB) (RMB) (RMB) (US$) Equity loss of subsidiaries (75,864,722 ) (138,758,136 ) (379,244,652 ) $ (53,452,382 ) Operating expenses: Selling and marketing - - General and administrative 29,178,255 7,630,726 60,553,856 8,534,722 Research and development 988,531 (887,280 ) 33,011 4,653 Total operating expenses 30,166,786 6,743,446 60,586,867 8,539,375 Loss from operations (106,031,508 ) (145,501,582 ) (439,831,519 ) (61,991,757 ) Other income (expenses): Financial expenses, net 27,107 1,119 1,907,804 268,894 Fair value changes of warrant liability - 21,358 4,458,844 628,449 Total other expense, net 27,107 22,477 6,366,648 897,343 Net loss (106,004,401 ) (145,479,105 ) (433,464,871 ) (61,094,414 ) Accretion to redemption value of convertible redeemable preferred shares (130,662,326 ) (137,991,697 ) - - Net loss attributable to Lakeshore Biopharma (236,666,727 ) (283,470,802 ) (433,464,871 ) (61,094,414 ) Net loss (106,004,401 ) (145,479,105 ) (433,464,871 ) (61,094,414 ) Foreign currency translation gain(loss) 38,864,606 (137,500,063 ) (3,767,798 ) (531,050 ) Total comprehensive loss (67,139,795 ) (282,979,168 ) (437,232,669 ) $ (61,625,464 ) Loss per share*: – Basic and Diluted (1.71 ) (2.35 ) (4.05 ) $ (0.57 ) Weighted average number of ordinary shares outstanding*: – Basic and Diluted 61,827,883 61,785,466 106,923,121 106,923,121 * Gives retroactive effect to the business combination in March 2023.
Schedule of Parent Company Statements of Cash Flows	Years Ended March 31, 2022 2023 2024 2024 (RMB) (RMB) (RMB) (US$) Net loss (106,004,401 ) (145,479,105 ) (433,464,871 ) $ (61,094,414 ) Equity loss of subsidiaries 75,864,722 138,758,136 379,244,652 53,452,382 Share-based compensation 7,764,448 3,505,001 9,789,686 1,379,801 Fair value changes of warrant liability - (21,358 ) (4,458,844 ) (628,449 ) Changes in operating assets and liabilities: Amounts due from related parties (23,299,705 ) (520,750,020 ) (105,794,347 ) (14,911,113 ) Amounts due to related parties (110,893 ) 260,208 110,992 15,644 Accrued expenses and other liabilities (24,732,348 ) 48,377,785 33,181,238 4,676,707 Prepaid expense - - (2,341,350 ) (330,000 ) Net cash used in operating activities (70,518,177 ) (475,349,353 ) (123,732,844 ) (17,439,442 ) Cash flows from investing activities: Payment for long-term investment (813,776 ) - (1,523,970 ) (214,795 ) Net cash used in investing activities (813,776 ) - (1,523,970 ) (214,795 ) Cash flows from financing activities: Proceeds from issuance of ordinary shares - - 284,196,000 40,055,814 Proceeds from acquisition - 252,457,329 - - Offering cost (35,884,661 ) - - Net cash provided by financing activities - 216,572,668 284,196,000 40,055,814 Effect of exchange rate on cash (6,353,461 ) 9,210,810 5,242,203 738,859 Net (decrease) increase in cash (77,685,414 ) (249,565,875 ) 164,181,389 23,140,436 Cash at the beginning of the year 330,296,949 252,611,535 3,045,660 429,268 Cash at the end of the year 252,611,535 3,045,660 167,227,049 $ 23,569,704 Non-cash transactions: Accretion to redemption value of convertible redeemable preferred shares 130,662,326 (137,991,697 ) - $ - Equity transaction from warrants - (8,870,007 ) - $ - Equity transaction from preferred shares - 1,636,897,084 - $ -

Organization and Business Des_3

Organization and Business Description (Details)	12 Months Ended
	Mar. 31, 2024 shares
Organization and Business Description [Line Items]
Number of companies and their subsidiaries owned	4
Lakeshore Biopharma [Member]
Organization and Business Description [Line Items]
Ordinary Share	1

Organization and Business Des_4

Organization and Business Description (Details) - Schedule of Lakeshore Group Legal Entity	12 Months Ended
	Mar. 31, 2024
Lakeshore Biopharma Co., Ltd. (“Lakeshore Biopharma”) [Member]
Schedule of Lakeshore Group Legal Entity [Line Items]
Nature of Operations	Holding Company	[1]
Date of Incorporation	Nov. 16, 2020	[1]
Place of Incorporation	Cayman Islands	[1]
YishengBio (Hong Kong) Holdings Limited (“HK Yisheng”) [Member]
Schedule of Lakeshore Group Legal Entity [Line Items]
Nature of Operations	Holding Company
Date of Incorporation	Dec. 28, 2020
Place of Incorporation	Hong Kong
Lakeshore Biopharma (Singapore) Pte. Ltd. (“Singapore Yisheng”) [Member]
Schedule of Lakeshore Group Legal Entity [Line Items]
Nature of Operations	Research and development of vaccines and therapeutic biologics	[2]
Date of Incorporation	Nov. 28, 2009	[2]
Place of Incorporation	Singapore	[2]
Yisheng US Biopharma Inc. (“US Yisheng”) [Member]
Schedule of Lakeshore Group Legal Entity [Line Items]
Nature of Operations	Research of vaccines and therapeutic biologics
Date of Incorporation	Sep. 29, 2009
Place of Incorporation	US
Liaoning Yisheng Biopharma Co., Ltd. (“Liaoning Yisheng”) [Member]
Schedule of Lakeshore Group Legal Entity [Line Items]
Nature of Operations	Research and development, manufacturing and commercialization of vaccines and therapeutic biologics	[3]
Date of Incorporation	May 26, 1994	[3]
Place of Incorporation	PRC	[3]
Beijing Yisheng Biotechnology Co., Ltd. (“Beijing Yisheng”) [Member]
Schedule of Lakeshore Group Legal Entity [Line Items]
Nature of Operations	Research and development of vaccines and therapeutic biologics
Date of Incorporation	Feb. 04, 2021
Place of Incorporation	PRC
Hudson Biomedical Group Co., Ltd. [Member]
Schedule of Lakeshore Group Legal Entity [Line Items]
Nature of Operations	Purpose of effecting a merger
Date of Incorporation	Aug. 15, 2022
Place of Incorporation	Cayman Islands
YS Biopharma (Philippines) Inc. (“Philippines Yisheng”) [Member]
Schedule of Lakeshore Group Legal Entity [Line Items]
Nature of Operations	Researching, developing, producing, wholesaling and commercializing pharmaceutical products
Date of Incorporation	May 09, 2023
Place of Incorporation	Philippines
[1] Lakeshore Biopharma, formerly known as YS Biopharma Co., Ltd, with the name effective on May 23, 2024.

Going Concern Uncertainty (Deta

Going Concern Uncertainty (Details)								12 Months Ended
		Apr. 30, 2024 USD ($)	Apr. 29, 2024 USD ($)	Mar. 31, 2024 USD ($)	Feb. 29, 2024 USD ($)	Feb. 09, 2024 USD ($) $ / shares shares	Dec. 27, 2023 USD ($)	Mar. 31, 2024 CNY (¥)	Mar. 31, 2024 USD ($)	Mar. 31, 2023 CNY (¥)	Mar. 31, 2022 CNY (¥)	Mar. 31, 2024 USD ($) $ / shares	Mar. 31, 2023 $ / shares
Going Concern Uncertainty [Line Items]
Net loss (in Yuan Renminbi)								¥ (433,464,871)	$ (61,094,414)	¥ (145,479,105)	¥ (106,004,401)
Accumulated deficit (in Yuan Renminbi)								(2,307,502,836)		(1,874,037,965)		$ (325,229,434)
Cash								246,351,231		¥ 370,108,059		34,721,808
Outstanding bank loans and other borrowings								417,500,000				$ 58,800,000
Repaying the loan							$ 40,000,000
Accrued interest			$ 3,100,000
Sale of ordinary shares (in Shares) | shares						95,269,762
Par value per share (in Dollars per share) | $ / shares	[1]											$ 0.00002	$ 0.00002
R-Bridge Healthcare Fund, LP [Member]
Going Concern Uncertainty [Line Items]
Repaid debt		$ 18,100,000		$ 10,000,000	$ 15,000,000
Repaid loan			$ 40,000,000
Cash [Member]
Going Concern Uncertainty [Line Items]
Cash								¥ 246,400,000				$ 34,700,000
Common Stock [Member]
Going Concern Uncertainty [Line Items]
Par value per share (in Dollars per share) | $ / shares						$ 0.00002
Private Placement [Member]
Going Concern Uncertainty [Line Items]
Sale of private placement						$ 40,000,000
Sale of ordinary shares (in Dollars per share) | $ / shares						$ 0.41986
[1] Gives retroactive effect to the business combination in March 2023.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details)	12 Months Ended
	Mar. 31, 2024 CNY (¥) shares	Mar. 31, 2023 CNY (¥)	Mar. 31, 2022 CNY (¥)	Mar. 31, 2024 USD ($) shares
Summary of Significant Accounting Policies [Line Items]
Advance to suppliers (in Yuan Renminbi) | ¥	¥ 2,724,906	¥ 54,870
Late fees	0.05%
Late fee charge of social insurance (in Yuan Renminbi) | ¥	¥ 10,700,000	¥ 9,900,000	¥ 9,500,000
Statutory income tax rate	25%	25%	25%
Number of operating segment	1
Bank	¥ 500,000			$ 70,472
Patents [Member]
Summary of Significant Accounting Policies [Line Items]
Estimated useful lives	15 years			15 years
Computer Software, Intangible Asset [Member]
Summary of Significant Accounting Policies [Line Items]
Estimated useful lives	10 years			10 years
Minimum [Member]
Summary of Significant Accounting Policies [Line Items]
Amortization term	48 years 9 months			48 years 9 months
Maximum [Member]
Summary of Significant Accounting Policies [Line Items]
Amortization term	50 years			50 years
United States [Member]
Summary of Significant Accounting Policies [Line Items]
Convenience translation rate	1			1
Statutory income tax rate	21%
State income tax rate	8.25%
China [Member]
Summary of Significant Accounting Policies [Line Items]
Convenience translation rate	7.095			7.095
Statutory income tax rate	25%
Singapore [Member]
Summary of Significant Accounting Policies [Line Items]
Statutory income tax rate	17%
Philippines [Member]
Summary of Significant Accounting Policies [Line Items]
Statutory income tax rate	20%
Subject to income tax rate	20%
Public Warrants [Member]
Summary of Significant Accounting Policies [Line Items]
Public warrants (in Shares) | shares	10,750,000			10,750,000
Private Warrants [Member]
Summary of Significant Accounting Policies [Line Items]
Public warrants (in Shares) | shares	6,000,000			6,000,000

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details) - Schedule of Consolidated Statements of Operations and Comprehensive Loss	12 Months Ended
	Mar. 31, 2024 CNY (¥)	Mar. 31, 2024 USD ($)	Dec. 31, 2023 CNY (¥)	Mar. 31, 2023 CNY (¥)	Dec. 31, 2022 CNY (¥)	Mar. 31, 2022 CNY (¥)
Condensed Statement of Income Captions [Line Items]
General and administrative, Total	¥ 140,086,062	$ 19,744,336	¥ 72,939,790	¥ 72,939,790	¥ 98,144,146	¥ 98,144,146
Impairment loss on inventory, property, plant and equipment and other assets, Total	¥ 157,415,875	$ 22,186,875	8,655,487	¥ 8,655,487	9,476,354	¥ 9,476,354
Previously Reported [Member]
Condensed Statement of Income Captions [Line Items]
General and administrative, Total			81,595,277		107,620,500
Impairment loss on inventory, property, plant and equipment and other assets, Total
Adjustment [Member]
Condensed Statement of Income Captions [Line Items]
(Decrease)/ Increase - General and administrative			(8,655,487)		(9,476,354)
(Decrease)/ Increase - Impairment loss on inventory, property, plant and equipment and other assets			¥ 8,655,487		¥ 9,476,354

Summary of Significant Accoun_5

Summary of Significant Accounting Policies (Details) - Schedule of Currency Exchange Rates Used in Preparing Lakeshore Group’s CFS	12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2022
United States of America, Dollars [Member]
Schedule of Currency Exchange Rates Used in Preparing Lakeshore Group’s CFS [Line Items]
Currency exchange rates as of Balance Sheet	7.095	6.8717
Currency exchange rates, Profit/Loss	6.9834	6.61	6.4598
Singapore, Dollars [Member]
Schedule of Currency Exchange Rates Used in Preparing Lakeshore Group’s CFS [Line Items]
Currency exchange rates as of Balance Sheet	5.2762	5.176
Currency exchange rates, Profit/Loss	5.2261	4.9346	4.785
Philippines, Pesos [Member]
Schedule of Currency Exchange Rates Used in Preparing Lakeshore Group’s CFS [Line Items]
Currency exchange rates as of Balance Sheet	0.1286
Currency exchange rates, Profit/Loss	0.1275

Summary of Significant Accoun_6

Summary of Significant Accounting Policies (Details) - Schedule of Property, Plant and Equipment to Its Residual Value Over its Estimated Useful Life	12 Months Ended
	Mar. 31, 2024
Leasehold improvement [Member]
Schedule of Property, Plant and Equipment to Its Residual Value Over its Estimated Useful Life [Line Items]
Leasehold improvement	Lesser of the lease term or life of assets
Minimum [Member] | Plant and building [Member]
Schedule of Property, Plant and Equipment to Its Residual Value Over its Estimated Useful Life [Line Items]
Estimated useful life of property, plant and equipment	6 years
Minimum [Member] | Machinery and equipment [Member]
Schedule of Property, Plant and Equipment to Its Residual Value Over its Estimated Useful Life [Line Items]
Estimated useful life of property, plant and equipment	5 years
Minimum [Member] | Furniture and fixtures [Member]
Schedule of Property, Plant and Equipment to Its Residual Value Over its Estimated Useful Life [Line Items]
Estimated useful life of property, plant and equipment	3 years
Minimum [Member] | Motor vehicle [Member]
Schedule of Property, Plant and Equipment to Its Residual Value Over its Estimated Useful Life [Line Items]
Estimated useful life of property, plant and equipment	4 years
Maximum [Member] | Plant and building [Member]
Schedule of Property, Plant and Equipment to Its Residual Value Over its Estimated Useful Life [Line Items]
Estimated useful life of property, plant and equipment	20 years
Maximum [Member] | Machinery and equipment [Member]
Schedule of Property, Plant and Equipment to Its Residual Value Over its Estimated Useful Life [Line Items]
Estimated useful life of property, plant and equipment	10 years
Maximum [Member] | Furniture and fixtures [Member]
Schedule of Property, Plant and Equipment to Its Residual Value Over its Estimated Useful Life [Line Items]
Estimated useful life of property, plant and equipment	7 years
Maximum [Member] | Motor vehicle [Member]
Schedule of Property, Plant and Equipment to Its Residual Value Over its Estimated Useful Life [Line Items]
Estimated useful life of property, plant and equipment	5 years

Summary of Significant Accoun_7

Summary of Significant Accounting Policies (Details) - Schedule of Percentage of Lakeshore Group’s Top 5 Vendors Accounting for Total Purchases - Vendors concentration risk [Member] - Total purchases [Member] ¥ in Millions, $ in Millions	12 Months Ended
	Mar. 31, 2024 CNY (¥)	Mar. 31, 2024 USD ($)	Mar. 31, 2023 CNY (¥)	Mar. 31, 2023 USD ($)	Mar. 31, 2022 CNY (¥)	Mar. 31, 2022 USD ($)
Vendor D [Member]
Concentration Risk [Line Items]
Concentration rick amount	¥ 36,567,150	$ 5,153,932			¥ 7,426,500	$ 1,169,859
Concentration risk percentage	20.20%	20.20%			4.40%	4.40%
Vendor I [Member]
Concentration Risk [Line Items]
Concentration rick amount	¥ 19,635,180	$ 2,767,467
Concentration risk percentage	10.80%	10.80%
Vendor C [Member]
Concentration Risk [Line Items]
Concentration rick amount	¥ 13,260,918	$ 1,869,051	¥ 4,746,530	$ 690,736	¥ 9,995,189	$ 1,574,492
Concentration risk percentage	7.30%	7.30%	3.70%	3.70%	5.90%	5.90%
Vendor J [Member]
Concentration Risk [Line Items]
Concentration rick amount	¥ 10,090,875	$ 1,422,252
Concentration risk percentage	5.60%	5.60%
Vendor G [Member]
Concentration Risk [Line Items]
Concentration rick amount	¥ 9,544,080	$ 1,345,184	¥ 10,053,600	$ 1,463,044
Concentration risk percentage	5.30%	5.30%	7.90%	7.90%
Top Vendors [Member]
Concentration Risk [Line Items]
Concentration rick amount			¥ 84,830,864	$ 12,344,960	¥ 75,442,385	$ 11,884,060
Concentration risk percentage			66.90%	66.90%	44.70%	44.70%
Vendor A [Member]
Concentration Risk [Line Items]
Concentration rick amount			¥ 48,006,500	$ 6,986,117	¥ 35,172,250	$ 5,540,508
Concentration risk percentage			37.90%	37.90%	20.90%	20.90%
Vendor F [Member]
Concentration Risk [Line Items]
Concentration rick amount			¥ 15,178,020	$ 2,208,772
Concentration risk percentage			12%	12%
Vendor H [Member]
Concentration Risk [Line Items]
Concentration rick amount			¥ 6,846,214	$ 996,291
Concentration risk percentage			5.40%	5.40%
Vendor B [Member]
Concentration Risk [Line Items]
Concentration rick amount					¥ 16,227,146	$ 2,556,181
Concentration risk percentage					9.60%	9.60%
Vendor E [Member]
Concentration Risk [Line Items]
Concentration rick amount					¥ 6,621,300	$ 1,043,020
Concentration risk percentage					3.90%	3.90%
Top Vendors [Member]
Concentration Risk [Line Items]
Concentration rick amount	¥ 89,098,203	$ 12,557,886
Concentration risk percentage	49.20%	49.20%

Summary of Significant Accoun_8

Summary of Significant Accounting Policies (Details) - Schedule of Balance and Percentage of Lakeshore Group’s Top 5 Vendors Accounting for Total Purchases - Vendors concentration risk [Member] - Accounts Payable [Member]	12 Months Ended
	Mar. 31, 2024 CNY (¥)	Mar. 31, 2023 CNY (¥)	Mar. 31, 2024 USD ($)	Mar. 31, 2023 USD ($)
Vendor D [Member]
Schedule of Percentage of YS Group’s Top 5 Vendors Accounting for Accounts Payable [Line Items]
Accounts payable	¥ 3,408,375		$ 480,391
Concentration risk	5%
Vendors [Member]
Schedule of Percentage of YS Group’s Top 5 Vendors Accounting for Accounts Payable [Line Items]
Accounts payable	¥ 3,408,375	¥ 3,236,538	$ 480,391	$ 470,996
Concentration risk	5%	4%
Vendor A [Member]
Schedule of Percentage of YS Group’s Top 5 Vendors Accounting for Accounts Payable [Line Items]
Accounts payable		¥ 3,220,000		468,589
Concentration risk		4%
Vendor F [Member]
Schedule of Percentage of YS Group’s Top 5 Vendors Accounting for Accounts Payable [Line Items]
Accounts payable		¥ 420		61
Concentration risk		0%
Vendor H [Member]
Schedule of Percentage of YS Group’s Top 5 Vendors Accounting for Accounts Payable [Line Items]
Accounts payable		¥ 16,118		$ 2,346
Concentration risk		0%

Accounts Receivable, Net (Detai

Accounts Receivable, Net (Details) - Schedule of Accounts Receivable, Net	Mar. 31, 2024 CNY (¥)	Mar. 31, 2024 USD ($)	Mar. 31, 2023 CNY (¥)
Schedule of Accounts Receivable, Net [Abstract]
Trade receivables	¥ 473,515,321	$ 66,739,298	¥ 487,418,616
Allowance for expected credit losses	(29,354,030)	(4,137,284)	(24,366,824)
Accounts receivable, net	¥ 444,161,291	$ 62,602,014	¥ 463,051,792

Accounts Receivable, Net (Det_2

Accounts Receivable, Net (Details) - Schedule of Analysis of the Movements in the Allowance for Doubtful Accounts	12 Months Ended
	Mar. 31, 2024 CNY (¥)	Mar. 31, 2024 USD ($)	Mar. 31, 2023 CNY (¥)	Mar. 31, 2022 CNY (¥)
Schedule of Analysis of the Movements in the Allowance for Doubtful Accounts [Abstract]
Balance at beginning of the year	¥ 24,366,824	$ 3,434,366	¥ 13,615,875	¥ 8,530,951
Additions	4,987,206	702,918	10,750,949	5,084,924
Balance at end of the year	¥ 29,354,030	$ 4,137,284	¥ 24,366,824	¥ 13,615,875

Inventories, Net (Details) - Sc

Inventories, Net (Details) - Schedule of Inventories	Mar. 31, 2024 CNY (¥)	Mar. 31, 2024 USD ($)	Mar. 31, 2023 CNY (¥)	Mar. 31, 2023 USD ($)	Mar. 31, 2022 CNY (¥)	Mar. 31, 2021 CNY (¥)
Inventories, Net [Abstract]
Raw materials	¥ 68,613,919	$ 9,670,743	¥ 50,453,180
Work in progress	49,083,445	6,918,033	61,275,177
Finished goods	153,879,476	21,688,439	78,432,041
Allowance for damaged inventories	(68,154,238)	(9,605,953)	(4,779,446)	$ (673,636)	¥ (5,503,029)	¥ (41,301,797)
Inventories, net	¥ 203,422,602	$ 28,671,262	¥ 185,380,952

Inventories, Net (Details) - _2

Inventories, Net (Details) - Schedule of Movements in the Allowance for Slow-Moving or Obsolete Inventories	12 Months Ended
	Mar. 31, 2024 CNY (¥)	Mar. 31, 2024 USD ($)	Mar. 31, 2023 CNY (¥)	Mar. 31, 2022 CNY (¥)
Schedule of movements in the allowance for slow-moving or obsolete inventories [Abstract]
Balance at beginning of the year	¥ 4,779,446	$ 673,636	¥ 5,503,029	¥ 41,301,797
Additions	68,221,016	9,615,365	3,670,046	4,393,629
Inventories written off	(4,846,224)	(683,048)	(4,393,629)	(40,192,397)
Balance at end of the year	¥ 68,154,238	$ 9,605,953	¥ 4,779,446	¥ 5,503,029

Property, Plant and Equipment_3

Property, Plant and Equipment, Net (Details)	12 Months Ended
	Mar. 31, 2024 CNY (¥)	Mar. 31, 2024 USD ($)	Mar. 31, 2023 CNY (¥)	Mar. 31, 2022 CNY (¥)	Mar. 31, 2024 USD ($)	Mar. 31, 2014 CNY (¥)
Property, Plant and Equipment, Net [Line Items]
Asset impairment	¥ 110,128,892		¥ 29,891,896		$ 15,522,043	¥ 29,900,000
Asset impairment on property, plant and equipment	80,236,996	$ 11,308,949
Property, Plant and Equipment [Member]
Property, Plant and Equipment, Net [Line Items]
Asset impairment on property, plant and equipment	¥ 80,200,000	$ 11,300,000

Property, Plant and Equipment_4

Property, Plant and Equipment, Net (Details) - Schedule of Property, Plant and Equipment	Mar. 31, 2024 CNY (¥)	Mar. 31, 2024 USD ($)	Mar. 31, 2023 CNY (¥)	Mar. 31, 2014 CNY (¥)
Schedule of Property, Plant and Equipment [Line Items]
Total Cost	¥ 789,019,434	$ 111,207,813	¥ 780,512,580
Less: accumulated depreciation	(205,542,536)	(28,970,054)	(178,864,241)
Less: asset impairment	(110,128,892)	(15,522,043)	(29,891,896)	¥ (29,900,000)
Property and equipment, net	473,348,006	66,715,716	571,756,443
Construction in Progress [Member]
Schedule of Property, Plant and Equipment [Line Items]
Total Cost	255,113,837	35,956,848	309,948,621
Plant and Buildings [Member]
Schedule of Property, Plant and Equipment [Line Items]
Total Cost	217,248,236	30,619,906	178,756,490
Machinery and Equipment [Member]
Schedule of Property, Plant and Equipment [Line Items]
Total Cost	255,507,522	36,012,336	237,637,928
Electronic Equipment [Member]
Schedule of Property, Plant and Equipment [Line Items]
Total Cost	10,335,481	1,456,727	11,117,440
Motor Vehicles [Member]
Schedule of Property, Plant and Equipment [Line Items]
Total Cost	3,081,506	434,321	3,031,087
Office Equipment and Furniture [Member]
Schedule of Property, Plant and Equipment [Line Items]
Total Cost	42,870,071	6,042,294	34,423,995
Leasehold Improvements [Member]
Schedule of Property, Plant and Equipment [Line Items]
Total Cost	¥ 4,862,781	$ 685,381	¥ 5,597,019

Prepaid Expenses and Other Cu_3

Prepaid Expenses and Other Current Assets, Net (Details) - Schedule of Prepaid Expenses and Other Current Asset, Net		Mar. 31, 2024 CNY (¥)	Mar. 31, 2024 USD ($)	Mar. 31, 2023 CNY (¥)
Prepaid Expenses and Other Current Assets, Net [Abstract]
Deposits	[1]	¥ 4,043,044	$ 569,844	¥ 4,339,791
Staff advances	[2]	174,810	24,638	606,859
Staff’s social security	[3]	158,872	22,392	252,090
Value added tax recoverable	[4]	1,598,117	225,246	4,249,718
Clinical trial insurance	[5]			178,699
Other receivables	[6]	1,395,246	196,652	901,355
Allowance	[7]			(115,743)
Total		¥ 7,370,089	$ 1,038,772	¥ 10,412,769
[1] Deposits primarily are to Centers for Disease Control and Prevention (“CDCs”) in connection with participation in the public tender process held by province-level CDCs. Staff advances primarily are paid to employees in advance of their expected business travel or in connection with various expenses incurred in the ordinary course of business, such as sales and marketing activities. Staff social security primarily is the portion of the government mandated defined contribution plan that should be made by employees. But this portion should be paid to the government by Lakeshore Group on behalf of the employees pursuant to PRC labor regulation. When Lakeshore Group pays wages to employees, this portion should be deducted accordingly. Value-added taxes (“VAT”) includes input tax on purchase and output tax on sales. VAT collected from customers relating to product sales and remitted to governmental authorities is presented on a net basis, and it is excluded from revenue. Lakeshore Group is in a net VAT recoverable position when its input tax on purchase in the current year is greater than the output tax on sales. Such net amount can be deducted in the following years. Clinical trial insurance is for human clinical trial legal liability insurance for evaluating the safety, immunogenicity and preliminary efficacy of multiple ascending doses of PIKA recombinant protein COID-19 Vaccine in the treatment of adult patients with mild to moderate COVID-19 infection. Other receivables primarily consist of prepayment to third parties, such as freight, water and electricity, and promotion fees. The allowance reflects Lakeshore Group’s best estimate of probable amounts not fully recoverable from the other receivables balance. Due to the fact that some employees resigned and lost contact, the cash paid to them in advance of their expected business travel or in connection with various expense incurred in the ordinary course of business might not be recovered.

Intangible Assets, Net (Details

Intangible Assets, Net (Details) - Schedule of Intangible Assets	Mar. 31, 2024 CNY (¥)	Mar. 31, 2024 USD ($)	Mar. 31, 2023 CNY (¥)
Schedule of Intangible Assets [Line Items]
Total Cost	¥ 157,225,338	$ 22,160,019	¥ 157,225,338
Less: Accumulated Amortization	(85,980,002)	(12,118,393)	(79,168,546)
Intangible Assets, net	71,245,336	10,041,626	78,056,792
Patents [Member]
Schedule of Intangible Assets [Line Items]
Total Cost	79,608,000	11,220,296	79,608,000
Licenses, Software and Laboratory Information System [Member]
Schedule of Intangible Assets [Line Items]
Total Cost	10,435,478	1,470,821	10,435,478
Land Use Rights [Member]
Schedule of Intangible Assets [Line Items]
Total Cost	¥ 67,181,860	$ 9,468,902	¥ 67,181,860

Bank Loans and Other Borrowin_3

Bank Loans and Other Borrowings (Details)

1 Months Ended

3 Months Ended

4 Months Ended

6 Months Ended

12 Months Ended

Jul. 29, 2024 CNY (¥)

Jul. 29, 2024 USD ($)

Jul. 17, 2024 CNY (¥)

Jul. 17, 2024 USD ($)

Jul. 15, 2024 CNY (¥)

Jul. 15, 2024 USD ($)

May 29, 2024 CNY (¥)

May 29, 2024 USD ($)

Apr. 29, 2024 USD ($)

Mar. 31, 2024 CNY (¥)

Mar. 31, 2024 USD ($)

Jan. 18, 2024 CNY (¥)

Jan. 08, 2024 CNY (¥)

Dec. 27, 2023 USD ($)

Dec. 08, 2023 CNY (¥)

Nov. 15, 2023 CNY (¥)

Jul. 20, 2023 CNY (¥)

May 29, 2023 CNY (¥)

Apr. 28, 2023 CNY (¥)

Jan. 16, 2023 CNY (¥)

Jan. 13, 2023 CNY (¥)

Nov. 08, 2022 CNY (¥)

May 06, 2022 CNY (¥)

Mar. 16, 2022 CNY (¥)

Sep. 13, 2021 CNY (¥)

Jul. 12, 2021 CNY (¥)

Jul. 30, 2024 CNY (¥)

Jul. 30, 2024 USD ($)

May 31, 2024 CNY (¥)

May 31, 2024 USD ($)

Apr. 30, 2024 CNY (¥)

Apr. 30, 2024 USD ($)

Mar. 31, 2024 USD ($)

Feb. 28, 2024 USD ($)

Sep. 18, 2023 CNY (¥)

Sep. 14, 2023 CNY (¥)

Nov. 25, 2022 CNY (¥)

Mar. 31, 2023 CNY (¥)

Jan. 16, 2024 CNY (¥)

Mar. 31, 2024 CNY (¥)

Mar. 31, 2024 USD ($)

Mar. 31, 2023 CNY (¥)

Mar. 31, 2022 CNY (¥)

Mar. 16, 2022 USD ($)

Bank Loans and Other Borrowings [Line Items]

Interest rate during the period

4.75%

Repayment of credit facility

¥ 2,900,000

Outstanding amount of credit facility

¥ 4,400,000

$ 600,000

Due amount of credit facility

900,000

100,000

Interest expense

¥ 47,500,000

¥ 32,000,000

¥ 2,800,000

R-Bridge Healthcare Fund, LP [Member]

Bank Loans and Other Borrowings [Line Items]

Credit facility maximum borrowings | $

$ 40,000,000

China Guangfa Bank Co., Ltd. [Member]

Bank Loans and Other Borrowings [Line Items]

Credit facility maximum borrowings

¥ 100,000,000

Term of credit facility

3 years

Credit facility amount

¥ 18,400,000

Interest rate during the period

4.50%

Repayment of credit facility

¥ 77,000,000

Outstanding amount of credit facility

¥ 18,400,000

$ 2,600,000

Shanghai Pudong Development Bank Co., Ltd. [Member]

Bank Loans and Other Borrowings [Line Items]

Credit facility maximum borrowings

¥ 140,000,000

Term of credit facility

1 year

1 year

3 years

Repayment of credit facility

¥ 91,300,000

¥ 3,400,000

$ 500,000

Outstanding amount of credit facility

¥ 83,400,000

$ 11,800,000

Due amount of credit facility

45,000,000

6,300,000

China CITIC Bank Shenyang Tiexi Branch [Member]

Bank Loans and Other Borrowings [Line Items]

Credit facility maximum borrowings

¥ 4,400,000

¥ 4,500,000

¥ 6,900,000

¥ 40,000,000

¥ 5,000,000

Credit facility amount

¥ 3,550,000

Interest rate during the period

4.55%

4.55%

5%

3.25%

Repayment of credit facility

¥ 27,600,000

Outstanding amount of credit facility

4,500,000

600,000

Due amount of credit facility

900,000

100,000

China Construction Bank Shenyang Heping Branch [Member]

Bank Loans and Other Borrowings [Line Items]

Credit facility maximum borrowings

¥ 988,000

¥ 31,300,000

Term of credit facility

1 year

1 year

1 year

Credit facility amount

¥ 712,400

¥ 43,800,000

Interest rate during the period

3.90%

3.90%

4%

Repayment of credit facility

39,000,000

5,500,000

¥ 988,000

¥ 31,300,000

Outstanding amount of credit facility

700,000

100,000

Zhongguancun Technology Leasing Co., Ltd [Member]

Bank Loans and Other Borrowings [Line Items]

Credit facility maximum borrowings

¥ 26,000,000

Interest rate during the period

5%

Repayment of credit facility

8,700,000

1,200,000

¥ 722,230

$ 8,700,000

Outstanding amount of credit facility

14,400,000

2,000,000

Working Capital [Member]

Bank Loans and Other Borrowings [Line Items]

Outstanding amount of credit facility

6,900,000

1,000,000

Industrial Bank Shenyang Branch [Member]

Bank Loans and Other Borrowings [Line Items]

Credit facility maximum borrowings

¥ 29,800,000

¥ 20,000,000

Term of credit facility

3 years

1 year

3 years

Interest rate during the period

4.80%

4%

4.25%

Repayment of credit facility

¥ 9,500,000

Outstanding amount of credit facility

30,500,000

4,300,000

Due amount of credit facility

13,100,000

1,900,000

R-Bridge Healthcare Fund, LP [Member]

Bank Loans and Other Borrowings [Line Items]

Credit facility maximum borrowings

¥ 274,868,000

Interest rate during the period

4%

Repayment of credit facility | $

$ 40,000,000

$ 10,000,000

$ 15,000,000

Repaying loan (in Dollars) | $

$ 40,000,000

Accrued interest (in Dollars) | $

$ 3,100,000

Minsheng Bank Shenyang Huanghe Street Branch [Member]

Bank Loans and Other Borrowings [Line Items]

Credit facility maximum borrowings

¥ 30,000,000

Interest rate during the period

4%

Outstanding amount of credit facility

30,000,000

4,200,000

CITIC Financial Leasing Co., Ltd [Member]

Bank Loans and Other Borrowings [Line Items]

Credit facility maximum borrowings

¥ 40,000,000

Tranche One [Member] | Shanghai Pudong Development Bank Co., Ltd. [Member]

Bank Loans and Other Borrowings [Line Items]

Credit facility amount

¥ 6,700,000

Interest rate during the period

5.30%

Tranche Two [Member] | Shanghai Pudong Development Bank Co., Ltd. [Member]

Bank Loans and Other Borrowings [Line Items]

Credit facility amount

85,000,000

Tranche Three [Member] | Shanghai Pudong Development Bank Co., Ltd. [Member]

Bank Loans and Other Borrowings [Line Items]

Credit facility amount

46,600,000

Tranche Four [Member] | Shanghai Pudong Development Bank Co., Ltd. [Member]

Bank Loans and Other Borrowings [Line Items]

Credit facility amount

¥ 38,400,000

Lakeshore Group [Member]

Bank Loans and Other Borrowings [Line Items]

Repayment of credit facility

¥ 3,100,000

$ 400,000

Outstanding amount of credit facility

29,800,000

4,200,000

Lakeshore Group [Member] | China Guangfa Bank Co., Ltd. [Member]

Bank Loans and Other Borrowings [Line Items]

Credit facility amount

¥ 35,800,000

Interest rate during the period

5.66%

Lakeshore Group [Member] | China CITIC Bank Shenyang Tiexi Branch [Member]

Bank Loans and Other Borrowings [Line Items]

Credit facility amount

¥ 12,800,000

Interest rate during the period

4.55%

Outstanding amount of credit facility

12,400,000

1,700,000

Due amount of credit facility

1,400,000

200,000

Lakeshore Group [Member] | China Construction Bank Shenyang Heping Branch [Member]

Bank Loans and Other Borrowings [Line Items]

Interest rate during the period

4%

Outstanding amount of credit facility

43,800,000

6,200,000

Lakeshore Group [Member] | Zhongguancun Technology Leasing Co., Ltd [Member]

Bank Loans and Other Borrowings [Line Items]

Repayment of credit facility

¥ 722,222

Lakeshore Group [Member] | Industrial Bank Shenyang Branch [Member]

Bank Loans and Other Borrowings [Line Items]

Outstanding amount of credit facility

¥ 20,000,000

$ 2,800,000

Subsequent Event [Member] | R-Bridge Healthcare Fund, LP [Member]

Bank Loans and Other Borrowings [Line Items]

Repayment of credit facility | $

$ 18,100,000

Forecast [Member]

Bank Loans and Other Borrowings [Line Items]

Repayment of credit facility

¥ 700,000

$ 100,000

Forecast [Member] | China CITIC Bank Shenyang Tiexi Branch [Member]

Bank Loans and Other Borrowings [Line Items]

Repayment of credit facility

¥ 500,000

$ 100,000

¥ 400,000

$ 100,000

¥ 12,400,000

$ 1,700,000

Forecast [Member] | Minsheng Bank Shenyang Huanghe Street Branch [Member]

Bank Loans and Other Borrowings [Line Items]

Repayment of credit facility

¥ 11,300,000

$ 1,600,000

Bank Loans and Other Borrowin_4

Bank Loans and Other Borrowings (Details) - Schedule of Bank Loans and Other Borrowings		12 Months Ended
		Mar. 31, 2024 CNY (¥)	Mar. 31, 2024 USD ($)	Mar. 31, 2023 CNY (¥)
Debt Instrument [Line Items]
Bank loans due within one year		¥ 318,540,732	$ 44,896,509	¥ 193,736,563
Bank loans due within one year		98,983,780	13,951,202	293,790,596
Total bank loans		417,524,512	58,847,711	487,527,159
China Guangfa Bank Co., Ltd. - Shenyang Branch [Member]
Debt Instrument [Line Items]
Bank loans due within one year	[1]	¥ 18,357,574	2,587,396	41,191,031
Interest Rate	[1]	4.50%
Shanghai Pudong Development Bank Co Ltd Shenyang Branch [Member]
Debt Instrument [Line Items]
Bank loans due within one year	[2]	¥ 44,983,415	6,340,157	82,964,518
Interest Rate	[2]	4%
Bank loans due within one year	[2]	¥ 38,428,802	5,416,322
Interest Rate	[2]	4%
China CITIC Bank Shenyang Tiexi Branch [Member]
Debt Instrument [Line Items]
Bank loans due within one year	[3]	¥ 12,388,064	1,746,027	23,596,350
Maturity Date		May 29, 2024
Interest Rate	[3]
Bank loans due within one year	[4]	¥ 5,503,290	775,658
Interest Rate	[4]	4.55%
China CITIC Bank Shenyang Tiexi Branch [Member]
Debt Instrument [Line Items]
Bank loans due within one year	[5]			5,000,000
Interest Rate	[5]	3.25%
Bank loans due within one year	[6]	¥ 3,618,982	510,075
Interest Rate	[6]	4.55%
China Construction Bank Shenyang Heping Branch [Member]
Debt Instrument [Line Items]
Bank loans due within one year	[7]	¥ 38,990,000	5,495,419	31,330,000
Interest Rate	[7]	4%
Bank loans due within one year	[7]	¥ 4,820,000	679,352	4,430,000
Interest Rate	[7]	4%
China Construction Bank Shenyang Heping Branch [Member]
Debt Instrument [Line Items]
Bank loans due within one year	[8]	¥ 712,400	100,409	988,000
Maturity Date		Jul. 19, 2024
Interest Rate	[8]	3.90%
Zhongguancun Technology Leasing Co., Ltd [Member]
Debt Instrument [Line Items]
Bank loans due within one year	[9]	¥ 8,666,664	1,221,517	8,666,664
Maturity Date		Nov. 07, 2025
Interest Rate	[9]	5%
Bank loans due within one year	[9],[10]	¥ 5,777,784	$ 814,346	14,492,596
Maturity Date		Nov. 07, 2025	Nov. 07, 2025
Interest Rate	[9]	5%
China CITIC Bank Shenyang Tiexi Branch [Member]
Debt Instrument [Line Items]
Bank loans due within one year	[4]	¥ 1,400,000	$ 197,322
Interest Rate	[4]	4.55%
Bank loans due within one year	[10]	¥ 3,503,099	493,742
Interest Rate	[10]	4.55%
China CITIC Bank Shenyang Tiexi Branch [Member]
Debt Instrument [Line Items]
Bank loans due within one year	[6]	¥ 900,000	126,850
Interest Rate	[6]	4.55%
China CITIC Bank Shenyang Tiexi Branch [Member]
Debt Instrument [Line Items]
Bank loans due within one year	[10]	¥ 880,000	124,031
Interest Rate	[10]	4.55%
Industrial Bank Shenyang Branch [Member]
Debt Instrument [Line Items]
Bank loans due within one year	[11]	¥ 29,776,670	4,196,853
Interest Rate	[11]	4%
Bank loans due within one year	[12]	¥ 19,993,041	2,817,906
Interest Rate	[12]	4.25%
R-Bridge Healthcare Fund, LP [Member]
Debt Instrument [Line Items]
Bank loans due within one year	[13]	¥ 118,354,060	16,681,333
Maturity Date		Sep. 15, 2026
Interest Rate	[13]	4%
Bank loans due within one year	[13]			274,868,000
Maturity Date		Sep. 15, 2026	Sep. 15, 2026
Interest Rate	[13]	4%
Minsheng Bank Shenyang Huanghe Street Branch [Member]
Debt Instrument [Line Items]
Bank loans due within one year	[14]	¥ 29,990,032	$ 4,226,925
Interest Rate	[14]	4%
CITIC Financial Leasing Co., Ltd [Member]
Debt Instrument [Line Items]
Bank loans due within one year	[15]	¥ 13,141,853	1,852,270
Maturity Date		May 29, 2026
Interest Rate	[15]	4.80%
Bank loans due within one year	[15]	¥ 17,338,782	$ 2,443,801
Maturity Date		May 29, 2026	May 29, 2026
Interest Rate	[15]	4.80%
Minimum [Member] | China Guangfa Bank Co., Ltd. - Shenyang Branch [Member]
Debt Instrument [Line Items]
Maturity Date		Sep. 01, 2024
Minimum [Member] | Shanghai Pudong Development Bank Co Ltd Shenyang Branch [Member]
Debt Instrument [Line Items]
Maturity Date		Apr. 12, 2024
Maturity Date		Apr. 12, 2025	Apr. 12, 2025
Minimum [Member] | China CITIC Bank Shenyang Tiexi Branch [Member]
Debt Instrument [Line Items]
Maturity Date		May 15, 2025	May 15, 2025
Minimum [Member] | China CITIC Bank Shenyang Tiexi Branch [Member]
Debt Instrument [Line Items]
Maturity Date		May 25, 2023
Maturity Date		Jul. 08, 2025	Jul. 08, 2025
Minimum [Member] | China Construction Bank Shenyang Heping Branch [Member]
Debt Instrument [Line Items]
Maturity Date		Jul. 24, 2024
Maturity Date		Oct. 15, 2025	Oct. 15, 2025
Minimum [Member] | China CITIC Bank Shenyang Tiexi Branch [Member]
Debt Instrument [Line Items]
Maturity Date		May 15, 2024
Maturity Date		Jul. 18, 2025	Jul. 18, 2025
Minimum [Member] | China CITIC Bank Shenyang Tiexi Branch [Member]
Debt Instrument [Line Items]
Maturity Date		Jul. 08, 2024
Minimum [Member] | China CITIC Bank Shenyang Tiexi Branch [Member]
Debt Instrument [Line Items]
Maturity Date		Jul. 18, 2024
Minimum [Member] | Industrial Bank Shenyang Branch [Member]
Debt Instrument [Line Items]
Maturity Date		Aug. 15, 2024
Maturity Date		Jul. 31, 2026	Jul. 31, 2026
Minimum [Member] | Minsheng Bank Shenyang Huanghe Street Branch [Member]
Debt Instrument [Line Items]
Maturity Date		Jul. 07, 2024
Maximum [Member] | China Guangfa Bank Co., Ltd. - Shenyang Branch [Member]
Debt Instrument [Line Items]
Maturity Date		Sep. 10, 2024
Maximum [Member] | Shanghai Pudong Development Bank Co Ltd Shenyang Branch [Member]
Debt Instrument [Line Items]
Maturity Date		Mar. 21, 2025
Maturity Date		Nov. 07, 2025	Nov. 07, 2025
Maximum [Member] | China CITIC Bank Shenyang Tiexi Branch [Member]
Debt Instrument [Line Items]
Maturity Date		Nov. 15, 2025	Nov. 15, 2025
Maximum [Member] | China CITIC Bank Shenyang Tiexi Branch [Member]
Debt Instrument [Line Items]
Maturity Date		Jul. 17, 2023
Maturity Date		Jan. 18, 2026	Jan. 18, 2026
Maximum [Member] | China Construction Bank Shenyang Heping Branch [Member]
Debt Instrument [Line Items]
Maturity Date		Dec. 06, 2024
Maturity Date		Nov. 14, 2025	Nov. 14, 2025
Maximum [Member] | China CITIC Bank Shenyang Tiexi Branch [Member]
Debt Instrument [Line Items]
Maturity Date		Nov. 15, 2024
Maturity Date		Jan. 18, 2026	Jan. 18, 2026
Maximum [Member] | China CITIC Bank Shenyang Tiexi Branch [Member]
Debt Instrument [Line Items]
Maturity Date		Jan. 18, 2025
Maximum [Member] | China CITIC Bank Shenyang Tiexi Branch [Member]
Debt Instrument [Line Items]
Maturity Date		Jan. 18, 2025
Maximum [Member] | Industrial Bank Shenyang Branch [Member]
Debt Instrument [Line Items]
Maturity Date		Sep. 17, 2024
Maturity Date		Sep. 03, 2026	Sep. 03, 2026
Maximum [Member] | Minsheng Bank Shenyang Huanghe Street Branch [Member]
Debt Instrument [Line Items]
Maturity Date		Jan. 16, 2025
[1] On September 13, 2021, Lakeshore Group entered into a credit facility of RMB100.0 million with China Guangfa Bank Co., Ltd. Shenyang Branch for three years to finance its working capital requirements. Lakeshore Group drew RMB35.8 million from June 19, 2023 to August 24, 2023, with interest at 5.66%, which was due from December 16, 2023 to March 12, 2024. The Company drew RMB 18.4 million from November 21, 2023 to March 1, 2024, with interest at 4.50%, which is due from September 1, 2024 to September 10, 2024. From June 2, 2023 to January 2, 2024, Lakeshore Group repaid RMB77.0 million. As of March 31, 2024, the balance of RMB18.4 million (US$2.6 million) was outstanding. On July 12, 2021, Lakeshore Group entered into a credit facility of RMB140.0 million with Shanghai Pudong Development Bank Co., Ltd. Shenyang Branch for three years to finance its working capital requirements. Lakeshore Group drew RMB6.7 million on April 28, 2023 with interest at 5.30%, which was due on December 23, 2023, and drew RMB85.0 million from September 27, 2023 to February 28, 2024, of which RMB46.6 million is due from March 21, 2024 to March 21, 2025 and RMB38.4 million is due from April 12, 2025 to November 7, 2025. From April 4, 2023 to March 21, 2024, Lakeshore Group repaid RMB91.3 million. As of March 31, 2024, the balance of RMB83.4 million (US$11.8 million) is outstanding, of which RMB45.0 million (US$6.3 million) is due within one year. In April, 2024, RMB3.4 million (US$0.5 million) was repaid. On January 13, 2023, Lakeshore Group entered into a credit facility of RMB40.0 million with China CITIC Bank Shenyang Tiexi Branch, due on November 1, 2025, to finance its working capital requirements. Lakeshore Group drew RMB12.8 million from May 24, 2023 to July 11, 2023 with interest at 5.00%, which was due from February 6, 2024 to May 29, 2024, and drew RMB3.55 million from July 17, 2023 to July 18,2023, with interest at 4.75%, which is due on May 29, 2024. From October 13, 2023 to February 19, 2024, Lakeshore Group repaid RMB27.6 million. As of March 31, 2024, the balance of RMB12.4 million (US$1.7 million) is outstanding. On May 29, 2024, RMB12.4 million (US$1.7 million) was repaid. On November 15, 2023, Lakeshore Group borrowed RMB6.9 million from China CITIC Bank Shenyang Tiexi Branch to finance working capital requirements, with interest at 4.55%. This loan will mature on November 15, 2025. As of March 31, 2024, the balance of RMB6.9 million (US$1.0 million) is outstanding, of which RMB1.4 million (US$0.2 million) is due within one year. In May 2024, RMB0.7 million (US$0.1 million) was repaid. On May 6, 2022, China CITIC Bank Shenyang Tiexi Branch issued one letter of credit of RMB5.0 million to Lakeshore Group with interest at 3.25%. As of March 31, 2024, Lakeshore Group repaid it. On January 8, 2024, Lakeshore Group borrowed RMB4.5 million with interest at 4.55% from China CITIC Bank Shenyang Tiexi Branch to finance working capital requirements. The loan will be due from July 8, 2024 to January 8, 2026. As of March 31, 2024, the balance of RMB4.5 million (US$0.6 million) is outstanding, of which RMB0.9 million (US$0.1 million) is due within one year. On July 4, 2024, RMB0.5 million (US$0.1 million) was repaid. On January 16, 2023, Lakeshore Group borrowed RMB988,000 with interest at 3.90% from China Construction Bank Shenyang Heping Branch for one year. On July 20, 2023, Lakeshore Group borrowed RMB712,400 with interest at 3.90% from China Construction Bank Shenyang Heping Branch for one year. On December 8, 2023, Lakeshore Group repaid RMB988,000. The balance of RMB0.7 million (US$0.1 million) as of March 31, 2024 was repaid on July 18, 2024. On November 8, 2022, Lakeshore Group borrowed RMB26.0 million with interest at 5.00% from Zhongguancun Technology Leasing Co., Ltd for 36 months. Lakeshore Group shall repay RMB722,222 monthly from December 15, 2022 to October 15, 2025 and pay the last repayment of RMB722,230 on November 7, 2025. Lakeshore Group repaid RMB2.9 million from December 2022 to March 2023 and 8.7 million from April 2023 to March 2024. As of March 31, 2024, the balance of RMB14.4 million (US$2.0 million) is outstanding, of which RMB8.7 million (US$1.2 million) is due within one year. On January 18, 2024, Lakeshore Group borrowed RMB4.4 million with interest at 4.55% from China CITIC Bank Shenyang Tiexi Branch to finance working capital requirements. The loan will be due from July 18, 2024 to January 18, 2026. As of March 31, 2024, the balance of RMB4.4 million (US$0.6 million) is outstanding, of which RMB0.9 million (US$0.1 million) is due within one year. On July 17, 2024, RMB0.4 million (US$0.1 million) was repaid. From August 16, 2023 to September 18, 2023, Lakeshore Group borrowed RMB29.8 million with interest at 4.00% from Industrial Bank Shenyang Branch for one year. The loan will be due from August 15, 2024 to September 17, 2024. As of March 31, 2024, the balance of RMB29.8 million (US$4.2 million) is outstanding. From August 14, 2023 to September 14, 2023, Lakeshore Group borrowed RMB20.0 million with interest at 4.25% from Industrial Bank Shenyang Branch for about three years. The loan will be due from July 31, 2026 to September 3, 2026. As of March 31, 2024, the balance of RMB20.0 million (US$2.8 million) is outstanding. On March 16, 2022, Lakeshore Group entered into a facility agreement with R-Bridge Healthcare Fund, LP (“R-Bridge”), as agent, to finance RMB274,868,000 (US$40,000,000) for 54 months with interest at 4.00%. On December 27, 2023, HK Yisheng received a letter from R-Bridge (the “R-Bridge Letter”), notifying the Company that it has reason to believe HK Yisheng defaulted under financial covenants and other obligations under the facility agreement, and under the instructions of the lenders to urge the Company to consider and reach an amicable solution with the lenders, including, without limitation, repaying the loan of $40.0 million in full, as soon as possible. The Company repaid $15.0 million, $10.0 million and $18.1 million respectively in February, March and April, 2024. As of April 29, 2024, the Company repaid its full amount of $40.0 million and accrued interest of $3.1 million. From July 7, 2023 to January 16, 2024, Lakeshore Group borrowed RMB30.0 million with interest at 4.0% from Minsheng Bank Shenyang Huanghe Street Branch, due from July 7, 2024 to January 16, 2025. As of March 31, 2024, the balance of RMB30.0 million (US$4.2 million) is outstanding. In July, 2024, RMB11.3 million (US$1.6 million) was repaid. On May 29, 2023, Lakeshore Group borrowed RMB40.0 million with interest at 4.80% from CITIC Financial Leasing Co., Ltd for three years. The loan will be due on May 29, 2026. From August 15, 2023 to February 18, 2024, Lakeshore Group repaid RMB9.5 million. As of March 31, 2024, the balance of RMB30.5 million (US$4.3 million) is outstanding, of which RMB13.1 million (US$1.9 million) is due within one year.

Leases (Details) - Schedule of

Leases (Details) - Schedule of Summary of Operating Leases	Mar. 31, 2024 CNY (¥)	Mar. 31, 2024 USD ($)	Mar. 31, 2023 CNY (¥)
Schedule of Summary of Operating Leases [Abstract]
Operating lease ROU assets	¥ 7,275,367	$ 1,025,422	¥ 11,132,428
Operating lease liabilities – current	5,156,540	726,785	4,753,547
Operating lease liabilities – non-current	¥ 1,783,593	$ 251,387	¥ 6,348,890
Weighted average remaining lease term	1 year 6 months	1 year 6 months	2 years 6 months
Weighted average discount rate	4.80%	4.80%	4.70%

Leases (Details) - Schedule o_2

Leases (Details) - Schedule of Lease Cost	12 Months Ended
	Mar. 31, 2024 CNY (¥)	Mar. 31, 2024 USD ($)	Mar. 31, 2023 CNY (¥)	Mar. 31, 2022 CNY (¥)
Schedule of Lease Cost [Abstract]
Operating lease cost	¥ 5,252,026	$ 740,243	¥ 5,002,684	¥ 4,594,967
Cash paid for operating leases	¥ 5,272,746	$ 743,164	¥ 3,349,856	¥ 4,587,894

Leases (Details) - Schedule o_3

Leases (Details) - Schedule of Summary of Maturity of Operating Lease - Mar. 31, 2024	CNY (¥)	USD ($)
Schedule of Summary of Maturity of Operating Lease [Abstract]
2025	¥ 5,386,340	$ 759,174
2026	1,813,582	255,614
Total lease payments	7,199,922	1,014,788
Less: Interest	(259,789)	(36,616)
Present value of operating lease liabilities	¥ 6,940,133	$ 978,172

Accrued Expenses and Other Cu_3

Accrued Expenses and Other Current Liabilities (Details) - CNY (¥) ¥ in Millions	Mar. 31, 2024	Mar. 31, 2023
Accrued Expenses and Other Current Liabilities [Abstract]
Salaries and social security insurance	¥ 14.6	¥ 2.3

Accrued Expenses and Other Cu_4

Accrued Expenses and Other Current Liabilities (Details) - Schedule of Accrued Expenses and Other Current Liabilities		Mar. 31, 2024 CNY (¥)	Mar. 31, 2024 USD ($)	Mar. 31, 2023 CNY (¥)
Schedule of Accrued Expenses and Other Current Liabilities [Abstract]
Salaries and social security insurance	[1]	¥ 59,297,454	$ 8,357,640	¥ 55,188,497
Promotion service fee	[2]	114,508,487	16,139,322	87,567,459
Taxes other than income tax		3,012,548	424,602	379,595
Late fees	[3]	10,683,258	1,505,745	9,927,056
Payable for property, plant and equipment		20,413,798	2,877,209	47,579,463
CDC transportation and storage fee		53,515,233	7,542,668	49,976,200
Guarantee deposits	[4]	119,313,398	16,816,547	108,795,884
Professional service fee	[5]	7,346,813	1,035,492	5,121,970
Interest payable	[6]	9,909,655	1,396,710	6,055,245
Other	[7]	10,737,325	1,513,366	6,945,275
Total		¥ 408,737,969	$ 57,609,301	¥ 377,536,644
[1] This includes unpaid salaries and outstanding social security insurance. During fiscal 2023, Lakeshore Group paid approximately RMB2.3 million to reduce its payable for salaries and social security insurance. During fiscal 2024, Lakeshore Group paid approximately RMB14.6 million to reduce its payable for salaries and social security insurance. Salaries and social security insurance payables consist of the following: Promotion service fee primarily represents fees for the vaccine promotion, including design and implementation of academic activities, and collection of market information. Late fees primarily are for corporate income tax, taxes other than income tax and social security insurance and housing reserve fund contributions due to the fact Lakeshore Group failed to pay income tax for calendar 2011 to calendar 2013, taxes other than income tax for calendar 2014 to the beginning of calendar 2021 and social security insurance for calendar 2015 to the beginning of calendar 2021. As of June, 2021, Lakeshore Group has paid the unpaid taxes, including income tax and other taxes other than income tax, as well as the late fees charge of them. From fiscal 2022, the late fee is incurred for unpaid social insurance. Guarantee deposits primarily are refundable deposits paid to Lakeshore Group by external service providers to guarantee the external service providers will provide us with high quality and reasonable professional services. The external service providers’ professional service scope includes conducting market research and analysis, monitoring product clinical information, collecting and reporting adverse events of the product use, providing academic visits and education seminars, assisting product shipment and payment collections. Their services don’t assume inventory risk for the vaccines before they are transferred to the end customers. Professional service fees primarily are from consultants and other advisors. Interest payable primarily includes interest and royalties payable to R-Bridge Healthcare Fund, LP. Others primarily are employees’ reimbursement and value added tax.

Accrued Expenses and Other Cu_5

Accrued Expenses and Other Current Liabilities (Details) - Schedule of Salaries and Social Security Insurance Payables	Mar. 31, 2024 CNY (¥)	Mar. 31, 2024 USD ($)	Mar. 31, 2023 CNY (¥)
Schedule of Salaries and Social Security Insurance Payables [Abstract]
Salaries	¥ 51,990,629	$ 7,327,784	¥ 47,390,831
Social security insurance	6,656,034	938,130	7,179,828
Union Fee	650,791	91,726	617,838
Total	¥ 59,297,454	$ 8,357,640	¥ 55,188,497

Warrants (Details)

Warrants (Details)	12 Months Ended
	Mar. 31, 2024 CNY (¥) shares	Mar. 31, 2024 USD ($) shares	Mar. 31, 2023 CNY (¥)
Warrants [Line Items]
Value of the private warrants (in Yuan Renminbi)	¥ 125,595,322	$ 17,701,947	¥ 332,538,382
Change in fair value (in Yuan Renminbi) | ¥	¥ 4,500,000
Public Warrants [Member]
Warrants [Line Items]
Warrants	10,750,000	10,750,000
Public Warrants [Member] | Business Combination [Member]
Warrants [Line Items]
Warrants	10,000,000	10,000,000
Private warrants [Member]
Warrants [Line Items]
Warrants	6,000,000	6,000,000
Value of the private warrants (in Yuan Renminbi) | ¥	¥ 4,500,000
Private warrants [Member] | Business Combination [Member]
Warrants [Line Items]
Warrants	6,000,000	6,000,000

Warrants (Details) - Schedule o

Warrants (Details) - Schedule of Private Warrants are Accounted for as Liabilities	Mar. 31, 2024
Fair Value of the Underlying Asset as of the Valuation Date [Member]
Schedule of Private Warrants are Accounted for as Liabilities [Line Items]
Key assumptions FV of private warrants	0.1
Strike Price [Member]
Schedule of Private Warrants are Accounted for as Liabilities [Line Items]
Key assumptions FV of private warrants	11.5
Life to Expiration (Years.) [Member]
Schedule of Private Warrants are Accounted for as Liabilities [Line Items]
Key assumptions FV of private warrants	4
Volatility [Member]
Schedule of Private Warrants are Accounted for as Liabilities [Line Items]
Key assumptions FV of private warrants	88.5
Number of Steps [Member]
Schedule of Private Warrants are Accounted for as Liabilities [Line Items]
Key assumptions FV of private warrants	100
Redemption Price (per share) [Member]
Schedule of Private Warrants are Accounted for as Liabilities [Line Items]
Key assumptions FV of private warrants	0.1

Warrants (Details) - Schedule_2

Warrants (Details) - Schedule of the Warrant Liabilities	12 Months Ended
	Mar. 31, 2024 CNY (¥)	Mar. 31, 2024 USD ($)	Mar. 31, 2023 CNY (¥)	Mar. 31, 2022 CNY (¥)
Schedule of the Warrant Liabilities [Line Items]
Warrant liabilities beginning balance	¥ 8,792,389
Change in fair value	(4,458,844)	$ (628,449)	¥ (21,358)
Foreign currency translation	214,459
Warrant liabilities Ending balance	4,548,004	641,015	8,792,389
Warrant liabilities Ending balance (in Dollars)	4,548,004		8,792,389
Private Warrants [Member]
Schedule of the Warrant Liabilities [Line Items]
Warrant liabilities beginning balance	8,792,389
Change in fair value	(4,458,844)
Foreign currency translation	214,459
Warrant liabilities Ending balance	4,548,004	$ 641,015	8,792,389
Warrant liabilities Ending balance (in Dollars)	¥ 4,548,004		¥ 8,792,389

Warrants Accounted as Equity-_2

Warrants Accounted as Equity-Method Instruments (Details)	12 Months Ended
	Mar. 31, 2024 $ / shares shares
Class of Warrant or Right [Line Items]
Exercise price of warrants	$ 0.1
Ordinary shares equals or exceeds per share	$ 10
Warrant redemption period	30 days
Warrant, description	(1) may be less than the value the holders would have received if they had exercised their Warrants at a later time where the underlying share price is higher and (2) may not compensate the holders for the value of the warrants, including because the number of Lakeshore Biopharma Ordinary Shares received is capped at 0.361 Lakeshore Biopharma Ordinary Shares per warrant (subject to adjustment) irrespective of the remaining life of the warrants
Business Combination [Member]
Class of Warrant or Right [Line Items]
Ordinary shares equals or exceeds per share	$ 18
Public warrants [Member]
Class of Warrant or Right [Line Items]
Shares issued | shares	10,000,000
Additional shares issued | shares	750,000
Warrant [Member]
Class of Warrant or Right [Line Items]
Warrant redemption period	30 days
Minimum [Member]
Class of Warrant or Right [Line Items]
Trading days	20
Maximum [Member]
Class of Warrant or Right [Line Items]
Trading days	30
Parent Company [Member]
Class of Warrant or Right [Line Items]
Exercise price of warrants	$ 0.01
Parent Company [Member] | Minimum [Member]
Class of Warrant or Right [Line Items]
Trading days	20
Parent Company [Member] | Maximum [Member]
Class of Warrant or Right [Line Items]
Trading days	30

Stock-Based Compensation (Detai

Stock-Based Compensation (Details)

12 Months Ended

Mar. 30, 2024 $ / shares shares

Mar. 25, 2024 $ / shares shares

Mar. 16, 2023 shares

Aug. 15, 2022 shares

Aug. 01, 2018 shares

Jul. 25, 2018 CNY (¥) shares

Feb. 01, 2018 $ / shares shares

Jan. 01, 2015 shares

Jan. 01, 2014

Jun. 21, 2010 shares

Mar. 31, 2024 $ / shares shares

Mar. 31, 2023 CNY (¥) shares

Mar. 31, 2022 shares

Mar. 31, 2020 shares

Stock-Based Compensation [Line Items]

Annual grant

Group granted

200,000

1,900,000

Grant-date FV of RSU (in Dollars per share) | $ / shares

$ 0.72

$ 0.65

$ 1.84

YS Group registered shares

143,750

Restricted Stock Units (RSUs) [Member]

Stock-Based Compensation [Line Items]

Group granted

692,500

Per share granted (in Dollars per share) | $ / shares

$ 7.24

Fair value of the underlying ordinary shares

405,000

Share-Based Payment Arrangement [Member]

Stock-Based Compensation [Line Items]

YS Group registered shares

0.00002

Share-Based Payment Arrangement, Tranche Two [Member] | Restricted Stock Units (RSUs) [Member]

Stock-Based Compensation [Line Items]

Vested over a period

2 months

Fair value of the underlying ordinary shares

5,000

Share-Based Payment Arrangement, Tranche One [Member] | Restricted Stock Units (RSUs) [Member]

Stock-Based Compensation [Line Items]

Vested over a period

3 months

Fair value of the underlying ordinary shares

30,000

Share Incentive Plan 2010 [Member]

Stock-Based Compensation [Line Items]

Contractual term

10 years

10 years

Authorized and reserved shares

2,725,650

Maximum number of shares percentage

1.50%

Vested over a period

3 years

Equal quarterly instalments

0.08%

Option vested

100%

Annual grant

127,500

Share Incentive Plan 2010 [Member] | Lakeshore Group’s [Member]

Stock-Based Compensation [Line Items]

Contractual term

10 years

Vested option exercised term

5 years

Share Incentive Plan 2020 [Member]

Stock-Based Compensation [Line Items]

Authorized and reserved shares

8,750,000

Fair value of the underlying ordinary shares

2,093,418

Shares reserved but not issued

6,656,582

Subscribe for ordinary shares

3,471,546

Share-Based Payment Arrangement, Employee [Member]

Stock-Based Compensation [Line Items]

Vested option exercised term

12 months

Share-Based Payment Arrangement, Employee [Member] | Restricted Stock Units (RSUs) [Member]

Stock-Based Compensation [Line Items]

Group granted

692,500

Unrecognized shares (in Yuan Renminbi) | ¥

Share-Based Payment Arrangement, Employee [Member] | Share-Based Payment Arrangement, Tranche One, Vesting in Six Equal Semi-annual Installments [Member] | Restricted Stock Units (RSUs) [Member]

Stock-Based Compensation [Line Items]

Vested over a period

3 years

Share-Based Payment Arrangement, Employee [Member] | Share-Based Payment Arrangement, Tranche One, Vesting in Eight Equal Semi-annual Installments [Member] | Restricted Stock Units (RSUs) [Member]

Stock-Based Compensation [Line Items]

Vested over a period

4 years

Share-Based Payment Arrangement, Employee [Member] | Share-Based Payment Arrangement, Tranche Two [Member] | Restricted Stock Units (RSUs) [Member]

Stock-Based Compensation [Line Items]

Fair value of the underlying ordinary shares

287,500

Share-Based Payment Arrangement, Nonemployee [Member] | Restricted Stock Units (RSUs) [Member]

Stock-Based Compensation [Line Items]

Group granted

270,000

Unrecognized shares (in Yuan Renminbi) | ¥

Independent directors

3

3

Awarded

7,500

Stock-Based Compensation (Det_2

Stock-Based Compensation (Details) - Schedule of Share Options Outstanding - ¥ / shares	12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2022
Schedule of Share Options Outstanding [Abstract]
Number of share options, At the beginning	3,253,565	3,253,565	3,253,565
Average exercise price per share option, At the beginning (in Yuan Renminbi per share)	¥ 32.402	¥ 29.3156	¥ 29.3156
Number of share options, Granted during the period
Average exercise price per share option, Granted during the period (in Yuan Renminbi per share)
Number of share options, Forfeited during the period
Average exercise price per share option, Forfeited during the period (in Yuan Renminbi per share)
Number of share options, Exercised during the period
Average exercise price per share option, Exercised during the period (in Yuan Renminbi per share)
Number of share options, Expired during the period
Average exercise price per share option, Expired during the period (in Yuan Renminbi per share)
Number of share options, At the ending	3,253,565	3,253,565	3,253,565
Average exercise price per share option, At the ending (in Yuan Renminbi per share)	¥ 32.402	¥ 32.402	¥ 29.3156

Stock-Based Compensation (Det_3

Stock-Based Compensation (Details) - Schedule of Exercise Prices and Exercise Periods	12 Months Ended
	Mar. 31, 2024 ¥ / shares shares
Schedule of Exercise Prices and Exercise Periods [Line Items]
Number of options	3,253,565
Exercise Price One [Member]
Schedule of Exercise Prices and Exercise Periods [Line Items]
Number of options	1,533,252
Exercise price | ¥ / shares	¥ 13.938
Exercise Price Two [Member]
Schedule of Exercise Prices and Exercise Periods [Line Items]
Number of options	613,369
Exercise price | ¥ / shares	¥ 25.8524
Exercise Price Three [Member]
Schedule of Exercise Prices and Exercise Periods [Line Items]
Number of options	1,106,944
Exercise price | ¥ / shares	¥ 52.5376
Minimum [Member] | Exercise Price One [Member]
Schedule of Exercise Prices and Exercise Periods [Line Items]
Exercise period	2021
Minimum [Member] | Exercise Price Two [Member]
Schedule of Exercise Prices and Exercise Periods [Line Items]
Exercise period	2021
Minimum [Member] | Exercise Price Three [Member]
Schedule of Exercise Prices and Exercise Periods [Line Items]
Exercise period	2021
Maximum [Member] | Exercise Price One [Member]
Schedule of Exercise Prices and Exercise Periods [Line Items]
Exercise period	2031
Maximum [Member] | Exercise Price Two [Member]
Schedule of Exercise Prices and Exercise Periods [Line Items]
Exercise period	2026
Maximum [Member] | Exercise Price Three [Member]
Schedule of Exercise Prices and Exercise Periods [Line Items]
Exercise period	2026

Stock-Based Compensation (Det_4

Stock-Based Compensation (Details) - Schedule of Stock-Based Compensation Expense	12 Months Ended
	Mar. 31, 2024 CNY (¥)	Mar. 31, 2024 USD ($)	Mar. 31, 2023 CNY (¥)	Mar. 31, 2022 CNY (¥)
Schedule of Stock-Based Compensation Expense [Line Items]
Total stock-based compensation	¥ 9,789,686	$ 1,379,801	¥ 3,505,001	¥ 7,764,448
Research and development [Member]
Schedule of Stock-Based Compensation Expense [Line Items]
Total stock-based compensation			(997,846)	975,171
General and administrative [Member]
Schedule of Stock-Based Compensation Expense [Line Items]
Total stock-based compensation	¥ 9,789,686	$ 1,379,801	¥ 4,502,847	¥ 6,789,277

Related Party Transactions an_3

Related Party Transactions and Balances (Details)	1 Months Ended	12 Months Ended
	Jul. 31, 2023 USD ($)	Mar. 31, 2022 CNY (¥)
Related Party Transactions and Balances [Line Items]
Purchase a vehicle (in Dollars) | $	$ 20,000
Yisheng Biopharma Holding Ltd (Hong Kong) [Member]
Related Party Transactions and Balances [Line Items]
Amounts due from related party		¥ 2,966,777
Loan repaid		¥ 33,055,610

Related Party Transactions an_4

Related Party Transactions and Balances (Details) - Schedule of Related Parties that had Balances or Transactions	12 Months Ended
	Mar. 31, 2024
Yisheng Biopharma Holdings Ltd [Member]
Schedule of Related Parties that had Balances or Transactions [Line Items]
Relationship with Lakeshore Group	An entity controlled by Yi Zhang*	[1]
Apex Prospect Limited [Member]
Schedule of Related Parties that had Balances or Transactions [Line Items]
Relationship with Lakeshore Group	A shareholder of Lakeshore Group
Yi Zhang [Member]
Schedule of Related Parties that had Balances or Transactions [Line Items]
Relationship with Lakeshore Group	A shareholder of Lakeshore Group	[1]
Hui Shao [Member]
Schedule of Related Parties that had Balances or Transactions [Line Items]
Relationship with Lakeshore Group	Chief Executive Officer
Nan Zhang [Member]
Schedule of Related Parties that had Balances or Transactions [Line Items]
Relationship with Lakeshore Group	Daughter of  Yi Zhang
Xu Zhang [Member]
Schedule of Related Parties that had Balances or Transactions [Line Items]
Relationship with Lakeshore Group	Daughter Yi Zhang
Rui Mi [Member]
Schedule of Related Parties that had Balances or Transactions [Line Items]
Relationship with Lakeshore Group	Spouse of  Yi Zhang
[1]Yi Zhang was the chairman of the board of directors for the years ended March 31, 2023 and 2022. The entity controlled by him was the related parties of Lakeshore Group during fiscal years 2023 and 2022.

Related Party Transactions an_5

Related Party Transactions and Balances (Details) - Schedule of Transactions with Related Parties - Yisheng Biopharma Holding Ltd (Hong Kong) [Member]	12 Months Ended
	Mar. 31, 2024 CNY (¥)	Mar. 31, 2024 USD ($)	Mar. 31, 2023 CNY (¥)	Mar. 31, 2022 CNY (¥)
Receivable Collected on Behalf of YS Group [Member]
Yisheng Biopharma Holdings Limited (Hong Kong)
Amounts due from related party				¥ 2,966,777
Repayment to YS Group [Member]
Yisheng Biopharma Holdings Limited (Hong Kong)
Amounts due from related party				¥ 33,055,610

Income Tax (Details)

Income Tax (Details) - USD ($)	1 Months Ended		12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2022
Income Tax [Line Items]
Statutory income tax rate			25%	25%	25%
Uncertain tax positions (in Dollars)
Singapore [Member]
Income Tax [Line Items]
Statutory income tax rate			17%
China [Member]
Income Tax [Line Items]
Statutory income tax rate			25%
Enterprises income tax rate			25%
High and new technology enterprises, income tax rate	15%	15%	15%
United States [Member]
Income Tax [Line Items]
Statutory income tax rate			21%
State income tax rate			8.25%
Philippines [Member]
Income Tax [Line Items]
Statutory income tax rate			20%

Income Tax (Details) - Schedule

Income Tax (Details) - Schedule of Effective Tax Rate		12 Months Ended
		Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2022
Schedule of Effective Tax Rate [Abstract]
PRC statutory income tax rate		25%	25%	25%
Effect of different tax rates in different jurisdictions		(13.32%)	(36.00%)	(18.26%)
Effect of PRC preferential tax rate		(3.39%)	8.72%	4.56%
Effect of research and development expenses deduction and others		9.97%	25.50%	33.20%
Non-deductible expenses		0.06%
Temporary differences	[1]	(4.77%)	0.79%	4.88%
Change in valuation allowance		(18.31%)	(23.23%)	(44.47%)
Effective tax rate		(4.76%)	0.78%	4.91%
[1] Temporary differences primarily relate to impairment of inventories, property, plant and equipment and government grants.

Income Tax (Details) - Schedu_2

Income Tax (Details) - Schedule of Net Deferred Tax Assets	Mar. 31, 2024 CNY (¥)	Mar. 31, 2024 USD ($)	Mar. 31, 2023 CNY (¥)
Deferred tax assets:
Write-down of inventories to net realizable value	¥ 10,223,137	$ 1,440,893	¥ 716,917
Impairment of property, plant and building	13,542,899	1,908,795	1,769,405
Deferred government grants	2,951,867	416,049	3,296,223
Losses available for offsetting against future taxable profits	81,220,037	11,447,503	39,366,020
Less: valuation allowance	(81,220,037)	(11,447,503)	(39,366,020)
Total deferred tax assets, net	26,717,903	3,765,737	5,782,545
Deferred tax liabilities:
Fair value adjustments arising from historical acquisition of subsidiaries	(3,083,714)	(434,632)	(3,876,964)
Total deferred tax liabilities	(3,083,714)	(434,632)	(3,876,964)
Net deferred tax asset	¥ 23,634,189	$ 3,331,105	¥ 1,905,581

Deferred Government Grants (Det

Deferred Government Grants (Details) - CNY (¥) ¥ in Millions	12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2025
Deferred Government Grants [Line Items]
Government grants deferred	¥ 3.6	¥ 4
Government Assistance, Other Subsidies [Member]
Deferred Government Grants [Line Items]
Government grants income	15.3	15.7
Government Grants for Property, Plant and Equipment [Member]
Deferred Government Grants [Line Items]
Government grant recognized income	2.4
Amortized deferred government grant		1.5
Government Grants for Research and Development [Member]
Deferred Government Grants [Line Items]
Government grants income	¥ 4.8	¥ 9
Forecast [Member] | Government Grants for Property, Plant and Equipment [Member]
Deferred Government Grants [Line Items]
Current deferred			¥ 1.5
Current deferred government grant			17.7
Forecast [Member] | Government Grants for Research and Development [Member]
Deferred Government Grants [Line Items]
Current deferred			0.5
Current deferred government grant			¥ 2.6

Deferred Government Grants (D_2

Deferred Government Grants (Details) - Schedule of Deferred Government Grants	12 Months Ended
	Mar. 31, 2024 CNY (¥)	Mar. 31, 2024 USD ($)	Mar. 31, 2023 CNY (¥)	Mar. 31, 2024 USD ($)
Government grants for property, plant and equipment
Total deferred government grants	¥ 22,295,638		¥ 25,902,208	$ 3,142,443
Less：current portion	2,015,693		2,295,701	284,100
Non-current portion	20,279,945		23,606,507	2,858,343
Government Grants for Property, Plant and Equipment [Member]
Government grants for property, plant and equipment
Balance at beginning of the year	20,575,012		22,030,690	2,899,931
Addition	3,600,000	$ 507,400
Recognized as income	(2,439,156)	(343,786)	(1,455,678)
Subtotal	21,735,856		20,575,012	3,063,545
Government Grants for Research and Development [Member]
Government grants for property, plant and equipment
Balance at beginning of the year	5,327,196		10,318,528	750,838
Addition			4,000,000
Recognized as income	(4,767,414)	$ (671,940)	(8,991,332)
Subtotal	¥ 559,782		¥ 5,327,196	$ 78,898

Commitments and Contingencies_2

Commitments and Contingencies (Details)						1 Months Ended			12 Months Ended
	Jun. 01, 2024 USD ($)	Apr. 30, 2024 CNY (¥)	Mar. 31, 2024 USD ($)	Feb. 20, 2024 shares	Dec. 31, 2023 CNY (¥)	May 31, 2024 CNY (¥)	May 31, 2024 USD ($)	Oct. 30, 2023 CNY (¥)	Mar. 31, 2018 CNY (¥)
Commitments and Contingencies [Line Items]
Shares to apex (in Shares) | shares				95,269,762
Aggregate amount of payment						¥ 919,000,000
Other fees						721,000,000
Aggregate to repay						723,000,000
Actual frozen amount (in Dollars) | $	$ 902,000,000
China [Member]
Commitments and Contingencies [Line Items]
Other fees						525,000,000
Hebei Defense Biological Products Supply Center [Member]
Commitments and Contingencies [Line Items]
Payment amount									¥ 2,465,807
Compensation received									1,636,755
Balance compensation									¥ 829,052
Research and development services						198,000,000
Hebei Defense Biological Products Supply Center [Member] | China [Member]
Commitments and Contingencies [Line Items]
Research and development services						198,000,000
Shenyang Baimu Technology Co., Ltd [Member]
Commitments and Contingencies [Line Items]
Payment amount								¥ 2,180,000
Aoxing Pharmaceutical Equipment [Member]
Commitments and Contingencies [Line Items]
Payment amount					¥ 155,000
Refund amount					¥ 1,860,000
Liaoning Yisheng [Member]
Commitments and Contingencies [Line Items]
Payment amount		¥ 164,141	$ 522,716
Interest		¥ 28,314	$ 34,400
Kaifeng Arbitration [Member]
Commitments and Contingencies [Line Items]
Sought an arbitration award (in Dollars) | $							$ 83,000,000
Kaifeng Arbitration [Member] | Beijing Yisheng [Member]
Commitments and Contingencies [Line Items]
Principal debt						¥ 59,000,000

Commitments and Contingencies_3

Commitments and Contingencies (Details) - Schedule of Commitments to Purchase Raw Materials or Service - Mar. 31, 2024	CNY (¥)	USD ($)
Schedule of Commitments to Purchase Raw Materials or Service [Line Items]
Total	¥ 120,451,701	$ 16,976,984
Research and Development [Member]
Schedule of Commitments to Purchase Raw Materials or Service [Line Items]
Total	51,593,189	7,271,767
Construction in Progress [Member]
Schedule of Commitments to Purchase Raw Materials or Service [Line Items]
Total	27,531,843	3,880,457
Other Professional Service Fee [Member]
Schedule of Commitments to Purchase Raw Materials or Service [Line Items]
Total	3,050,850	430,000
Purchase Raw Materials [Member]
Schedule of Commitments to Purchase Raw Materials or Service [Line Items]
Total	¥ 38,275,819	$ 5,394,760

Segment Information (Details)

Segment Information (Details)	12 Months Ended
	Mar. 31, 2024
Segment Reporting Information [Line Items]
Number of operating segment	1

Segment Information (Details) -

Segment Information (Details) - Schedule of Non-Current Assets	Mar. 31, 2024 CNY (¥)	Mar. 31, 2024 USD ($)	Mar. 31, 2023 CNY (¥)
PRC [Member]
Segment Reporting Information [Line Items]
Non-current assets	¥ 527,009,381	$ 74,278,983	¥ 645,210,788
Other Countries/Regions [Member]
Segment Reporting Information [Line Items]
Non-current assets	¥ 17,583,961	$ 2,478,360	¥ 4,602,447

Subsequent Events (Details)

Subsequent Events (Details)	Aug. 01, 2024 CNY (¥)	May 17, 2024 CNY (¥)	Mar. 31, 2024 CNY (¥)	Mar. 31, 2024 USD ($)	Mar. 31, 2023 CNY (¥)
Subsequent Events [Line Items]
Borrowings			¥ 318,540,732	$ 44,896,509	¥ 193,736,563
Subsequent Event [Member] | Guangfa Bank Shenyang Branch [Member]
Subsequent Events [Line Items]
Borrowings		¥ 19,800,000
Subsequent Event [Member] | Guangfa Bank Shenyang Branch [Member]
Subsequent Events [Line Items]
Interest borrowing rate		4%
Forecast [Member] | Beijing HRJK Real Estate Co., Ltd [Member]
Subsequent Events [Line Items]
Borrowings	¥ 93,400,000
Forecast [Member] | Shanghai Pudong Development Bank Co., Ltd. [Member]
Subsequent Events [Line Items]
Interest borrowing rate	5%

Parent Company Only Condensed_3

Parent Company Only Condensed Financial Information (Details)	12 Months Ended
	Mar. 31, 2024
Parent Company Only Condensed Financial Information [Line Items]
Subsidiaries exceed percentage	25%
PRC Subsidiaries [Member]
Parent Company Only Condensed Financial Information [Line Items]
Subsidiaries exceed percentage	25%

Parent Company Only Condensed_4

Parent Company Only Condensed Financial Information (Details) - Schedule of Parent Company Balance Sheets - Parent Company [Member] - Reportable Legal Entities [Member]		Mar. 31, 2024 CNY (¥)	Mar. 31, 2024 USD ($)	Mar. 31, 2023 CNY (¥)
Current Assets
Cash		¥ 167,227,049	$ 23,569,704	¥ 3,045,660
Total current assets		1,313,008,292	185,061,070	1,043,032,556
Non-current assets
Long-term investments, net		165,416,495	23,314,517	158,734,357
Long-term prepaid expense		2,341,350	330,000
Total non-current assets		167,757,845	23,644,517	158,734,357
Total Assets		1,480,766,137	208,705,587	1,201,766,913
Current Liabilities
Accrued expenses and other liabilities		887,485,236	125,086,010	461,105,636
Warrants liability		4,548,004	641,015	8,792,389
Total current liabilities		895,559,835	126,224,079	473,313,628
Total Liabilities		895,559,835	126,224,079	473,313,628
Shareholders’ equity:
Ordinary shares, par value US$0.00002 per share; 9,950,000,000 shares authorized; 93,058,197 and 190,227,959 shares issued and outstanding as of March 31, 2023 and 2024, respectively*	[1]	26,105	3,679	12,297
Additional paid-in capital		2,950,862,914	415,907,387	2,656,891,036
Accumulated deficit		(2,307,502,836)	(325,229,434)	(1,874,037,965)
Accumulated other comprehensive loss		(58,179,881)	(8,200,124)	(54,412,083)
Total shareholders’ equity		585,206,302	82,481,508	728,453,285
Total liabilities and shareholders’ equity		1,480,766,137	208,705,587	1,201,766,913
Related Party [Member]
Current Assets
Amounts due from related parties		1,145,781,243	161,491,366	1,039,986,896
Current Liabilities
Amounts due to related parties		¥ 3,526,595	$ 497,054	¥ 3,415,603
[1] Gives retroactive effect to the business combination in March 2023.

Parent Company Only Condensed_5

Parent Company Only Condensed Financial Information (Details) - Schedule of Parent Company Balance Sheets (Parentheticals) - Parent Company [Member] - Reportable Legal Entities [Member] - $ / shares		Mar. 31, 2024	Mar. 31, 2023
Condensed Balance Sheet Statements, Captions [Line Items]
Ordinary shares, par value (in Dollars per share)	[1]	$ 0.00002	$ 0.00002
Ordinary shares, shares authorized	[1]	9,950,000,000	9,950,000,000
Ordinary shares, shares issued	[1]	190,227,959	93,058,197
Ordinary shares, shares outstanding	[1]	190,227,959	93,058,197
[1] Gives retroactive effect to the business combination in March 2023.

Parent Company Only Condensed_6

Parent Company Only Condensed Financial Information (Details) - Schedule of Parent Company Statements of Operations and Comprehensive Loss - Parent Company [Member] - Reportable Legal Entities [Member]		12 Months Ended
		Mar. 31, 2024 CNY (¥) ¥ / shares shares	Mar. 31, 2024 USD ($) $ / shares shares	Mar. 31, 2023 CNY (¥) ¥ / shares shares	Mar. 31, 2022 CNY (¥) ¥ / shares shares
Schedule of Parent Company Statements of Operations and Comprehensive Loss [Abstract]
Equity loss of subsidiaries		¥ (379,244,652)	$ (53,452,382)	¥ (138,758,136)	¥ (75,864,722)
Operating expenses:
Selling and marketing
General and administrative		60,553,856	8,534,722	7,630,726	29,178,255
Research and development		33,011	4,653	(887,280)	988,531
Total operating expenses		60,586,867	8,539,375	6,743,446	30,166,786
Loss from operations		(439,831,519)	(61,991,757)	(145,501,582)	(106,031,508)
Other income (expenses):
Financial expenses, net		1,907,804	268,894	1,119	27,107
Fair value changes of warrant liability		4,458,844	628,449	21,358
Total other expense, net		6,366,648	897,343	22,477	27,107
Net loss		(433,464,871)	(61,094,414)	(145,479,105)	(106,004,401)
Accretion to redemption value of convertible redeemable preferred shares				(137,991,697)	(130,662,326)
Foreign currency translation gain(loss)		(3,767,798)	(531,050)	(137,500,063)	38,864,606
Net loss attributable to Lakeshore Biopharma		(433,464,871)	(61,094,414)	(283,470,802)	(236,666,727)
Net loss		(433,464,871)	(61,094,414)	(145,479,105)	(106,004,401)
Total comprehensive loss		¥ (437,232,669)	$ (61,625,464)	¥ (282,979,168)	¥ (67,139,795)
Loss per share*:
Basic loss per share (in Dollars per share and Yuan Renminbi per share) | (per share)	[1]	¥ (4.05)	$ (0.57)	¥ (2.35)	¥ (1.71)
Weighted average number of ordinary shares outstanding*:
Weighted average number of ordinary shares outstanding basic (in Shares)	[1]	106,923,121	106,923,121	61,785,466	61,827,883
[1] Gives retroactive effect to the business combination in March 2023.

Parent Company Only Condensed_7

Parent Company Only Condensed Financial Information (Details) - Schedule of Parent Company Statements of Operations and Comprehensive Loss (Parentheticals) - Parent Company [Member] - Reportable Legal Entities [Member]		12 Months Ended
		Mar. 31, 2024 $ / shares shares	Mar. 31, 2024 ¥ / shares shares	Mar. 31, 2023 ¥ / shares shares	Mar. 31, 2022 ¥ / shares shares
Schedule of Parent Company Statements of Operations and Comprehensive Loss [Abstract]
Diluted loss per share (in Dollars per share and Yuan Renminbi per share) | (per share)	[1]	$ (0.57)	¥ (4.05)	¥ (2.35)	¥ (1.71)
Weighted average number of ordinary shares outstanding Diluted	[1]	106,923,121	106,923,121	61,785,466	61,827,883
[1] Gives retroactive effect to the business combination in March 2023.

Parent Company Only Condensed_8

Parent Company Only Condensed Financial Information (Details) - Schedule of Parent Company Statements of Cash Flows - Parent Company [Member] - Reportable Legal Entities [Member]	12 Months Ended
	Mar. 31, 2024 CNY (¥)	Mar. 31, 2024 USD ($)	Mar. 31, 2023 CNY (¥)	Mar. 31, 2022 CNY (¥)
Schedule of parent company statements of cash flows [Abstract]
Net loss	¥ (433,464,871)	$ (61,094,414)	¥ (145,479,105)	¥ (106,004,401)
Equity loss of subsidiaries	379,244,652	53,452,382	138,758,136	75,864,722
Share-based compensation	9,789,686	1,379,801	3,505,001	7,764,448
Fair value changes of warrant liability	(4,458,844)	(628,449)	(21,358)
Changes in operating assets and liabilities:
Amounts due from related parties	(105,794,347)	(14,911,113)	(520,750,020)	(23,299,705)
Amounts due to related parties	110,992	15,644	260,208	(110,893)
Accrued expenses and other liabilities	33,181,238	4,676,707	48,377,785	(24,732,348)
Prepaid expense	(2,341,350)	(330,000)
Net cash used in operating activities	(123,732,844)	(17,439,442)	(475,349,353)	(70,518,177)
Cash flows from investing activities:
Payment for long-term investment	(1,523,970)	(214,795)		(813,776)
Net cash used in investing activities	(1,523,970)	(214,795)		(813,776)
Cash flows from financing activities:
Proceeds from issuance of ordinary shares	284,196,000	40,055,814
Proceeds from acquisition			252,457,329
Offering cost			(35,884,661)
Net cash provided by financing activities	284,196,000	40,055,814	216,572,668
Effect of exchange rate on cash	5,242,203	738,859	9,210,810	(6,353,461)
Net (decrease) increase in cash	164,181,389	23,140,436	(249,565,875)	(77,685,414)
Cash at the beginning of the year	3,045,660	429,268	252,611,535	330,296,949
Cash at the end of the year	167,227,049	23,569,704	3,045,660	252,611,535
Non-cash transactions:
Accretion to redemption value of convertible redeemable preferred shares			(137,991,697)	130,662,326
Equity transaction from warrants			(8,870,007)
Equity transaction from preferred shares			¥ 1,636,897,084